

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INVIVO THERAPEUTICS CORPORATION, *et al.*,¹

Debtors.

Chapter 11

Case No. 24-10137 (MFW)

(Jointly Administered)

Ref. No. 18

CERTIFICATION OF COUNSEL

I, Joshua B. Brooks, counsel to the above-captioned debtors and debtors-in-possession (the “Debtors”) hereby certify as follows to the best of my knowledge, information, and belief:

1. On February 1, 2024 (the “Petition Date”), the Debtors filed voluntary petitions for relief under Chapter 11 of Title 11 of the United States Code, 11 U.S.C. §§ 101, *et seq.* in the United States Bankruptcy Court for the District of Delaware (the “Court”).

2. On February 1, 2024, the Debtors filed the *Motion of Debtors for Entry of Orders: (A)(I) Approving Bid Procedures Relating to the Sale of Substantially All of the Debtors’ Assets, (II) Approving Stalking Horse Bid Protections, (III) Scheduling a Hearing to Consider the Sale, (IV) Approving the Form and Manner of Notice of Sale by Auction, (V) Establishing Notice and Procedures for the Assumption and Assignment of Contracts and Leases, and (VI) Granting Related Relief; and (B)(I) Approving Asset Purchase Agreement and Authorizing the Sale of Certain Assets of the Debtors Outside the Ordinary Course of Business, (II) Authorizing the Sale of Assets Free and Clear of All Liens, Claims, Encumbrances and Interests, (III) Authorizing the Assumption and Assignment of Certain Executory Contracts and Unexpired Leases, and (IV) Granting Related Relief* [D.I. 18] (the “Motion”).

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number, are: InVivo Therapeutics Corporation (6670) and InVivo Therapeutics Holdings Corp. (8166). The Debtors’ mailing address is 1500 District Avenue, Burlington, MA 01803.



3. As of the date hereof, no formal objections or other responses to the Motion have been filed or served on the Debtors. The Debtors received informal comments from the Office of the United States Trustee for the District of Delaware (the “U.S. Trustee”) to the proposed form of order filed with the Motion (the “Proposed Order”).

4. To resolve the U.S. Trustee’s informal comments, the Debtors have revised the Proposed Order, a copy of which is attached hereto as **Exhibit A** (the “Revised Proposed Order”). A copy of the Revised Sale Order compared against the Proposed Order is attached hereto as **Exhibit B**. The Debtors provided a copy of the Revised Proposed Order to the U.S. Trustee, and the U.S. Trustee has advised that it does not object to entry of the Revised Proposed Order.

5. In accordance with the Court’s electronic order processing procedures, a clean copy of the Revised Proposed Order shall be uploaded to CM/ECF.

6. Accordingly, the Debtors respectfully requests that the Court enter the Revised Proposed Order at its earliest convenience.

Dated: February 21, 2024
Wilmington, Delaware

LANDIS RATH & COBB LLP

/s/ Joshua B. Brooks
Matthew B. McGuire (No. 4366)
Joshua B. Brooks (No. 6765)
919 Market Street, Suite 1800
Wilmington, Delaware 19801
Telephone: (302) 467-4400
Facsimile: (302) 467-4450
Email: mcguire@lrclaw.com
brooks@lrclaw.com

*Proposed Counsel for the Debtors
and Debtors-In-Possession*

EXHIBIT A

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INVIVO THERAPEUTICS CORPORATION, *et al.*,¹

Debtors.

Chapter 11

Case No. 24-10137 (MFW)

(Jointly Administered)

Ref. No. 18

ORDER: (A) APPROVING BID PROCEDURES RELATING TO THE SALE OF SUBSTANTIALLY ALL OF THE DEBTORS' ASSETS, (B) APPROVING STALKING HORSE BID PROTECTIONS, (C) SCHEDULING A HEARING TO CONSIDER THE SALE, (D) APPROVING THE FORM AND MANNER OF NOTICE OF SALE BY AUCTION, (E) ESTABLISHING NOTICE AND PROCEDURES FOR THE ASSUMPTION AND ASSIGNMENT OF CONTRACTS AND LEASES, AND (F) GRANTING RELATED RELIEF

Upon the Motion² filed by the above-captioned debtors and debtors-in-possession (together, the "Debtor"), pursuant to sections 105(a), 363, 365, 503 and 507 of title 11 of the United States Code, 11 U.S.C. §§ 101, *et seq.* (the "Bankruptcy Code"), and Rules 2002, 6003, 6004, 6006, 9007 and 9008 of the Federal Rules of Bankruptcy Procedure (the "Bankruptcy Rules"), and rule 6004-1 of the Local Rules of Bankruptcy Practice and Procedure of the United States Bankruptcy Court for the District of Delaware (the "Local Rules"), for entry of an order (the "Order"), (i) approving the procedures (the "Bid Procedures") substantially in the form attached hereto as Exhibit 1, with respect to the proposed sale (the "Sale") of substantially all of the Debtors' assets (the "Assets"), (ii) scheduling a hearing on the Sale (the "Sale Hearing") and setting objection and bidding deadlines with respect to the Sale, (iii) approving the form and manner of notice of the Sale and the auction (the "Auction") for the Assets, a copy of which is attached hereto

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number, are: InVivo Therapeutics Corporation (6670) and InVivo Therapeutics Holdings Corp. (8166). The Debtors' mailing address is 1500 District Avenue, Burlington, MA 01803.

² Capitalized terms used but not defined herein shall have the same meanings given to such terms as in the Motion.

as Exhibit 2 (the “Sale Notice”), (iv) establishing procedures to determine cure amounts and deadlines for objections to the assumption and assignment of executory contracts and unexpired leases as set forth in the Motion (collectively, the “Contract Procedures”); and (v) granting related relief; and it appearing that the notice of the Motion provided is appropriate and sufficient under the circumstances and that no other or further notice need be given; and it appearing that the relief requested is in the best interests of the Debtors’ estates, their creditors and other parties in interest; and after due deliberation and good and sufficient cause appearing therefor:

THE COURT HEREBY FINDS AND CONCLUDES THAT:³

A. This Court has jurisdiction over this matter and over the properties of the Debtors and their estates pursuant to 28 U.S.C. §§ 157 and 1334. This proceeding is a core proceeding pursuant to 28 U.S.C. § 157. Venue is proper in this district and in this Court pursuant to 28 U.S.C. §§ 1408 and 1409.

B. The statutory and rule-based predicates for the relief requested in the Motion are Bankruptcy Code sections 105(a), 363, 365, 503 and 507, Bankruptcy Rules 2002, 6003, 6004, 6006, 9007, 9008 and Local Rule 6004-1.

C. Notice of the Motion having been given as set forth in the Motion is sufficient in light of the circumstances and the nature of the relief requested in the Motion and no other or further notice is necessary or required, except as otherwise set forth herein.

D. The Debtors have articulated good and sufficient reasons for this Court to grant the relief requested in the Motion regarding the Sale process, including, without limitation:

³ The findings and conclusions set forth herein constitute the Court’s findings of fact and conclusions of law pursuant to Bankruptcy Rule 7052, made applicable to this proceeding pursuant to Bankruptcy Rule 9014. To the extent that any of the following findings of fact constitute conclusions of law, they are adopted as such. To the extent any of the following conclusions of law constitute findings of fact, they are adopted as such.

(i) approving the Bid Procedures; (ii) approving the Stalking Horse Bid Protections; (iii) scheduling the Auction and the Sale Hearing; (iv) approving the Sale Notice; and (v) approving the Cure Notice and Contract Procedures.

E. The Debtors have demonstrated a sound business justification for authorizing them to offer the Stalking Horse Bid Protections to any potential Stalking Horse Bidder.

F. The Bid Procedures were proposed in good faith by the Debtors, and are fair, reasonable and appropriate under the circumstances, and are properly designed to maximize the recovery from any sale of the Assets.

G. The form and scope of the Sale Notice attached hereto as Exhibit 2 is appropriate and reasonably calculated to provide all interested parties with timely and proper notice of the Sale, the Sale Hearing and the Auction and no other and further notice is required.

H. The Contract Procedures and the notices related thereto, including the Cure Notice attached hereto as Exhibit 3 and the Additional Cure Notice attached as Exhibit 4 are appropriate and reasonably calculated to provide all Contract Parties with proper notice of the potential assumption and assignment of Contracts or unexpired leases and any Cure Amounts relating thereto and no further or other notice is required.

I. The entry of this Order is in the best interests of the Debtors, their estates, their creditors, and other parties in interest; and it is therefore:

ORDERED, ADJUDGED AND DECREED THAT:

1. The relief requested in the Motion is GRANTED as set forth herein.
2. The Bid Procedures and Contract Procedures are approved in all respects and the relief requested in the Motion as it pertains to the Bid Procedures and Contract Procedures, is granted.

3. All objections to the relief requested in the Motion with respect to the Bid Procedures or the Contract Procedures that have not been withdrawn, waived, or settled as announced to the Court at the hearing on the Motion or as reflected in this Order or by stipulation or withdrawal filed with the Court, are overruled.

4. The Bid Procedures attached hereto as Exhibit 1 are hereby approved and fully incorporated into this Order, and shall apply with respect to the Auction and the proposed Sale of the Assets.

5. The Debtors are authorized to take any and all actions necessary or appropriate, consistent with the terms of this Order, to implement the Bid Procedures.

6. The Stalking Horse Procedures are approved as set forth herein:

- a. To the extent the Debtors designate a Stalking Horse Bidder with respect to any of the assets, the Debtors shall promptly upon execution of a Stalking Horse Agreement (and in no event more than one (1) calendar day following such execution) file with the Court and serve upon the U.S. Trustee, the Committee (if any), and those parties who have filed the appropriate notice pursuant to Bankruptcy Rule 2002 requesting notice of all pleadings filed in the Chapter 11 Cases, and cause to be published on the website maintained by the Debtors' claims and noticing agent in these Chapter 11 Cases, located at the Debtors' claims agent's website at <https://www.kccllc.net/invivo>, a notice that contains information about the Stalking Horse Bidder (and if the Stalking Horse Bidder is a newly formed entity, then the Stalking Horse Bidder's parent company or sponsor), the Stalking Horse Bid, attaches the proposed Stalking Horse Agreement, states whether the Stalking Horse Bidder has any connection to the Debtors other than those that arise from the Stalking Horse Bid, and describes any Stalking Horse Bid Protections proposed to be afforded to the Stalking Horse Bidder (as defined herein) (the "Notice of Stalking Horse Bidder") :
- b. Any objections (each, a "Stalking Horse Objection") to the designation of a Stalking Horse Bidder, including any Stalking Horse Bid Protections pursuant to the terms and provisions of a Stalking Horse Agreement, must (i) be in writing; (ii) state the name and address of the objecting party and the amount and nature of the Claim or Interest of such party; (iii) state with particularity the basis and nature of any objection; (iv) conform to the Bankruptcy Rules and the Local Rules; and (v) be filed with the Court and served upon the Sale Notice Parties within seven (7) calendar days after the

filing of the relevant Notice of Stalking Horse Bidder. If no timely Stalking Horse Objection is filed and served with respect to the Stalking Horse Bid, upon the expiration of the objection deadline, the Debtors will submit the proposed order approving the Stalking Horse Bidder and the Stalking Horse Bid to the Court, which may enter such order without a hearing, including with respect to any Bid Protections set forth in the Stalking Horse Supplement. **For the avoidance of doubt, no determination is made in this Order with regard to authorizing any Bid Protections.**

7. Pursuant to the Bid Procedures, the Debtors may designate one or more Stalking Horse Bidders on or before March 26, 2024 at 4:00 p.m. (ET).

8. The Debtors shall have the right to determine at the Auction that any Qualified Bid shall be the Back-Up Bid.

9. Pursuant to the Bid Procedures, a Potential Bidder that desires to make a bid shall deliver written copies of its bid to the parties identified in the Bid Procedures no later than 4:00 p.m. (ET) on March 29, 2024, (the “Bid Deadline”) and shall comply with all other requirements set forth in the Bid Procedures in making such a bid for the Assets.

10. To the extent the Debtors receive at least two Qualified Bids, the Debtors shall conduct the Auction commencing at 10:00 a.m. (ET) on April 3, 2024, at the offices of Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware 19801, or by remote audio and/or video link.

11. If the Debtors do not receive a Qualified Bid, the Debtors will not hold the Auction. No later than 4:00 p.m. (ET) on April 1, 2024, the Debtors shall notify all Qualified Bidders and counsel to the Committee, if any, whether the Auction will occur.

12. Upon conclusion of the bidding at any Auction, the Auction shall be closed, and the Debtors, in consultation with the Committee, if any, shall (i) review each Qualified Bid on the basis of financial and contractual terms and the factors relevant to the Sale process and the contract assumption process, including, without limitation, those factors affecting the speed and certainty

of consummating the proposed Sale and the amount of the cash (or cash equivalents) consideration and (ii) identify the highest or otherwise best offer for the Assets (the “Successful Bid” and the entity submitting such Successful Bid, the “Successful Bidder”), the Back-Up Bid and the Back-Up Bidder and advise the Qualified Bidders of such determinations. The Debtors shall file with the Court notice of such determinations by the earlier of (a) five (5) business hours after the close of the auction or (b) noon of the day after the close of the auction. If the Successful Bidder or the Back-Up Bidder is a special purpose entity, the notice shall also identify the entity or entities that are the primary equity holders, or otherwise control, the special purpose entity.

13. The Debtors, in their reasonable business judgment, in consultation with the Committee, if any, may (a) determine which Qualified Bid, if any, is the highest or otherwise best offer; and (b) reject, at any time before entry of an order of the Court approving a Qualified Bid, any bid that is (i) inadequate or insufficient; (ii) not in conformity with the requirements of the Bankruptcy Code, the Bid Procedures, or the terms and conditions of the Sale; or (iii) contrary to the best interests of the Debtors, their estates, their creditors, or other stakeholders.

14. The Debtors’ presentation of a particular Qualified Bid to the Court for approval does not constitute the Debtors’ acceptance of such Qualified Bid. Other than as expressly set forth in the Bid Procedures Order, the Debtors will be deemed to have accepted a bid only when the bid has been approved by the Court at the Sale Hearing.

15. After the Successful Bid, the next highest or otherwise best offer, as determined by the Debtors, in consultation with the Committee, if any, (the “Back-Up Bid”) shall remain open, and the entity submitting such Back-Up Bid (the “Back-Up Bidder”) shall be required to fully perform under such Back-Up Bid, until the consummation of a Sale Transaction with the Successful Bidder. In the event the Successful Bidder fails to consummate the Sale as a result of

the Successful Bidder's default or breach under the applicable purchase agreement in accordance with the terms of such purchase agreement by the closing date contemplated in such purchase agreement, the Debtors shall be, among other things, free to enter into a new purchase agreement with the Back-Up Bidder at the purchase price contemplated in the Back-Up Bid. Following the approval of the Sale of the Assets to the Successful Bidder at the Sale Hearing, if such Successful Bidder fails to consummate the approved Sale within thirty (30) days after entry of an Order approving such Sale, the Debtors shall be authorized, in consultation with the Committee, if any, but not required, to deem the Back-Up Bid, as disclosed at the Sale Hearing, the Successful Bid, and the Debtors may consummate the Sale to the Back-Up Bidder without further order of the Court.

16. The Contract Procedures, setting forth, among other things, the procedures for determining the Cure Amounts and the deadline for objecting to the Cure Amounts and/or the proposed assumption and assignment of executory contracts and unexpired leases, as provided in the Motion, are hereby approved in their entirety. Notice of the Contract Procedures in the form attached hereto as Exhibit 3 and service of such notice of the Contract Procedures to the Contract Parties, are appropriate and sufficient under the circumstances, and no other or further notice of the Contract Procedures need to be given.

17. The Court shall conduct the Sale Hearing commencing on April 5, 2024 at 10:00 a.m. (ET), at which time the Court will consider approval of the Sale to the Successful Bidder and entry of the Sale Order.

18. Objections to approval of the Sale and entry of the Sale Order, including the sale of the Assets free and clear of all Encumbrances pursuant to Bankruptcy Code section 363(f), with such Encumbrances to attach to the Sale Proceeds (if any) (a "Sale Objection"), must be in writing

and filed with the Court and served on (i) counsel for the Debtors, Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware 19801 (Attn: Matthew B. McGuire, Esq. (e-mail: mcguire@lrclaw.com) and Joshua B. Brooks, Esq. (e-mail: brooks@lrclaw.com)); and Wilmer Cutler Pickering Hale and Dorr LLP, 7 World Trade Center, 250 Greenwich Street, New York, New York, 10007 (Attn: George Shuster, Esq. (e-mail: george.shuster@wilmerhale.com) and Benjamin Loveland, Esq. (e-mail: benjamin.loveland@wilmerhale.com)); (ii) counsel to the Committee, if any; and (iii) the Office of the United States Trustee, 844 King Street, Suite 2207, Wilmington, Delaware 19801 (Attn: Joseph Cudia, Esq. (email: Joseph.Cudia@usdoj.gov)), so as to be received by such parties prior to 4:00 p.m. (ET) on March 29, 2024 (the “Sale Objection Deadline”).

19. Amounts listed by the Debtors and to propose alternative Cure Amounts, and/or (b) the proposed assumption and assignment of the Contracts in connection with the Sale, including, without limitation, the Debtors’ ability to assign the Contracts without the Contract Parties’ consent (a “Contract Objection”), must be in writing and filed with the Court and served on (i) counsel for the Debtors, Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware 19801 (Attn: Matthew B. McGuire, Esq. (e-mail: mcguire@lrclaw.com) and Joshua B. Brooks, Esq. (e-mail: brooks@lrclaw.com)); and Wilmer Cutler Pickering Hale and Dorr LLP, 7 World Trade Center, 250 Greenwich Street, New York, New York, 10007 (Attn: George Shuster, Esq. (e-mail: george.shuster@wilmerhale.com) and Benjamin Loveland, Esq. (e-mail: benjamin.loveland@wilmerhale.com)); (ii) counsel to the Committee, if any; and (iii) the Office of the United States Trustee, 844 King Street, Suite 2207, Wilmington, Delaware 19801 (Attn: Joseph Cudia, Esq. (email: Joseph.Cudia@usdoj.gov)), so as to be received by such parties prior to 4:00 p.m. (ET) on the date that is fourteen (14) days following service of the Cure Notice

but no later than March 29, 2024 (the “Contract Objection Deadline”); provided, however, that objections to the adequate assurance of future performance to be provided by the Successful Bidder (or any designee thereof) may be made at the Sale Hearing or at another date set by the Court; provided, however, that if the Debtors amend the Cure Notice to add a contract or lease, the non-Debtor party to the added contract or lease shall have until the earlier of (i) fourteen (14) days after service of notice of adding a contract or lease; or (ii) the Sale Hearing to submit a Contract Objection with respect to the contract or lease added by the Debtors’ amendment (the “Amended Contract Objection Deadline”); provided further, that if the Debtors amend the Cure Notice to reduce the Cure Amount of a Contract or lease, except where such reduction was upon mutual agreement of the parties, the non-Debtor party to the Contract or lease with the reduced Cure Amount shall have until the Amended Contract Objection Deadline to object to the Cure Amount; and provided further, that in the event the Auction results in a Successful Bidder, the Contract Parties shall have until the Amended Contract Objection Deadline to object to the assignment of executory contracts and unexpired leases to such Successful Bidder, other than to the Cure Amount which shall be subject to the Contract Objection Deadline, with any such objection being heard at the Sale Hearing or at a later-scheduled hearing as the Court deems appropriate.

20. Unless a Contract Objection is filed and served before the Contract Objection Deadline or the Amended Contract Objection Deadline, as applicable, all Contract Parties shall be (i) forever barred from objecting to the proposed Cure Amounts and from asserting any additional cure or other amounts (other than as may be asserted in an Additional Cure Notice), and the Debtors and the Successful Bidder shall be entitled to rely solely upon the proposed Cure Amounts set forth in the Cure Notices; (ii) deemed to have consented to the assumption and assignment, (iii) forever barred and estopped from asserting or claiming against the Debtors or the Successful

Bidder, as applicable, that any additional amounts are due or other defaults exist (other than as may be asserted in an Additional Cure Notice), that conditions to assignment must be satisfied under such Contracts, including without limitation adequate assurance of future performance; (iv) precluded from objecting to the Cure Amount (if any) and the assumption and assignment; and (v) barred and estopped from asserting or claiming that their Contract contains an enforceable consent right; provided, however, that a counterparty to an Assumed Executory Contract shall not be barred from seeking additional amounts on account of any defaults occurring between the service of the Cure Notice and the assumption of the Contract.

21. The Debtors, the Contract Party, and the Successful Bidder may consensually resolve any Contract Objection prior to the Sale Hearing. In the event a Contract Objection is not resolved, such Contract Objection will be heard at the Sale Hearing or thereafter, or the Successful Bidder may designate such Contract as a Contract that will not be assumed and assigned to the Successful Bidder, in which case such Contract shall not be assumed and shall remain property of the Debtors' estates, subject to any further orders of the Court.

22. The Debtors are hereby authorized to share certain of the Contracts that contain confidentiality restrictions with Qualified Bidders subject to the terms of the non-disclosure agreement by and between the Debtors and each Qualified Bidder, provided that each such Qualified Bidder requesting access to such confidential contracts enters into a non-disclosure agreement with the Debtors, in a form acceptable to the Debtors.

23. All Qualified Bidders are deemed to have submitted to the exclusive jurisdiction of the Court with respect to all matters between and among any Qualified Bidder and the Debtors related to the Auction and the Sale.

24. The Sale Notice attached hereto as Exhibit 2 is approved. The Sale Notice provides all parties in interest good and sufficient notice of the relief sought in the Motion, including, but not limited to, the Auction, the Bid Deadline, the Bid Procedures, the Sale Hearing, and the Sale.

25. Within two (2) business days of the entry of the Bid Procedures Order, the Debtors shall serve by first class mail, postage prepaid, copies of: (i) this Order and (ii) the Sale Notice upon the following entities: (a) the Office of the United States Trustee for the District of Delaware; (b) counsel to the Committee, if any, or if none is formed, the creditors holding the twenty (20) largest unsecured claims as set forth on the list filed with the Debtors' petitions; (c) all taxing authorities having jurisdiction over any of the Assets subject to the Sale, including the Internal Revenue Service; (d) the Environmental Protection Agency; (e) the U.S. Securities Exchange Commission; (f) the state/local environmental agencies in the jurisdictions where the Debtors own or lease real property; (g) all parties that have requested notice pursuant to Bankruptcy Rule 2002 as of the date prior to the date of entry of the Bid Procedures Order; (h) all persons or entities known to the Debtors that have or have asserted a lien on, or security interest in, all or any portion of the Assets; (i) all of the Debtors' known creditors; (j) the Food and Drug Administration; and (k) all potential bidders previously identified or otherwise known to the Debtors (collectively, the "Sale Notice Parties"). The Debtors are also authorized and directed to publish the Sale Notice in the national edition of either the *Wall Street Journal National Edition* or *USA Today* or similar publication.

26. The Cure Notice attached hereto as Exhibit 3 provides proper notice to all parties in interest and is approved. The Debtors shall serve the Cure Notice on all Contract Parties by first class mail not less than fourteen days prior to the Sale Objection Deadline.

27. The Additional Cure Notice attached hereto as Exhibit 4 provides proper notice to all parties in interest and is approved. The Debtors shall serve the Additional Cure Notice pursuant to the additional assumption procedures as provided in the Motion.

28. All of the dates set forth on the attached Schedule 1 are hereby approved.

29. This Order shall constitute findings of fact and conclusions of law and shall take effect immediately upon execution hereof.

30. Notwithstanding the possible applicability of Bankruptcy Rule 6003 or 6004(h) or otherwise, the terms and conditions of this Order shall be immediately effective and enforceable upon its entry, and no automatic stay of execution shall apply to this Order.

31. This Court shall retain jurisdiction over any matters related to or arising from the implementation of this Order and the Bid Procedures.

Dated: _____, 2024
Wilmington, Delaware

United States Bankruptcy Judge

SCHEDULE 1

Deadline for Debtors to Serve Notice of Sale Hearing and Notice of Entry of Bid Procedures Order	Within two (2) business days after entry of the Bid Procedures Order
Deadline for Debtors to Serve Cure Notices	Not less than fourteen (14) days prior to the Sale Objection Deadline
Deadline for Debtors to designate Stalking Horse Bidder	March 26, 2024 at 4:00 p.m. (ET)
Bid Deadline	March 29, 2024 at 4:00 p.m. (ET)
Deadline to Object to Cure Amounts	4:00 p.m. (ET) on the date that is fourteen (14) days after service of the Cure Notice
Deadline to Object to Assumption and Assignment of Contracts and Leases to Successful Bidder	4:00 p.m. (ET) on the date that is fourteen (14) days after service of the Cure Notice
Amended Contract Objection Deadline	The earlier of (a) 4:00 p.m. on the date that is fourteen (14) days after service of notice of adding a contract or lease or (b) the Sale Hearing
Sale Objection Deadline	March 29, 2024 at 4:00 p.m. (ET)
Auction, if necessary	April 3, 2024 at 10:00 a.m. (ET)
Deadline of Debtors to File and Serve Notice of Successful Bidder and Amount of Bid	Within 1 day after the close of the Auction
Sale Hearing	April 5, 2024 at 10:00 a.m. (ET)

EXHIBIT 1

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INVIVO THERAPEUTICS CORPORATION, *et al.*,¹

Debtors.

Chapter 11

Case No. 24-10137 (MFW)

(Jointly Administered)

BID PROCEDURES

Overview

On February 1, 2024, InVivo Therapeutics Holdings Corp. and InVivo Therapeutics Corporation, as debtors and debtors in possession (together, the “Debtors”), filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Court”).

On February [], 2024, the Court entered an order [D.I.] (the “Bid Procedures Order”)² which, among other things, authorized the Debtors to solicit bids and approved these procedures (the “Bid Procedures”) for the consideration of the highest or otherwise best bid for all or a portion of the Debtors’ assets on the terms and conditions set forth herein (a “Sale Transaction”).

The Bid Procedures describe, among other things: (i) the procedures for bidders to submit bids for the Debtors’ assets; (ii) the manner in which bidders and bids become Qualified Bidders and Qualified Bids; (iii) the process for negotiating the bids received; (iv) the conduct of the Auction if the Debtors receive Qualified Bids; (v) the procedure for the ultimate selection of any Successful Bidder; and (vi) the process for approval of a Sale Transaction at the Sale Hearing (as defined herein).

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number, are: InVivo Therapeutics Corporation (6670) and InVivo Therapeutics Holdings Corp. (8166). The Debtors’ mailing address is 1500 District Avenue, Burlington, MA 01803.

² Capitalized terms used but not otherwise defined in these Procedures shall have the meanings ascribed to such terms in the Order and the *Motion of Debtors for Entry of Orders: (a)(I) Approving Bid Procedures Relating to the Sale of Substantially All of the Debtors’ Assets, (II) Approving Stalking Horse Bid Protections, (III) Scheduling a Hearing to Consider the Sale, (IV) Approving the Form and Manner of Notice of Sale by Auction, (V) Establishing Notice and Procedures for the Assumption and Assignment of Contracts and Leases, and (VI) Granting Related Relief; and (B)(I) Approving Asset Purchase Agreement and Authorizing the Sale of Certain Assets of the Debtors Outside the Ordinary Course of Business, (II) Authorizing the Sale of Assets Free and Clear of All Liens, Claims, Encumbrances and Interests, (III) Authorizing the Assumption and Assignment of Certain Executory Contracts and Unexpired Leases, and (IV) Granting Related Relief* [D.I. 18] (the “Motion”).

The Debtors reserve the right, subject to the exercise of their reasonable business judgment, to modify or terminate these Bid Procedures, to waive terms and conditions set forth herein, to extend any of the deadlines or other dates set forth herein, to adjourn the Auction and/or Sale Hearing, and/or to terminate discussions with any and all prospective bidders at any time and without specifying the reasons therefor, in each case, to the extent not materially inconsistent with these Bid Procedures and/or the Bid Procedures Order.

Summary of Key Dates

Key Event	Deadline
Deadline to designate Stalking Horse Bidder	March 26, 2024 at 4:00 p.m. (ET)
Deadline to submit Bids	March 29, 2024 at 4:00 p.m. (ET)
Deadline to file objections to (i) Sale Transaction, and (ii) Cure Costs	March 29, 2024 at 4:00 p.m. (ET)
Deadline for Debtors to notify Bidders of status as Qualified Bidders	April 1, 2024
Auction, if necessary, to be conducted at the offices of Landis Rath & Cobb LLP, 919 N. Market Street, Suite 1800, Wilmington DE 19801 or by remote audio and/or video link	April 3, 2024 at 10:00 a.m. (ET)
Deadline of Debtors to File and Serve Notice of Successful Bidder and Amount of Bid	Earlier of (a) five (5) business hours after close of the Auction or (b) noon of the day after the close of the Auction
Deadline to file objections to Adequate Assurance of future performance	At the Sale Hearing
Sale Hearing	April 5, 2024 (subject to the Court's availability)

Assets to be Sold

The Debtors intend to offer substantially all of their assets for Sale. Parties may submit bids for the purchase and sale of any and all of the Debtors' assets, in accordance with the terms and conditions set forth herein.

Due Diligence

The Debtors have posted copies of all material documents related to the Debtors' assets to the Debtors' confidential electronic data room (the "Data Room"). To access the Data Room, a party must submit to the Debtors' advisors:

1. an executed confidentiality agreement in form and substance reasonably satisfactory to the Debtors (unless such party is already a party to an existing confidentiality agreement with the Debtors that is acceptable to the Debtors for this due diligence process, in which case such agreement shall govern); and
2. sufficient information, as reasonably requested by the Debtors, to allow the Debtors to determine that the interested party intends to access the Data Room for a purpose consistent with these Bid Procedures.

An interested party that meets the aforementioned requirements to the satisfaction of the Debtors shall be a "Potential Bidder." As soon as practicable, the Debtors will provide such Potential Bidder access to the Data Room; provided, however, that, such access may be terminated by the Debtors in their reasonable discretion at any time for any reason whatsoever, including that a Potential Bidder does not become a Qualified Bidder, violates these Bid Procedures or these Bid Procedures are terminated.

Each Potential Bidder shall comply with all reasonable requests for information and due diligence access by the Debtors or their advisors regarding the ability of such Potential Bidder to consummate a Sale Transaction.

Until the Bid Deadline, the Debtors will provide any Potential Bidder with reasonable access to the Data Room and any additional information requested by Potential Bidders (subject to any restrictions pursuant to applicable law) that the Debtors believe to be reasonable and appropriate under the circumstances. All additional due diligence requests shall be directed to the Debtors' investment bankers, SSG Advisors, LLC, Attn: J. Scott Victor (jsvictor@ssgca.com) and Teresa Kohl (tkohl@ssgca.com). Unless prohibited by law or otherwise determined by the Debtors, the availability of additional due diligence to a Potential Bidder will cease if (i) the Potential Bidder does not become a Qualified Bidder, (ii) these Bid Procedures are terminated, or (iii) the Potential Bidder breaches any obligations under its confidentiality agreement.

Neither the Debtors nor any of their representatives shall be obligated to furnish any information of any kind whatsoever relating to the Debtors' assets to any person or entity who (i) is not a Potential Bidder, (ii) does not comply with the participation requirements set forth herein, or (iii) in the case of competitively sensitive information, is a competitor of the Debtors.

Designation of Stalking Horse Bidders

Designation of Stalking Horse Bidders. The Debtors, in consultation with any official committee of unsecured creditors appointed in the Chapter 11 Cases (the "Committee"), may designate one or more Stalking Horse Bidders and enter into Stalking Horse Agreements with such Stalking Horse Bidders. The Debtors may designate one or more Stalking Horse Bidders on or before March 26, 2024 at 4:00 p.m. (ET). To the extent the Debtors designate a Stalking Horse

Bidder with respect to any of the assets, the Debtors shall promptly upon execution of a Stalking Horse Agreement (and in no event more than one (1) calendar day following such execution) file with the Court and serve upon the U.S. Trustee, the Committee (if any), and those parties who have filed the appropriate notice pursuant to Bankruptcy Rule 2002 requesting notice of all pleadings in these Chapter 11 Cases, and cause to be published on the website maintained by the Debtors' claims and noticing agent in these Chapter 11 Cases, located at Debtors' claims agent's website at [https:// www.kccllc.net/invivo](https://www.kccllc.net/invivo) a notice that contains information about the Stalking Horse Bidder (and if the Stalking Horse Bidder is a newly formed entity, then the Stalking Horse Bidder's parent company or sponsor), the Stalking Horse Bid, attaches the proposed Stalking Horse Agreement, states whether the Stalking Horse Bidder has any connection to the Debtors other than those that arise from the Stalking Horse Bid, and describes any Stalking Horse Bid Protections proposed to be afforded to the Stalking Horse Bidder (as defined herein) (the "Notice of Stalking Horse Bidder").

Stalking Horse Bid Protections. The Debtors, in consultation with any Committee, may (i) establish initial overbid minimum and subsequent bidding increment requirements; (ii) offer each Stalking Horse Bidder a break-up fee and/or expense reimbursement in an amount agreed to by the Debtors (a "Termination Payment"); (iii) provide that, if the Stalking Horse Bidder bids on certain assets at the Auction, the Stalking Horse Bidder will be entitled to a credit in the amount of its Termination Payment against the increased purchase price for the assets; and (iv) provide other appropriate and customary protections to a Stalking Horse Bidder (the Termination Payment and the other bid protection described in this paragraph collectively are referred to as the "Stalking Horse Bid Protections").

Objections to Designation of Stalking Horse Bidders. Any objections (each, a "Stalking Horse Objection") to the designation of a Stalking Horse Bidder, including any Stalking Horse Bid Protections pursuant to the terms and provisions of a Stalking Horse Agreement, must (i) be in writing; (ii) state the name and address of the objecting party and the amount and nature of the Claim or Interest of such party; (iii) state with particularity the basis and nature of any objection; (iv) conform to the Bankruptcy Rules and the Local Rules; and (v) be served upon the Notice Parties³ within seven (7) calendar days after the filing of the relevant Notice of Stalking Horse Bidder. If no timely Stalking Horse Objection is filed and served with respect to the Stalking Horse Bid, upon expiration of the objection deadline, the Debtors will submit a proposed order approving the Stalking Horse Bidder and the Stalking Horse Bid to the Court, which may enter such order without a hearing, including with respect to any Stalking Horse Bid Protections.

For all purposes under the Bid Procedures, any Stalking Horse Bidder approved as such pursuant to these Bid Procedures and the Bid Procedures Order shall be considered a Qualified Bidder, and the applicable Stalking Horse Bid shall be considered a Qualified Bid. In the event that the applicable Stalking Horse Bid is the only Qualified Bid received by the Debtors in respect of the applicable assets by the Bid Deadline, the Debtors may cancel the Auction.

³ Notice Parties means: (a) the Debtors; (b) the Committee; (c) the Office of the United States Trustee; and (d) all parties who have appeared in these Chapter 11 Cases pursuant to Bankruptcy Rule 2002.

Bid Deadline

A Potential Bidder that desires to make a bid on any of the Debtors' assets shall deliver electronic copies of its bid so as to be received no later than March 29, 2024 at 4:00 p.m. (ET) (the "**Bid Deadline**"); provided that, the Debtors may extend the Bid Deadline without further order of the Court subject to providing notice to all Potential Bidders and any Stalking Horse Bidders. The submission of a bid by the Bid Deadline shall constitute a binding and irrevocable offer to acquire the assets specified in such bid. Any party that does not submit a bid by the Bid Deadline will not be allowed to (i) submit any offer after the Bid Deadline or (ii) participate in any Auction. Bids should be submitted by email to the following Debtor representatives:

SSG Advisors LLC	J. Scott Victor	jsvictor@ssgca.com
	Teresa Kohl	tkohl@ssgca.com
Wilmer Cutler Pickering Hale and Dorr LLP	George W. Shuster Jr.	george.shuster@wilmerhale.com
	Benjamin Loveland	benjamin.loveland@wilmerhale.com
Landis Rath & Cobb LLP	Mathew B. McGuire	mcguire@lrclaw.com
	Joshua B. Brooks	brooks@lrclaw.com

Form and Content of Qualified Bid

A bid is a signed document from a Potential Bidder received by the Bid Deadline that identifies the purchaser by its legal name and any other party that will be participating in connection with the bid, and includes the material terms of the offer to purchase a portion of or substantially all of the Debtors' assets (a "**Bid**"). To constitute a "Qualified Bid" a Bid must include, at a minimum, the following:

- i. **Acquired Assets.** Each Bid must clearly identify, in writing and as applicable, the particular assets the Potential Bidder seeks to acquire from the Debtors, including any contracts and leases of the Debtors that would be assumed and assigned in connection with a proposed Sale Transaction.⁴ For the avoidance of doubt, a Qualified Bid may include a Bid for less than all or substantially all of the Debtors' assets.
- ii. **Purchase Price; Form of Consideration; Cash Requirements; Assumed Liabilities.** Each Bid must clearly set forth, as applicable:
 - (A) **Purchase Price.** Each Bid must clearly identify the purchase price to be paid (the "**Purchase Price**"), and whether the Bid is based on an all-cash

⁴ Specifically, each Bid should indicate its preferred method of addressing the BHC and MIT in-licenses, whether assumption and assignment, renegotiation with the licensors, or other method.

offer or consists of certain non-cash components, including, without limitation and/or the assumption of liabilities;

- (B) Cash Requirements. Each Bid must provide sufficient cash consideration for the payment of any applicable Termination Payment in cash in full;
 - (C) Assumed Liabilities. Each Bid must clearly identify, in writing and as applicable, the particular liabilities, if any, including executory contracts, the Bidder seeks to assume. For the avoidance of doubt, a Qualified Bid may include a bid for less than all or substantially all of the Debtors' liabilities; and
- iii. Proposed APA. Each Bid must include an executed asset purchase agreement (the "Proposed APA") for the assets included in such Bid, together with a redline comparing the Proposed APA to the form APA attached hereto as Exhibit A.
 - iv. Unconditional Offer. A statement that the Bid is formal, binding, and unconditional, is not subject to any further due diligence or financing contingency, and is irrevocable until the Debtors notify the Potential Bidder that such Bid is not a Successful Bid or a Back-Up Bid, or until the first business day after the close of a Sale Transaction.
 - v. Proof of Financial Ability to Perform. Each Bid must contain such financial and other information that allows the Debtors to make a reasonable determination as to the Potential Bidder's financial and other capabilities to consummate a Sale Transaction including, without limitation, such financial and other information setting forth adequate assurance of future performance in satisfaction of the requirements under section 365(f)(2)(B) of the Bankruptcy Code, and the Potential Bidder's willingness to perform under any contracts that are assumed and assigned to such party. Without limiting the foregoing, such information must include current financial statements or similar financial information certified to be true and correct as of the date thereof, proof of financing commitments if needed to consummate the transaction (not subject to, in the Debtors' discretion, any unreasonable conditions), contact information for verification of such information, including any financing sources, and any other information reasonably requested by the Debtors necessary to demonstrate that such Potential Bidder has the ability to consummate a Sale Transaction in a timely manner.
 - vi. Designation of Contracts and Leases. Each Bid must identify with particularity each and every executory contract and unexpired lease, the assumption and assignment of which is a condition to closing a Sale Transaction;⁵ **provided, however,** that the Bid may allow for the Potential Bidder to remove executory contracts and unexpired leases from the list of contracts to be assumed and assigned any time prior to the closing of a Sale Transaction; **provided, further, however,** that to the extent the Debtors identify any additional executory contracts or

⁵ See FN 4 above.

unexpired leases after the Bid is submitted, the Bid may allow for the Potential Bidder to add such executory contracts and unexpired leases to the list of contracts to be assumed and assigned any time from and after the Bid is submitted.

- vii. Required Approvals. A statement or evidence (1) of the Potential Bidder's plan and ability to obtain all requisite governmental, regulatory, or other third-party approvals; and (2) that the Bid is reasonably likely to be consummated, if selected as the Successful Bid, within a time frame required by the Bid Procedures Order and otherwise acceptable to the Debtors.
- viii. Authorization. Each Bid must include evidence of corporate authorization and approval from the Potential Bidder's board of directors (or comparable governing body) with respect to the submission, execution, and delivery of a Bid, participation in the Auction, and closing of the transactions contemplated by the Potential Bidder's Proposed APA in accordance with the terms of the Bid and these Bid Procedures.
- ix. No Entitlement to Expense Reimbursement or Other Amounts. With the exception of any Stalking Horse Bid, expressly state that the Bid does not entitle the Potential Bidder to any break-up fee, termination fee, expense reimbursement or similar type of payment or reimbursement, and a waiver of any substantial contribution administrative expense claims under section 503(b) of the Bankruptcy Code related to the bidding process.
- x. Joint Bids. The Debtors may approve joint Bids in their reasonable discretion on a case-by-case basis.
- xi. Representations and Warranties. Each Bid must include the following representations and warranties:
 - (A) a statement that the Potential Bidder has had an opportunity to conduct any and all due diligence regarding the applicable assets prior to submitting its Bid;
 - (B) a statement that the Potential Bidder has relied solely upon its own independent review, investigation, and/or inspection of any relevant documents and the assets in making its Bid and did not rely on any written or oral statements, representations, promises, warranties, or guaranties whatsoever, whether express or implied, by operation of law or otherwise, regarding the assets or the completeness of any information provided in connection therewith, except as expressly stated in the representations and warranties contained in the Potential Bidder's Proposed APA ultimately accepted and executed by the Debtors;
 - (C) a statement that the Potential Bidder agrees to serve as Back-Up Bidder, if its Bid is selected as the next or highest or next best bid after the Successful Bid with respect to the applicable assets;

- (D) a statement that the Potential Bidder has not engaged in any collusion with respect to the submission of its Bid; and
 - (E) a statement that the Potential Bidder agrees to be bound by the terms of the Bid Procedures.
- xii. A Potential Bidder must also accompany its Bid with:
- (A) a cash deposit in the amount of ten percent (10%) of the Purchase Price (a “Good Faith Deposit”);
 - (B) the contact information of the specific person(s) whom the Debtors or their advisors should contact in the event that the Debtors have any questions or wishes to discuss the Bid submitted by the Potential Bidder;
 - (C) a covenant to cooperate with the Debtors to provide pertinent factual information regarding the Potential Bidder’s operations reasonably required to analyze issues arising with respect to any applicable regulatory requirements; and
 - (D) if the value of a Bid includes additional non-cash components, a detailed analysis of the value of any additional non-cash component of the Bid and backup documentation to support such value.

Good Faith Deposit

A Good Faith Deposit must be deposited, prior to the Bid Deadline, with an escrow agent selected by the Debtors (the “Escrow Agent”) pursuant to an escrow agreement to be provided by the Debtors. To the extent a Qualified Bid is modified before, during, or after the Auction, the Debtors reserve the right to require that such Qualified Bidder adjust its Good Faith Deposit so that it equals ten percent (10%) of the Purchase Price. If a Qualified Bidder is required to adjust its Good Faith Deposit, its status as a Qualified Bidder shall be suspended pending satisfaction of such adjustment.

Review of Bids; Designation of Qualified Bids

The Debtors, in consultation with the Committee, if any, will evaluate Bids that are timely submitted and may engage in negotiations with Potential Bidders who submitted Bids as the Debtors deem appropriate in the exercise of their business judgment, based upon the Debtors’ evaluation of the content of each Bid.

A Bid received for assets that is determined by the Debtors (in consultation with the Committee) to meet the requirements set forth herein will be considered a “Qualified Bid” and any bidder that submits a Qualified Bid (including any Stalking Horse Bid) will be considered a “Qualified Bidder.”

By no later than April 1, 2024 (the “Qualified Bid Deadline”), the Debtors shall determine, in their reasonable judgment (after consultation with the Committee, if any) which of the Bids

received by the Bid Deadline qualify as a Qualified Bid. The Debtors shall notify each Bidder who submits a Qualified Bid of its status as a Qualified Bidder by the Qualified Bid Deadline.

In evaluating the Bids, the Debtors may take into consideration the following non-binding factors:

1. the amount of the purchase price and/or other non-cash consideration, as applicable, set forth in the Bid;
2. the assets included in or excluded from the Bid, including any executory contracts or leases proposed to be assumed;
3. the value to be provided to the Debtors under the Bid, including the net economic effect upon the Debtors' estates, taking into account any Stalking Horse Bidder's rights to any Termination Payment;
4. any benefit to the Debtors' bankruptcy estates from any assumption of liabilities or waiver of liabilities;
5. the transaction structure and execution risk, including conditions to, timing of, and certainty of closing; termination provisions; availability of financing and financial wherewithal to meet all commitments; and required governmental or other approvals;
6. the impact on employees and employee claims against the Debtors;
7. the impact on trade creditors; and
8. any other factor the Debtors may reasonably deem relevant consistent with their fiduciary duties.

The Debtors reserve the right to work with any Potential Bidder in advance of the Auction to cure any deficiencies in a Bid that is not initially deemed a Qualified Bid. The Debtors may amend or waive the conditions precedent to being a Qualified Bidder at any time, in their reasonable business judgment and in a manner consistent with their fiduciary duties and applicable law (as reasonably determined in good faith by the Debtors in consultation with their legal counsel).

The Debtors may accept a single Bid or multiple partial Bids for non-overlapping assets such that, if taken together, such multiple partial bids would otherwise meet the standards for a single Qualified Bid as to any assets or combinations of assets that the Debtors determine to auction (in which event those multiple bidders shall be treated as a single Qualified Bidder for purposes of the Auction).

Without the written consent of the Debtors, a Qualified Bidder may not modify, amend, or withdraw its Qualified Bid, except for proposed amendments to increase the Purchase Price or otherwise improve the terms of the Qualified Bid for the Debtors during the period that such Qualified Bid remains binding as specified herein; provided that, any Qualified Bid may be improved at the Auction as set forth in these Bid Procedures.

The Debtors shall make a determination regarding the following:

- (A) the assets and/or any combination of assets to be auctioned by the Debtors; and

- (B) which Bids have been determined to be Qualified Bids and the applicable assets relating to such Qualified Bids.

Failure to Receive Qualified Bids For Substantially Similar Assets

If no Qualified Bid (other than the applicable Stalking Horse Bid, if any) is received by the Qualified Bid Deadline, the Debtors will not conduct the Auction, and shall file a notice with the Court indicating that no Auction will be held. The Debtors shall also publish such notice on the website of its claims and noticing agent, [https:// www.kccllc.net/invivo](https://www.kccllc.net/invivo).

Auction Procedures

If the Debtors receive two or more Qualified Bids for substantially the same assets, the Debtors may, in their business judgment, conduct the Auction in person or by remote audio and/or video link on April 3, 2024, beginning at 10:00 a.m. (ET) at the offices of Landis Rath & Cobb LLP, 919 N. Market Street, Wilmington, DE 19801. Only a Qualified Bidder will be eligible to participate at the Auction, subject to such limitations as the Debtors may impose in good faith. In addition, the U.S. Trustee and professionals and/or other representatives of the Debtors, Committee, and any creditors or equity holders of the Debtors shall be permitted to attend and observe the Auction. Each Qualified Bidder shall be required to confirm, both before and after the Auction, that it has not engaged in any collusion with respect to the submission of any bid, the bidding, or the Auction.

The Debtors, in consultation with the Committee, if any, may adopt rules for the Auction at any time that the Debtors reasonably determine to be appropriate to promote a value-maximizing auction. Any rules developed by the Debtors will provide that all bids in the Auction will be made and received on an open basis, and all other bidders participating in the Auction will be entitled to be present for all bidding with the understanding that the true identity of each bidder placing a bid at the Auction will be fully disclosed to all other bidders participating in the Auction and that all material terms of a bid submitted in response to any successive bids made at the Auction will be disclosed to all other bidders. Each Qualified Bidder will be permitted what the Debtors reasonably determine to be an appropriate amount of time to respond to the previous bid at the Auction. The Auction will be conducted openly and shall be transcribed or recorded.

The Debtors may, in their discretion and in consultation with the Committee, if any, identify the highest or otherwise best Qualified Bid as the successful bid (a “Successful Bid” and the bidder submitting such bid, a “Successful Bidder”). The Debtors may also identify a Qualified Bidder that submitted the next highest or otherwise best Qualified Bid as a back-up bid (a “Back-Up Bid” and the bidder submitting such bid, a “Backup Bidder”). A Back-Up Bid shall remain open and irrevocable until the earliest to occur of (i) consummation of a Sale Transaction with the Successful Bidder and (ii) the release of such Back-Up Bid by the Debtors in writing (such date, the “Back-Up Bid Expiration Date”). If a Sale Transaction with a Successful Bidder is terminated prior to the Back-Up Bid Expiration Date, the Back-Up Bidder shall be deemed a Successful Bidder and shall be obligated to consummate the Back-Up Bid as if it were a Successful Bid. Provided, however, that the Debtors are not required to accept any bid or designate a Successful Bidder or Back-Up Bidder.

Within one day after the Auction, a Successful Bidder shall submit to the Debtors fully executed documentation memorializing the terms of a Successful Bid. A Successful Bid may not be assigned to any party without the consent of the Debtors.

At any time before entry of an order approving an applicable Sale Transaction envisioned by a Qualified Bid, the Debtors reserve the right to and may reject such Qualified Bid if such Qualified Bid, in the Debtors' judgment (after consultation with the Committee, if any), is: (i) inadequate or insufficient; (ii) not in conformity with the requirements of the Bankruptcy Code, these Bid Procedures, or the terms and conditions of the applicable Sale Transaction; or (iii) contrary to the best interests of the Debtors and their estates.

Post-Auction Process

By the earlier of (a) five (5) business hours of the close of the Auction or (b) noon of the day after the close of the Auction, or as soon as reasonably practicable thereafter, the Debtors shall file with the Court a notice of a Successful Bid, Successful Bidder, Back-Up Bid, and Back-Up Bidder. Unless otherwise required pursuant to the Debtors' fiduciary duties, the Debtors shall not consider any bids submitted after the conclusion of the Auction.

Within seven (7) days after the Auction, the Debtors shall direct the Escrow Agent to return the deposit of any bidder, who is not declared a Successful Bidder or Back-Up Bidder. Within five (5) days after the Back-Up Bid Expiration Date, the Debtors shall direct the Escrow Agent to return the deposit of a Back-Up Bidder. Upon the authorized return of any such deposit, the bid of such Potential Bidder, Qualified Bidder or Back-Up Bidder, as applicable, shall be deemed revoked and no longer enforceable.

A Successful Bidder's deposit shall be applied against the cash portion of the purchase price of such bidder's Successful Bid upon the consummation of a Sale Transaction.

In addition to the foregoing, the deposit of a Qualified Bidder will be forfeited to the Debtors if (i) the Qualified Bidder attempts to modify, amend, or withdraw its Qualified Bid, except as permitted herein, during the time the Qualified Bid remains binding and irrevocable or (ii) the Qualified Bidder is selected as a Successful Bidder or Back-Up Bidder and refuses or fails to enter into the required definitive documentation or to consummate a Sale Transaction according to these Bid Procedures.

Notices Regarding Assumption and Assignment

The Debtors shall provide all notices regarding the proposed assumption and assignment of contracts and leases in accordance with the Assumption and Assignment Procedures included in the Bid Procedures Order.

Sale Hearing

If the Debtors elect to proceed with a Sale Transaction, the Debtors will seek the entry of an order authorizing and approving the Sale Transaction at a hearing before the Court on April 5, 2024, or at a date otherwise designated by the Court (the "Sale Hearing"). The Debtors, in the exercise of their business judgment, may adjourn the Sale Hearing without notice or with limited

and shortened notice to parties, including by (i) an announcement of such adjournment at the Sale Hearing or at the Auction or (ii) the filing of a notice of adjournment with the Court prior to the commencement of the Sale Hearing.

Objections to a Sale Transaction, including any objection to the sale of the Debtors' assets free and clear of liens, claims, encumbrances, and other interests pursuant to section 363(f) of the Bankruptcy Code (each, a "Sale Objection"), shall (i) be in writing; (ii) state the name and address of the objecting party and the amount and nature of the Claim or Interest of such party; (iii) state with particularity the basis and nature of any objection, and provide proposed language that, if accepted and incorporated by the Debtors, would obviate such objection; (iv) conform to the Bankruptcy Rules and the Local Rules; (v) be filed with the Court; and (vi) be served upon the Notice Parties (as defined in the in the Bid Procedures Order) by March 29, 2024 at 4:00 p.m. (ET) (the "Sale Objection Deadline"); provided that, the Debtors may extend the Sale Objection Deadline, as the Debtors deem appropriate in the exercise of their reasonable business judgment. If a timely Sale Objection cannot otherwise be resolved by the parties, such objection shall be heard by the Court at the Sale Hearing.

A Successful Bidder shall appear at the Sale Hearing and be prepared to have a representative(s) testify in support of the Successful Bid and such Successful Bidder's ability to close in a timely manner and provide adequate assurance of its future performance under any and all executory contracts and unexpired leases to be assumed and/or assigned as part of the proposed transaction.

Any party who fails to file with the Court and serve on the Objection Notice Parties a Sale Objection by the Sale Objection Deadline may be forever barred from asserting, at the Sale Hearing or thereafter, any Sale Objection to the relief requested in the Motion with regard to a Successful Bidder, or to the consummation and performance of a Sale Transaction, contemplated by an asset purchase agreement between the Debtors and a Successful Bidder, including the transfer of assets to a Successful Bidder, free and clear of all liens, claims, encumbrances, and other interests pursuant to section 363(f) of the Bankruptcy Code. Failure to object shall constitute consent for the purposes of section 363(f)(2) of the Bankruptcy Code.

Consent to Jurisdiction and Authority as Condition to Bidding

All bidders that participate in the bidding process shall be deemed to have (i) consented to the core jurisdiction of the Court to enter any order or orders, which shall be binding in all respects, in any way related to these Bid Procedures, the bid process, the Auction, the Sale Hearing, or the construction and enforcement of any agreement or any other document relating to an applicable Sale Transaction; (ii) waived any right to a jury trial in connection with any disputes relating to these Bid Procedures, the bid process, the Auction, the Sale Hearing, or the construction and enforcement of any agreement or any other document relating to a Sale Transaction; and (iii) consented to the entry of a final order or judgment in any way related to these Bid Procedures, the bid process, the Auction, the Sale Hearing, or the construction and enforcement of any agreement or any other document relating to an applicable Sale Transaction if it is determined that the Court would lack Article III jurisdiction to enter such a final order or judgment absent the consent of the parties.

Reservation of Rights

The Debtors reserve the right to, in their reasonable business judgment, in a manner consistent with their fiduciary duties and applicable law to modify these Bid Procedures; waive terms and conditions set forth herein with respect to all Potential Bidders; extend the deadlines set forth herein; announce at the Auction modified or additional procedures for conducting the Auction; alter the assumptions set forth herein; and provide reasonable accommodations to any Stalking Horse Bidder with respect to such terms, conditions, and deadlines of the bidding and Auction process to promote further bids on any assets, in each case, to the extent not materially inconsistent with these Bid Procedures and the Bid Procedures Order. The Debtors shall not be obligated to consummate or pursue any transaction with respect to any asset.

EXHIBIT A

ASSET PURCHASE AGREEMENT

BY AND BETWEEN

[PURCHASER],

as Purchaser,

and

INVIVO THERAPEUTICS HOLDINGS CORP.

and

INVIVO THERAPEUTICS CORPORATION,

collectively, as Seller

Dated as of [●], 2024

THIS DOCUMENT DOES NOT INDICATE ANY DECISION TO SELL ANY ASSETS, OR TO TAKE ANY OTHER ACTION DESCRIBED HEREIN. THIS DOCUMENT IS NOT INTENDED TO CREATE, NOR WILL IT BE DEEMED TO CREATE, A LEGALLY BINDING OR ENFORCEABLE OFFER, ACCEPTANCE OF AN OFFER, OR AGREEMENT, OF ANY TYPE OR NATURE, UNLESS AND UNTIL AGREED TO AND EXECUTED BY ALL PARTIES.

TABLE OF CONTENTS

	<u>Page</u>
ARTICLE I.	
DEFINITIONS AND EFFECTIVENESS.....	1
1.1 Certain Definitions	1
ARTICLE II.	
ACQUISITION AND TRANSFER OF ASSETS; ASSUMPTION OF LIABILITIES	11
2.1 Transfer of Assets.....	11
2.2 Excluded Assets.....	12
2.3 Assumed Liabilities.....	12
2.4 Excluded Liabilities.....	12
2.5 Assumed Executory Contracts	12
2.6 Waiver and Release of Acquired Avoidance Actions.....	12
2.7 Liens Attach to Sale Proceeds.....	13
ARTICLE III.	
CONSIDERATION	13
3.1 Consideration.....	13
3.2 Payment of Purchase Price at Closing	13
3.3 Assumed Liabilities.....	13
3.4 Deposit.....	13
3.5 Allocation of Consideration	13
ARTICLE IV.	
CLOSING AND TERMINATION	14
4.1 Closing.....	14
4.2 Conveyances at Closing	14
4.3 Additional Deliveries	14
4.4 Transaction Expenses	15
4.5 Prorations.....	15
4.6 Termination of Agreement	15
4.7 Procedure Upon Termination	16
4.8 Effect of Termination	17

ARTICLE V.

	REPRESENTATIONS AND WARRANTIES OF SELLER	17
5.1	Organization and Power	17
5.2	Corporate Authorization.....	17
5.3	Binding Effect	17
5.4	Ownership of Acquired Assets.....	17
5.5	Taxes.....	18
5.6	Real Property	18
5.7	Intellectual Property	18
5.8	Litigation	19
5.9	Environmental Matters	19
5.10	Compliance With Laws	19
5.11	Permits; Regulatory Matters.....	20
5.12	Labor Matters	Error! Bookmark not defined.
5.13	Finders’ Fees	20
5.14	No Other Representations or Warranties	20

ARTICLE VI.

	REPRESENTATIONS AND WARRANTIES OF PURCHASER	21
6.1	Organization and Power	21
6.2	Authorization	21
6.3	Binding Effect	21
6.4	Funding.....	21
6.5	Adequate Assurances Regarding Assumed Executory Contracts.....	21
6.6	Finders’ Fees	21
6.7	Good Faith Purchaser	21
6.8	Purchaser Experience	22
6.9	Non-Reliance on Seller Estimates, Projections, Forecasts, Forward- Looking Statements and Business Plans	22

ARTICLE VII.

	CERTAIN COVENANTS.....	22
7.1	Bankruptcy Sale Process.	22
7.2	Stalking Horse Provisions.	23
7.3	Pre-Closing Operating Covenants of Seller.	24

7.4 Access to Information26
 7.5 Reasonable Efforts; Further Assurances of Each Party26
 7.6 Regulatory Affairs27

ARTICLE VIII.

CONDITIONS TO CLOSING27
 8.1 Conditions Precedent to the Obligations of Seller and Purchaser27
 8.2 Conditions Precedent to the Obligations of Seller27
 8.3 Conditions Precedent to the Obligations of Purchaser28

ARTICLE IX.

MISCELLANEOUS28
 9.1 Transfer Taxes28
 9.2 Releases28
 9.3 Survival29
 9.4 Injunctive Relief29
 9.5 Entire Agreement; Amendments and Waivers29
 9.6 Counterparts; Electronic Signatures29
 9.7 Governing Law29
 9.8 Waiver of Jury Trial30
 9.9 Notices30
 9.10 Binding Effect; Assignment31
 9.11 Third Party Beneficiaries31
 9.12 Publicity31
 9.13 Severability31
 9.14 Non-Recourse31
 9.15 Time of the Essence32
 9.16 Miscellaneous32

EXHIBITS

Exhibit A Acquired Assets
 Exhibit B Assumed Executory Contracts
 Exhibit C Assumed Liabilities
 Exhibit D Excluded Assets
 Exhibit E Bill of Sale
 Exhibit F Form of Assignment and Assumption Agreement

SCHEDULES

Schedule 4.5 Prorations Exceptions

ASSET PURCHASE AGREEMENT

This **ASSET PURCHASE AGREEMENT** (this “Agreement”), dated as of [●], 2024, is made and entered into by and among [PURCHASER], a [jurisdiction of organization] [type of entity] (“Purchaser”), and **INVIVO THERAPEUTICS HOLDINGS CORP.**, a Nevada corporation (“Holdings”), and **INVIVO THERAPEUTICS CORPORATION**, a Delaware corporation (“InVivo” and, together with Holdings, “Seller”). Certain capitalized terms used herein are defined in Article I.

RECITALS

WHEREAS, Seller is a research and research and clinical-stage biomaterials and biotechnology company with a focus on the development of its investigational Neuro-Spinal Scaffold implant (the “NSS Implant”) for the treatment of spinal cord injuries (the “Business”);

WHEREAS, Seller commenced a case (the “Chapter 11 Case”) under chapter 11 of title 11 of the United States Code, 11 U.S.C. § 101 et seq. (the “Bankruptcy Code”), in the United States Bankruptcy Court for the District of Delaware (the “Court”);

WHEREAS, Purchaser desires to acquire certain assets of Seller identified herein, and Seller desires to sell, convey, assign, and transfer to Purchaser such assets, pursuant to the terms and conditions of this Agreement;

WHEREAS, it is intended that the Acquired Assets (defined below) will be sold and purchased pursuant to the terms of this Agreement in a sale authorized by the Court pursuant to section 363 of the Bankruptcy Code; and

WHEREAS, in connection with such a sale, it is intended that the Court shall approve the assumption and assignment of certain Executory Contracts (defined below) under section 365 of the Bankruptcy Code.

NOW, THEREFORE, in consideration of the foregoing and the mutual representations, warranties, covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, Purchaser and Seller hereby agree as follows:

ARTICLE I.

DEFINITIONS AND EFFECTIVENESS

1.1 Certain Definitions. For purposes of this Agreement, the following terms used in this Agreement shall have the respective meanings assigned to them below:

(a) “Accounts Receivable” means (i) any and all accounts receivable, trade accounts and other amounts (including overdue accounts receivable, refunds, rebates, and other credits) owed to Seller relating to, or arising in connection with the operation and conduct of, the Business prior to the Closing and any other similar rights of Seller to payment from third parties arising prior to the Closing and the full benefit of all security for such accounts or rights to

payment; (ii) all other accounts or notes receivable of Seller as of the Closing and the full benefit of all security for such accounts or notes receivable; and (iii) any and all claims, remedies or other rights relating to any of the foregoing, together with any interest or unpaid financing charges accrued thereon, in each case that have not been satisfied or discharged prior to the close of business on the day immediately preceding the Closing or have not been written off or sent to collection prior to the close of business on the day immediately preceding the Closing (it being understood that the receipt of a check prior to the close of business on the day immediately preceding the Closing Date shall constitute satisfaction or discharge of the applicable account or note receivable to the extent of the payment represented thereby).

(b) “Acquired Assets” means the assets of Seller related to the Program, as set forth on Exhibit A hereto.

(c) “Acquired Avoidance Actions” means any and all Avoidance Actions against any vendor, customer, or other counterparty of the Business, including without limitation the Persons listed on Annex A-[●] to Exhibit A.

(d) “Acquired Claims” [RESERVED].¹

(e) “Affiliate” means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, such Person, and the term “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through ownership of voting securities, by contract or otherwise.

(f) “Alternative Transaction” means a sale, transfer or other disposition of all or any substantial portion of the Acquired Assets to any Person or Persons other than Purchaser, in any transaction or series of transactions.

(g) “Assumed Executory Contracts” means the Executory Contracts to be assumed and assigned to Purchaser pursuant to section 365 of the Bankruptcy Code in accordance with the Bidding Procedures, as set forth on Exhibit B hereto.

(h) “Assumed Liabilities” means only those liabilities expressly set forth on Exhibit C hereto.²

(i) “Auction” shall have the meaning set forth in the Bidding Procedures.

(j) “Avoidance Action” means any and all claims, rights and causes of action of Seller arising under chapter 5 of the Bankruptcy Code or similar federal, state or local laws.

¹ NTD: Treatment of Acquired Claims to be proposed by Purchaser.

² NTD: Seller would expect any Purchaser to assume royalty obligations in respect of the Specified Licenses.

(k) “Backup Bidder” shall have the meaning set forth in the Bidding Procedures.

(l) “Bankruptcy Matters” means (a) the amount, extent, or type of Cash and Cash Equivalents of Seller or any other Excluded Assets, or any Excluded Liabilities; (b) any failure, in and of itself, of Seller to meet any projections, budgets, plans or forecasts of revenues, earnings or other financial performance measures or operating statistics filed with the Court; or (c) the announcement, commencement, or continuation of the Chapter 11 Cases or any action approved by the Court in the Chapter 11 Case.

(m) “Bankruptcy Rules” means the Federal Rules of Bankruptcy Procedure.

(n) “Bidding Procedures” means the procedures governing the submission, evaluation and qualification of competing bids for the Acquired Assets, and the auction among qualified bidders for the purchase of the Acquired Assets, as described in the Bidding Procedures Order.

(o) “Bidding Procedures Motion” means a motion filed by Seller, reasonably satisfactory in form and substance to Seller, seeking approval of (i) the sale process described in the Sale Motion and the Bidding Procedures, and (ii) the Stalking Horse Provisions.

(p) “Bidding Procedures Order” means an Order of the Court, reasonably satisfactory in form and substance to Seller, approving the sale process described in the Sale Motion and the Bidding Procedures, including, without limitation, the Stalking Horse Provisions.

(q) “Break-Up Fee” shall have the meaning set forth in Section 7.2.

(r) “Business Day” means any day other than a Saturday, Sunday or a legal holiday on which banking institutions in the State of Delaware are not required to open.

(s) “Cash and Cash Equivalents” means all of Seller’s cash (including petty cash but excluding any checks that remain uncashed or uncleared prior to the close of business on the Closing Date), checking account balances, marketable securities, certificates of deposits, time deposits, bankers’ acceptances, commercial paper and government securities and other cash equivalents.

(t) “Cash Purchase Price” means an amount in cash equal to \$[●], subject to adjustment as provided in Section 3.2 and Section 4.5.

(u) “Claim” has the meaning set forth in section 101(5) of the Bankruptcy Code.

(v) “Contract” means any written or oral contract, lease, purchase order, service order, sales order, or instrument or other agreement, arrangement or commitment that is binding upon a Person or its property, and any amendments, modifications or supplements thereto.

(w) “Copyright” means all copyrights, including copyrights in software and in the content contained on any Web site, artwork (including editable jpeg images), packaging material, patient information leaflets, promotional material, advertising material, and those which are registered, applied for registration or used, whether registrable or not, by Seller, and rights to sue for past infringement thereof.

(x) “Cure Costs” means, for any Assumed Executory Contract, the amount required to be paid under section 365 of the Bankruptcy Code to effectuate the assumption and assignment of such Assumed Executory Contract by Seller to Purchaser (giving effect to any mutual agreement with the contract counterparty to such Assumed Executory Contract).

(y) “Deposit” means the good-faith deposit in the amount of \$[●].³

(z) “Deposit Escrow Agent” means the Person serving from time to time as escrow agent under the Deposit Escrow Agreement, provided that counsel to Seller may serve as the Deposit Escrow Agent.

(aa) “Deposit Escrow Agreement” means the escrow agreement being entered into by Seller and Purchaser or their representatives as of the date of this Agreement, reasonably satisfactory in form and substance to Seller and Purchaser, pursuant to which the Deposit Escrow Agent will hold the Deposit, provided that email confirmation of escrow terms from counsel to Seller may serve as the Deposit Escrow Agreement if counsel to Seller serves as the Deposit Escrow Agent.

(bb) “Documents” means all of Seller’s written files, documents, instruments, papers, books, reports, records, tapes, microfilms, photographs, letters, budgets, forecasts, plans, operating records, safety and environmental reports, data, studies and documents, Tax Returns, ledgers, journals, title policies, customer lists, regulatory filings, operating data and plans, research material, technical documentation (design specifications, engineering information, test results, maintenance schedules, functional requirements, operating instructions, logic manuals, processes, flow charts, etc.), user documentation (installation guides, user manuals, training materials, release notes, working papers, etc.), marketing documentation (sales brochures, flyers, pamphlets, web pages, etc.), and other similar materials related to, used in, or held for use in connection with the Program or any of the Acquired Assets, in each case whether or not in electronic form.

(cc) “Encumbrance” means any lien, interest, encumbrance, Claim, right, demand, charge, mortgage, deed of trust, option, pledge, security interest or similar interest, title defect, hypothecation, easement, right of way, restrictive covenant, condition, restriction, encroachment, rights of first refusal, preemptive right, judgment, conditional sale or other title retention agreements and other imposition, imperfection or defect of title or restriction on transfer or use of any nature whatsoever, whether secured or unsecured, choate or inchoate, filed or unfiled, scheduled or unscheduled, recorded or unrecorded, contingent or non-contingent, material or non-

³ NTD: This amount should be 10% of the value of the purchase price.

material, known or unknown; provided, however that the term “Encumbrance” does not include the Assumed Liabilities.

(dd) “Environmental Law” means any applicable law, regulation, order, decree or permit requirement of any governmental jurisdiction relating to: (a) the protection, investigation or restoration of the environment, human health and safety, or natural resources, (b) the handling, use, storage, treatment, transport, disposal, release or threatened release of any Hazardous Substance or (c) noise, odor or wetlands protection.

(ee) “Excluded Assets” means those assets and properties of Seller that are not Acquired Assets including, without limitation, the assets set forth on Exhibit D hereto.

(ff) “Excluded Liabilities” means those Encumbrances or Liabilities of Seller or related to the Acquired Assets or any other assets of Seller, whether actual or contingent, accrued or unaccrued, matured or unmatured, liquidated or unliquidated, or known or unknown, that are not the Assumed Liabilities set forth on Exhibit C hereto.

(gg) “Executory Contracts” means all executory contracts (including licenses) and unexpired leases related to the Business in effect as of the date hereof to which Seller is a party.

(hh) “Expense Reimbursement” shall have the meaning set forth in Section 7.2.

(ii) “FDA” means the United States Food and Drug Administration.

(jj) “Final Order” means an Order or judgment of the Court or any other court of competent jurisdiction entered by the Clerk of the Court or such other court on the docket in Seller’s Chapter 11 Cases or the docket of such other court, which has not been modified, amended, reversed, vacated or stayed and as to which (a) the time to appeal, petition for *certiorari*, or move for a new trial, reargument or rehearing has expired and as to which no appeal, petition for *certiorari* or motion for new trial, reargument or rehearing shall then be pending or (b) if an appeal, writ of *certiorari*, new trial, reargument or rehearing thereof has been sought, such Order or judgment of the Court or other court of competent jurisdiction shall have been affirmed by the highest court to which such Order was appealed, or *certiorari* shall have been denied, or a new trial, reargument or rehearing shall have been denied or resulted in no modification of such Order, and the time to take any further appeal, petition for *certiorari* or move for a new trial, reargument or rehearing shall have expired, as a result of which such Order shall have become final in accordance with Rule 8002 of the Bankruptcy Rules; provided, however, that the possibility that a motion under Rule 60 of the Federal Rules of Civil Procedure, or any analogous rule under the Bankruptcy Rules, may be filed relating to such Order, shall not cause such Order not to be a Final Order.

(kk) “Final Sale Notice” means a notice distributed in accordance with the Bidding Procedures regarding the transactions contemplated by this Agreement and the Sale Order.

(ll) “GAAP” means United States generally accepted accounting principles.

(mm) “Governmental Body” means any government, quasi-governmental entity, or other governmental or regulatory body, agency or political subdivision thereof of any nature, whether foreign, federal, state, provincial or local, or any ministry agency, branch, department, official, entity, instrumentality or authority thereof, or any court or arbitrator (public or private) or any judicial, quasi-judicial or administrative body, or any regulatory body of applicable jurisdiction, including any Regulating Authority.

(nn) “Hazardous Substance” means: (a) any substance that is regulated or which falls within the definition of a “hazardous substance,” “hazardous waste” or “hazardous material” pursuant to any Environmental Law or (b) any petroleum product or by-product, asbestos-containing material, polychlorinated biphenyls, radioactive materials or radon.

(oo) “Initial Notice of Proposed Assumed Executory Contracts” means a notice filed by Seller with the Court in accordance with the Bidding Procedures identifying the Executory Contracts Purchaser intends, as of the date of such notice, to assume as of the Closing Date.

(pp) “Intellectual Property” means all of the following anywhere in the world and all legal rights, title or interest in the following arising under Law: (i) all Patents and applications for Patents and all related reissues, reexaminations, divisions, renewals, extensions, provisionals, continuations and continuations-in-part, including any future applications or filings of the foregoing; (ii) all Copyrights, Copyright registrations and Copyright applications, copyrightable works and all other corresponding rights; (iii) all mask works, mask work registrations and mask work applications and all other corresponding rights; (iv) all advertising material, trade dress and trade names, logos, Internet addresses and domain names, Trademarks and service marks and related registrations and applications, including any intent to use applications, supplemental registrations and any renewals or extensions, all other indicia of commercial source or origin and all goodwill associated with any of the foregoing; (v) all inventions (whether patentable or unpatentable and whether or not reduced to practice), know how, technology, technical data, trade secrets, confidential business information, manufacturing and production processes and techniques, research and development information, clinical trial data and information, safety data and pharmacovigilance data, financial, marketing and business data, pricing and cost information, business and marketing plans, advertising and promotional materials, customer, distributor, reseller and supplier lists and information, correspondence, records, and other documentation, and other proprietary information of every kind; (vi) all computer software (including source and object code), firmware, development tools, algorithms, files, records, technical drawings and related documentation, data and manuals; (vii) all databases and data collections; (viii) all licenses and permits to the extent transferable; (ix) all rights pertaining to the foregoing, including those arising under international treaties and convention rights, (x) all rights and powers to assert, defend and recover title to any of the foregoing, (xi) all rights to assert, defend, sue, and recover damages for any past, present and future infringement, misuse, misappropriation, impairment, unauthorized use or other violation of any rights in or to any of the foregoing, (xii) all proceeds, income, royalties, damages and payments now and/or hereafter due

and payable under and/or in respect of all of the foregoing (including with respect to past, present or future infringement or violation thereof), (xiii) all administrative rights arising from the foregoing, including the right to prosecute applications and oppose, interfere with or challenge the applications of others, the rights to obtain renewals, continuations, divisions, and extensions of legal protection pertaining to any of the foregoing, and (xiv) all other intellectual property rights irrespective of not being registered or applied for registration.

(qq) “Laws” (and each, a “Law”) means all federal, state, provincial, local or foreign laws, statutes, common law, rules, codes, regulations, restrictions, ordinances, Orders, decrees, approvals, directives, judgments, rulings, injunctions, writs and awards of, or issued, promulgated, enforced or entered by, any and all Governmental Bodies, or court of competent jurisdiction, or other legal requirement or rule of law, including common law.

(rr) “Legal Proceeding” means any judicial, administrative or arbitral actions, suits, proceedings (public or private) or claims or any proceedings by or before a Governmental Body.

(ss) “Liability” means, as to any Person, any debt, adverse claim, liability, duty, responsibility, obligation, commitment, assessment, cost, expense, loss, expenditure, charge, fee, penalty, fine, contribution or premium of any kind or nature whatsoever of such Person, whether known or unknown, asserted or unasserted, absolute or contingent, direct or indirect, accrued or unaccrued, liquidated or unliquidated, or due or to become due, including all costs and expenses relating thereto.

(tt) “Material Adverse Effect” means any effect that is materially adverse to the value of the Acquired Assets; provided, however, that (x) any decrease in value of the Acquired Assets that is less than twenty-five percent (25%) shall not be deemed material for purposes of this definition, and (y) no effect (by itself or when aggregated or taken together with any and all other effects) directly or indirectly resulting from, arising out of, attributable to, or related to any of the following shall be deemed to be or constitute a “Material Adverse Effect,” and no effect (by itself or when aggregated or taken together with any and all other such effects) directly or indirectly resulting from, arising out of, attributable to, or related to any of the following shall be taken into account when determining whether a “Material Adverse Effect” has occurred or may, would or could occur: (a) general economic conditions (or changes in such conditions) in the United States or any other country or region in the world, or conditions in the global economy generally; (b) conditions (or changes in such conditions) in the securities markets, credit markets, currency markets or other financial markets in the United States or any other country or region in the world, including (i) changes in interest rates in the United States or any other country or region in the world and changes in exchange rates for the currencies of any countries and (ii) any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market operating in the United States or any other country or region in the world; (c) conditions (or changes in such conditions) in the industries in which Seller conducts business; (d) political conditions (or changes in such conditions) in the United States or any other country or region in the world or acts of war, sabotage or terrorism (including any escalation or general worsening of any such acts of war, sabotage or terrorism) in the United States or any other country or region in the world; (e) earthquakes, hurricanes,

tsunamis, tornadoes, floods, mudslides, wild fires or other natural disasters, weather conditions and other force majeure events in the United States or any other country or region in the world; (f) any global or national health concern, epidemic, disease outbreak, pandemic (whether or not declared as such by any Governmental Body and including the “Coronavirus” or “COVID-19”) or any Law issued by a Governmental Body requiring business closures, quarantine or “sheltering-in-place” or similar restrictions that arise out of such health concern, epidemic, disease outbreak or pandemic (including the “Coronavirus” or “COVID-19”) or any change in such Law following the date of this Agreement; (g) the announcement of this Agreement or the pendency or consummation of the transactions contemplated thereby, including (i) the identity of Purchaser, (ii) the loss or departure of officers or other employees of Seller, (iii) the termination or potential termination of (or the failure or potential failure to renew or enter into) any contracts with suppliers, distributors or other business partners, whether as a direct or indirect result of the loss or departure of officers or employees of Seller or otherwise, and (iv) any other negative development (or potential negative development) in the relationships of Seller with any of its suppliers, distributors or other business partners; (h) any actions taken or failure to take action, in each case, to which Purchaser has approved, consented to or requested; or compliance with the terms of, or the taking of any action required or contemplated by, this Agreement; or the failure to take any action prohibited by this Agreement; (i) changes or developments in law or other legal or regulatory conditions (including rules, regulations, administrative policies, actions, requests, recommendations, determinations, statements, positions, and decisions of the FDA), or the interpretation thereof, or changes in GAAP or other accounting standards (or the interpretation thereof), or that result from any action taken for the purpose of complying with any of the foregoing; (j) any product or product candidate of Seller, including any change, event, circumstance or development relating to the potential or actual use or sale of any such product or product candidate, the suspension, recall, rejection, refusal of, request to refile or any delay in obtaining or making any regulatory application or filing relating to any such product or product candidate or any clinical trial in respect thereof, any other negative actions, requests, recommendations, determinations, statements, positions, or decisions of the FDA or any other Governmental Body relating to any such product or product candidate or any clinical trial in respect thereof, any other competitive or regulatory development affecting any such product or product candidate, or the failure to conduct successful clinical trials on a timely basis for any such product candidate; (l) any product or product candidate of any Person (other than Seller), including the entry into the market of any product potentially or actually competitive with any product or product candidate of Seller; (l) any clinical trials or studies undertaken by any Person and any date resulting therefrom or other results thereof, and any negative publicity or unfavorable media attention resulting therefrom; (m) any fees or expenses incurred in connection with the transactions contemplated by this Agreement; (n) changes in Seller’s stock price or the trading volume of Seller’s stock, or any failure by Seller to meet any public estimates or expectations of Seller’s revenue, earnings or other financial performance or results of operations for any period, or any failure by Seller to meet any internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations (but not, in each case, the underlying cause of such changes or failures, unless such changes or failures would otherwise be excepted from this definition), or any cessation, suspension, or other limitation on the listing or trading of Seller’s stock; (o) any legal proceedings made or brought by any of the current or former stockholders of Seller (on their own behalf or on

behalf of Seller) against Seller, Purchaser, or any of their directors or officers, including legal proceedings arising out of or in connection with any other transactions contemplated by or this Agreement; or (p) any Bankruptcy Matters.

(uu) “Order” means any order, writ, judgment, injunction, decree, stipulation, determination, decision, verdict, ruling, subpoena, or award entered by or with any Governmental Body (whether temporary, preliminary or permanent).

(vv) “Overbid Protection” shall have the meaning set forth in Section 7.2(a) of this Agreement.

(ww) “Patents” means all patents and industrial designs, including any continuations, divisionals, continuations-in-part, renewals, reissues and applications for any of the foregoing, and rights to pursue future applications and filings for any of the foregoing and to rights to sue for past infringement thereof.

(xx) “Permits” means all licenses, permits (including environmental, construction and operation permits), provider numbers, franchises, certificates, approvals, consents, waivers, clearances, exemptions, classifications, registrations, orders and other similar documents and authorizations issued by any Governmental Body and/or any self-regulatory body or organization to or for the benefit of Seller and used, or held for use, in connection with the operation of the Business or applicable to ownership of the Acquired Assets or assumption of the Assumed Liabilities.

(yy) “Person” means an individual, corporation, partnership, limited liability company, unlimited liability company, joint venture, association, trust, unincorporated organization, labor union, estate, Governmental Body or other entity or group.

(zz) “Petition Date” means the date Seller commences its Chapter 11 Cases under chapter 11 of the Bankruptcy Code in the Court.

(aaa) “Program” means Seller’s NSS Implant development program, including all rights to the NSS Implant and all indications thereof and improvements thereon as of the date of this Agreement.

(bbb) “Regulatory Approvals” means any consents, waivers, approvals, Orders, Permits or authorizations of any Governmental Body required in connection with the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereunder.

(ccc) “Representatives” means, with respect to any Person, such Person’s directors, managers, officers, employees, investment bankers, attorneys, accountants and other advisors or representatives.

(ddd) “Sale” means the transactions contemplated by this Agreement whereby Purchaser purchases the Acquired Assets free and clear of all Encumbrances in accordance with section 363 of the Bankruptcy Code.

(eee) “Sale Hearing” means the hearing before the Court to approve this Agreement and seeking entry of the Sale Order.

(fff) “Sale Motion” means a motion filed by Seller, reasonably satisfactory in form and substance to Seller and Purchaser, (a) seeking approval of this Agreement and the transactions contemplated herein, including the sale of Seller’s assets, free and clear of all Encumbrances and the assumption and assignment of all Assumed Executory Contracts, to Purchaser, and (b) seeking an order containing, without limitation, a finding that Purchaser has acted in good faith and is entitled to the protections of section 363(m) of the Bankruptcy Code.

(ggg) “Sale Order” means an Order of the Court, reasonably satisfactory in form and substance to Seller and Purchaser, (a) approving this Agreement and the transactions contemplated herein, including, without limitation, the sale of the Acquired Assets free and clear of all Encumbrances, and the assumption and assignment of all Assumed Executory Contracts, to Purchaser, and (b) including, without limitation, a finding that Purchaser has acted in good faith and is entitled to the protections of section 363(m) of the Bankruptcy Code.

(hhh) “SEC” means the United States Securities and Exchange Commission.

(iii) “Seller’s Knowledge” means the actual knowledge as of the date hereof (without any duty to inquire or investigate) of the individuals identified on Schedule [●].

(jjj) “Seller Owned Intellectual Property” means any Intellectual Property owned by Seller that is material to the Business as currently conducted.

(kkk) “Seller SEC Reports” means all registration statements, forms, reports and other documents filed by Seller with the SEC since January 1, 2022 or that Seller may file after the date hereof until the Closing (including exhibits and all other information incorporated therein).

(lll) “Specified Licenses” means [●].⁴

(mmm) “Stalking Horse Provisions” means the provisions described in Section 7.2 of this Agreement.

(nnn) “Subsidiary” means, with respect to any Person, (a) any other Person that directly, or indirectly through one or more intermediaries, is controlled by such Person; or (b) any other Person where a majority of its equity interests are held, directly, or indirectly through one or more intermediaries, by such Person. For purposes of this definition, “control” (including, with correlative meaning, the terms “controlling” and “controlled”) means the possession, directly

⁴ NTD: This concept is intended to capture any licenses the assumption of which is a Purchaser condition to the sale. Note that Seller expects any Purchaser to address the process and expense of any license consents or modifications that may be required to transfer any license rights or related assets to Purchaser.

or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through ownership of voting securities, by contract or otherwise.

(ooo) “Successful Bidder” shall have the meaning set forth in the Bidding Procedures.

(ppp) “Supplemental Notice of Proposed Assumed Executory Contracts” means a notice filed by Seller with the Court in accordance with the Bidding Procedures identifying the Executory Contracts Purchaser intends, as of the date of such notice, to assume as of the Closing Date and that were not listed on the Initial Notice of Proposed Assumed Executory Contracts.

(qqq) “Tax” and “Taxes” mean any and all taxes, charges, fees, tariffs, duties, impositions, levies or other assessments, imposed by any Laws or Governmental Body, and including any interest, penalties or additional amounts attributable to, imposed upon, or with respect thereto.

(rrr) “Tax Return” means any return, report, information return, declaration, claim for refund or other document (including any schedule or related or supporting information) supplied or required to be supplied to any Governmental Body with respect to Taxes, including attachments thereto and amendments thereof.

(sss) “Third Party” means any Person that is not a party hereto or an Affiliate of a party hereto.

(ttt) “Trademarks” means trademarks, trade names, service marks, designs, logos, brand names, emblems, signs or insignia, slogans, Internet addresses and domain names, other similar designations of source or origin and general intangibles of like nature, together with the registrations and applications for registrations pertaining to any of the foregoing, any derivations of any of the foregoing, all goodwill associated therewith, and rights to sue for past infringement thereof.

(uuu) “Transaction Documents” means this Agreement and any and all other instruments required to effectuate the transactions contemplated by this Agreement.

ARTICLE II.

ACQUISITION AND TRANSFER OF ASSETS; ASSUMPTION OF LIABILITIES

2.1 Transfer of Assets. Subject to approval of the Court, and upon the terms and subject to the conditions and provisions contained herein, at the Closing, Seller shall sell, convey, transfer, assign and deliver to Purchaser, and Purchaser shall acquire and accept from Seller, all of Seller’s right, title, and interest in the Acquired Assets, free and clear of all Encumbrances, subject to Section 2.3 below. Notwithstanding anything to the contrary contained in this Agreement, Purchaser may, by notice to Seller, at any time on or before the Closing Date, in its sole discretion, alter or amend Exhibit A to this Agreement by removing an Acquired Asset.

2.2 Excluded Assets. Notwithstanding anything to the contrary in this Agreement, the Acquired Assets shall not include, and Seller shall retain, all of its rights, title and interest in and to, and shall not sell, convey, transfer, assign or deliver to Purchaser, any of the Excluded Assets.

2.3 Assumed Liabilities. At the Closing, Purchaser shall assume and have sole responsibility for the Assumed Liabilities.

2.4 Excluded Liabilities. For the avoidance of doubt, notwithstanding any other terms, provisions and conditions of this Agreement, Purchaser shall not assume, or otherwise be responsible or liable for, the Excluded Liabilities.

2.5 Assumed Executory Contracts. To the maximum extent permitted by the Bankruptcy Code and in accordance with the Bidding Procedures, each Assumed Executory Contract shall be assumed and assigned to Purchaser pursuant to section 365 of the Bankruptcy Code as of the later of: (a) for any Assumed Executory Contract listed on the Initial Notice of Proposed Assumed Executory Contracts, (1) if no objection is filed by the Closing Date, the Closing Date, or (2) if an objection is filed by the Closing Date, the date such assumption and assignment is approved by an Order of the Court, and (b) for any Assumed Executory Contract listed on a Supplemental Notice of Proposed Assumed Executory Contracts, (1) if no objection is filed by the date specified in such Supplemental Notice of Proposed Assumed Executory Contracts, such date, or (2) if an objection is filed by the date specified in such Supplemental Notice of Proposed Assumed Executory Contracts, the date such assumption and assignment is approved by an Order of the Court.

(a) On or before the Closing Date, Purchaser may, at any time and for any reason, in its sole discretion, elect to remove any Executory Contract from Exhibit B, in which case such Executory Contract shall not be an Assumed Executory Contract, and, at the request of Purchaser on or prior to the Closing Date, Seller shall reject such Executory Contract as soon as practicable following the Closing Date. On or before the date on which the Sale Order is entered, Purchaser may, at any time and for any reason, in its sole discretion, elect to add to Exhibit B any Executory Contract not previously listed thereon, and such Executory Contract shall be an Assumed Executory Contract.

(b) Purchaser shall be responsible and liable for, and shall pay, all Cure Costs.

(c) Seller shall provide Purchaser with no less than five (5) Business Days' prior written notice of the filing of any motion to reject any Executory Contract not designated as an Assumed Executory Contract on Exhibit B as of the date of this Agreement.

2.6 Waiver and Release of Acquired Avoidance Actions. Without limiting the provisions of Section 9.2 hereof, Purchaser shall be deemed to have waived and released all of the Acquired Avoidance Actions immediately following the Closing, and Purchaser shall not take any action to pursue or enforce any of the Acquired Avoidance Actions. Notwithstanding any provision of the contrary herein, Purchaser agrees that, in addition to Seller, any defendant in any Acquired Avoidance Action is a third-party beneficiary of this section and shall be entitled to rely on and enforce this section.

2.7 Liens Attach to Sale Proceeds. Any liens on the Acquired Assets existing as of the Closing Date will attach to the proceeds from the sale of the Acquired Assets according to such liens' relative priorities.

ARTICLE III.

CONSIDERATION

3.1 Consideration. The aggregate consideration (collectively, the "Purchase Price") to be paid for the acquisition of the Acquired Assets shall consist of the following, which shall be payable in accordance with the terms and conditions set forth in this Article III and Article IV: (i) the Cash Purchase Price; *plus* (ii) assumption of the Assumed Liabilities set forth on Exhibit C; *plus* (iii) any Cure Costs.

3.2 Payment of Purchase Price at Closing. The Purchase Price as described in Section 3.1 shall be satisfied at the Closing, subject to the terms and conditions contained in this Article III and Article IV.

3.3 Assumed Liabilities. Purchaser shall assume the Assumed Liabilities pursuant to the assignment and assumption agreement substantially in the form attached hereto as Exhibit F (the "Assignment and Assumption Agreement").

3.4 Deposit. Purchaser has provided the Deposit in good faith to the Deposit Escrow Agent to be held in trust in a non-interest-bearing account pursuant to the terms and conditions of the Deposit Escrow Agreement. If the Closing occurs, the Deposit shall be paid to Seller and applied against the Cash Purchase Price at the Closing. If the Closing does not occur, then the Deposit shall be disbursed as follows: (i) in the event of a termination of this Agreement by Seller pursuant to Section 4.6(n), Seller shall be entitled to retain the Deposit as liquidated damages; (ii) in the event of a termination of this Agreement for any reason other than by Seller pursuant to Section 4.6(n), the Deposit shall be returned to Purchaser; or (iii) in the event of a termination of this Agreement and the Deposit has not been disbursed in accordance with clauses (i) or (ii) of this Section 3.4, then the Deposit shall be disbursed as any court of competent jurisdiction may direct.

3.5 Allocation of Consideration. Within thirty (30) calendar days after the Closing Date, Purchaser shall deliver to Seller an allocation of the Purchase Price among the Acquired Assets (the "Allocation"). Such Allocation shall become part of this Agreement for all purposes. Seller and Purchaser agree to report, pursuant to section 1060 of the Internal Revenue Code of 1986 and the regulations promulgated thereunder, if and when required, the Allocation of the Purchase Price, as adjusted, in a manner entirely consistent with such Allocation in the preparation and filing of all Tax Returns (including IRS form 8594). Neither Seller nor Purchaser shall take any action that would call into question the bona fide nature of such Allocation; and neither party shall take any position for Tax purposes which is inconsistent with such Allocation, unless required to do so under applicable law. Notwithstanding the foregoing, the Allocation shall not be binding upon any person or entity that is not a party to this Agreement.

ARTICLE IV.

CLOSING AND TERMINATION

4.1 Closing. Provided that the conditions to closing set forth herein have been satisfied or, if waiveable, have been waived in accordance herewith, the closing of the transactions contemplated herein (the “Closing”) shall be held via e-mail or such other place as agreed to between Purchaser and Seller, within three (3) calendar days following the first day that all such conditions have been satisfied or, if waiveable, waived, on a Business Day mutually agreeable to Purchaser and Seller. The date on which the Closing occurs in accordance with the previous sentence is referred to as the “Closing Date”. Unless otherwise agreed by the parties in writing, the Closing shall be deemed effective and all right, title and interest of Seller in the Acquired Assets to be acquired by Purchaser hereunder shall be considered to have passed to Purchaser and the assumption of all of the Assumed Liabilities shall be considered to have occurred as of 12:01 a.m. Eastern Time on the Closing Date.

4.2 Conveyances at Closing. At the Closing, Seller and Purchaser shall take the following actions:

(a) Purchaser shall pay to or as directed by Seller, by wire transfer in immediately available funds, the Cash Purchase Price as set forth in Section 3.1, as adjusted (without duplication) pursuant to Section 3.2, Section 3.4, and Section 4.5;

(b) Seller shall deliver or make available to Purchaser possession of the Acquired Assets;

(c) Seller and Purchaser shall execute and deliver to one another a duly executed bill of sale with respect to the Acquired Assets, substantially in the form attached hereto as Exhibit E (the “Bill of Sale”);

(d) Seller shall provide to Purchaser all such other duly executed instruments as Purchaser may reasonably require to effectuate the transfer, assignment and conveyance of the Acquired Assets;

(e) Seller and Purchaser shall execute and deliver to one another the Assignment and Assumption Agreement with respect to the Assumed Liabilities; and

(f) Seller shall provide Purchaser with executed written consents, in form and substance reasonably satisfactory to Purchaser, from each licensor of a Specified License, consenting to the assignment to Purchaser of each corresponding Specified License, unless the Court or another court of competent jurisdiction has entered a Final Order that such consent is not required; provided, however, that any Cure Costs in respect of any Specified License shall be borne by Purchaser and all liabilities in respect of any Specified License shall be Assumed Liabilities.

4.3 Additional Deliveries. After the Closing Date, Seller shall deliver to Purchaser such other instruments and documents, and shall take such other actions, as shall be reasonably requested by Purchaser to vest in Purchaser all of Seller’s right, title and interest in and to the Acquired Assets and otherwise to effectuate the transactions described herein.

4.4 Transaction Expenses. Except as expressly provided herein in respect of the Expense Reimbursement (to the extent due and owing), each party shall bear its own costs and expenses, including attorney, accountant and other consultant fees, in connection with the execution and negotiation of this Agreement and the Transaction Documents and the consummation of the transactions contemplated by this Agreement.

4.5 Prorations. To the extent there are obligations in respect of the Acquired Assets that arose during or relate to the period up to and including the Closing Date (“Pre-Closing Obligations”) and obligations that arose during or relate to the period following the Closing Date, including any and all real or personal property tax obligations (“Post-Closing Obligations”), Purchaser and Seller shall allocate such obligations between themselves on a ratable basis that fairly reflects the portions (up to 100%) of such obligations that are Pre-Closing Obligations and that shall be paid by Seller, and the portions (up to 100%) of such obligations that are Post-Closing Obligations and that shall be paid by Purchaser. To the extent that any net amount is owing to Purchaser or Seller, as the case may be under this Section 4.5 as of the Closing, the Purchase Price shall be decreased or increased, as the case may be, to the extent such prorations are identified as of the Closing, and to the extent such prorations cannot or are not identified until after the Closing, then any net amount owing to Seller or Purchaser shall be paid by the party owing such amount. Any net amount owing to Purchaser under this Section 4.5, shall be an administrative expense of Seller’s bankruptcy estate under section 503(b) and section 507(a)(2) of the Bankruptcy Code. Notwithstanding the foregoing, this Section 4.5 shall not apply to the items listed on Schedule 4.5, which items shall be paid by Seller and/or Purchaser as indicated thereon.

4.6 Termination of Agreement. This Agreement may be terminated at any time prior to the Closing as follows:

- (a) by the mutual written consent of Seller and Purchaser;
- (b) by Purchaser or Seller, if the Petition Date has not occurred on or before [●], 2024.
- (c) by Purchaser or Seller, upon entry into an agreement to consummate (subject to Purchaser’s obligation to serve as a Backup Bidder pursuant to Section 7.1(h)), or the consummation of, an Alternative Transaction, provided, however, that upon a termination pursuant to this Section 4.6(c), Seller shall perform its obligations under Section 4.8 and Section 7.2;
- (d) by Purchaser or Seller, if the Closing shall not have been consummated prior to [●], 2024 (the “Outside Date”); provided, that if the Closing shall not have occurred on or before the Outside Date due to a material breach of any representations, warranties, covenants or agreements contained in this Agreement by Purchaser or Seller, then Purchaser (if Purchaser is in breach) or Seller (if Seller is in breach), respectively, may not terminate this Agreement pursuant to this Section 4.6(d); provided further, that if Purchaser is selected as the Backup Bidder at the conclusion of the Auction, Purchaser shall not be permitted to terminate this Agreement until the earlier of (i) ninety (90) days after entry of the Sale Order if the Closing shall not have occurred by such date, and (ii) the date on which Seller consummates an Alternative Transaction;

(e) by Purchaser, if the Auction has not been held on or before [●], 2024, unless Seller determines in accordance with the Bidding Procedures not to conduct any Auction;

(f) by Purchaser or Seller, if there shall be any Law that makes consummation of the transactions contemplated hereby illegal or otherwise prohibited, or there shall be in effect a final non-appealable order of a Governmental Body of competent jurisdiction restraining, enjoining or otherwise prohibiting the consummation of the transactions contemplated hereby; it being agreed that the parties hereto shall promptly appeal any such adverse determination which is appealable (and pursue such appeal with reasonable diligence);

(g) by Purchaser or Seller, if the Chapter 11 Cases are dismissed or converted to cases under chapter 7 of the Bankruptcy Code, or if a chapter 11 trustee or examiner with expanded powers is appointed, provided, however, that no party shall have such a termination right if it has sought, consented to, or otherwise supported such dismissal or conversion;

(h) by Purchaser, if the Court enters an order granting stay relief to any third party with respect to any material portion of the Acquired Assets, if such stay relief allows such third party to exercise control over, or reduce the value to Purchaser of, the Acquired Assets;

(i) by Purchaser, if there occurs a Material Adverse Effect;

(j) by Purchaser or Seller, if the Sale Order shall not have been entered on or before [●], 2024 (subject to Purchaser's obligation to serve as a Backup Bidder pursuant to Section 7.1(h));

(k) by Purchaser, if the Court enters an Order denying any motion or other filing filed by Seller relating to the sale of the Acquired Assets hereunder;

(l) by Purchaser or Seller, if the Bidding Procedures Order or Sale Order is stayed, reversed, vacated, modified or amended (except as modified or amended in any immaterial respect or with the consent of Purchaser, which consent may be withheld in its sole discretion for material modifications and amendments);

(m) by Seller, if Purchaser fails to satisfy any of its material obligations at Closing;

(n) by Purchaser, if the Auction is conducted and Purchaser is not named by Seller as the Successful Bidder or the Backup Bidder at the conclusion of the Auction; or

(o) by Purchaser, if Seller is in breach of any of its material obligations hereunder and, to the extent such breach is reasonably capable of cure within such period, such breach has not been cured by Seller within fifteen (15) calendar days after written notification by Purchaser.

4.7 Procedure Upon Termination. In the event of a termination of this Agreement pursuant to Section 4.6, (a) written notice thereof shall be given promptly by the terminating party

to the other party hereto, specifying the provision hereof pursuant to which such termination is made, (b) this Agreement shall thereupon terminate and become void and of no further force and effect, and (c) the consummation of the transactions contemplated by this Agreement shall be abandoned without further action of the parties hereto. If this Agreement is terminated as provided herein, each party shall return all documents, work papers and other material of any other party relating to the transactions contemplated hereby, whether so obtained before or after the execution hereof, to the party furnishing the same.

4.8 Effect of Termination. In the event that this Agreement is validly terminated pursuant to Section 4.6, each of the parties shall be relieved of its duties and obligations arising under this Agreement effective as of the date of such termination and such termination shall be without Liability to Purchaser or Seller; provided, however, that Section 4.6, Section 4.7, Section 7.2 (other than in the case of a termination Seller under Section 4.6(n)), and this Section 4.8 shall survive any such termination and shall be enforceable hereunder. In no event shall any termination of this Agreement relieve any party hereto of any Liability for any willful breach of this Agreement by such party. Upon termination of this Agreement, (a) the Deposit shall be delivered to any applicable party as provided in Section 3.4 and (b) Purchaser shall be entitled to the Stalking Horse Provisions to the extent set forth in Section 7.2.

ARTICLE V.

REPRESENTATIONS AND WARRANTIES OF SELLER

Seller represents and warrants to Purchaser that the statements contained in this Article V are true and correct as of the date of this Agreement, except as disclosed in the Seller SEC Reports filed or furnished prior to the date of this Agreement or in filings made by Seller in the Chapter 11 Cases prior to the date of this Agreement.

5.1 Organization and Power. Seller is a corporation duly organized, validly existing and in good standing under the Laws of the State of Nevada. Seller has all requisite corporate power and authority to own the Acquired Assets.

5.2 Corporate Authorization. Subject to entry of the Sale Order, Seller has full corporate power and authority to execute and deliver any and all Transaction Documents and to perform the obligations thereunder. Subject to entry of the Sale Order, the execution, delivery and performance of Seller of the Transaction Documents have been duly and validly authorized and no additional corporate authorization or consent is required in connection therewith.

5.3 Binding Effect. Subject to entry of the Sale Order, this Agreement has been duly executed and delivered by Seller. This Agreement, when executed and delivered by Purchaser, and the other Transaction Documents when executed and delivered, will, upon the entry of the Sale Order, constitute the valid and legally binding obligations of Seller, enforceable against Seller in accordance with their respective terms.

5.4 Ownership of Acquired Assets. Seller owns (or, in the case of Intellectual Property licensed by Seller from a Third Party, including Specified Licenses, has license rights to) all Acquired Assets and, subject to entry of the Sale Order, has the right to transfer all of its right,

title, and interest in the Acquired Assets to Purchaser, in each case, effective at Closing and free and clear of any Encumbrances.

5.5 Taxes. Except for matters that, individually or in the aggregate, are not reasonably likely to have a Material Adverse Effect:

(a) Seller has filed all Tax Returns that it was required to file, and all such Tax Returns were correct and complete. Seller has paid (or caused to be paid) on a timely basis all Taxes due and owing by Seller, other than Taxes that are being contested in good faith through appropriate proceedings and for which the most recent financial statements contained in the Seller SEC Reports reflect an adequate reserve in accordance with GAAP.

(b) As of the date of this Agreement, no examination or audit of any Tax Return of Seller by any Governmental Body is currently in progress or has been proposed in writing. There are no liens for Taxes on any of the assets or properties of Seller.

(c) Seller does not have any liability for any Taxes of any Person (other than Seller) (i) under Treasury Regulation Section 1.1502-6 (or any similar provision of Tax law in any jurisdiction) or as a transferee or successor, or (ii) pursuant to any Tax sharing or Tax indemnification agreement or other similar agreement (other than pursuant to commercial agreements or arrangements that are not primarily related to Taxes).

(d) Seller has not entered into any “listed transaction” within the meaning of Treasury Regulation Section 1.6011-4(b)(2).

5.6 Real Property.

(a) Seller does not own any real property.

(b) Other than general office space leased on a month-to-month basis, Seller does not lease, sublease, or license from any Third Party any real property material to the conduct of the Business as currently conducted.

5.7 Intellectual Property.

(a) To Seller’s Knowledge, Seller owns, licenses, sublicenses or otherwise possesses legally enforceable rights to use all Intellectual Property held by Seller for use in the conduct of the Business as currently conducted (in each case excluding generally commercially available, off-the-shelf software programs), except where the absence of which, individually or in the aggregate, is not reasonably likely to have a Material Adverse Effect, subject, in the case of the Specified Licenses, to the rights of the licensors in respect of the Specified Licenses.

(b) To Seller’s Knowledge, all issued Patents and registrations for Trademarks and Copyrights included in the Seller Owned Intellectual Property are subsisting and have not expired or been cancelled.

(c) To Seller's Knowledge, the conduct of the Program as currently conducted, does not infringe, violate or constitute a misappropriation of any Intellectual Property of any Third Party, except for such infringements, violations and misappropriations that, individually or in the aggregate, are not reasonably likely to have a Material Adverse Effect. Between January 1, 2022 and the date of this Agreement, Seller has not received any written claim or notice from any Person (i) alleging any such infringement, violation or misappropriation or (ii) advising that such Person is challenging or threatening to challenge the ownership, use, validity or enforceability of any Seller Owned Intellectual Property, except, in each case in clauses (i) and (ii), for any such infringement, violation, misappropriation or challenge that is not reasonably likely to have a Material Adverse Effect.

(d) To Seller's Knowledge, Seller has implemented commercially reasonable measures to maintain the confidentiality of the Seller Owned Intellectual Property of a nature that Seller intends to keep confidential.

(e) To Seller's Knowledge, Seller is not in default under any Specified License in any manner that would allow the licensor under any Specified License to terminate such Specified License or otherwise limit or terminate the rights of Seller under such Specified License.

(f) To Seller's Knowledge, no third party is infringing, violating or misappropriating any of the Seller Owned Intellectual Property, except for infringements, violations or misappropriations that, individually or in the aggregate, are not reasonably likely to have a Material Adverse Effect.

5.8 Litigation. As of the date of this Agreement, there is no action, suit, proceeding, claim, arbitration or investigation pending and of which Seller has been notified or, to Seller's Knowledge, threatened against Seller, in each case that, individually or in the aggregate, is reasonably likely to have a Material Adverse Effect. As of the date of this Agreement, there are no judgments, orders or decrees outstanding against Seller that, individually or in the aggregate, are reasonably likely to have a Material Adverse Effect.

5.9 Environmental Matters.

(a) Except for matters that, individually or in the aggregate, are not reasonably likely to have a Material Adverse Effect: (i) Seller is not in violation of any Environmental Law; and (ii) Seller has all permits, licenses and other authorizations required under any Environmental Law and Seller is in compliance with such permits, licenses and other authorizations.

(b) The only representations and warranties of Seller in this Agreement as to any environmental matters or any other obligation or liability with respect to Hazardous Substances or materials of environmental concern are those contained in this Section 5.10. Without limiting the generality of the foregoing, the representations and warranties contained in Sections 5.11 and 5.11 do not relate to environmental matters.

5.10 Compliance With Laws. Seller is, and since January 1, 2022 has been, in compliance with, and is not in violation of, any applicable statute, law or regulation with respect to the conduct of the Program, or the ownership or operation of its properties or assets,

except for failures to comply or violations that, individually or in the aggregate, are not reasonably likely to have a Material Adverse Effect.

5.11 Permits; Regulatory Matters.

(a) Seller or its agents and representatives have all Permits required to conduct the Program as currently conducted, including all such Permits required by the FDA, and any other federal, state or foreign agencies or bodies with material regulatory authority over the Business (together with the FDA, the “Regulating Authorities”), except for such Permits the absence of which, individually or in the aggregate, are not reasonably likely to have a Material Adverse Effect (the “Seller Authorizations”).

(b) Except for matters that, individually or in the aggregate, are not reasonably likely to have a Material Adverse Effect, since January 1, 2022 or that have been disclosed in writing to Purchaser or in Seller’s public filings with the SEC, Seller: (i) has not received any written notice or correspondence from any Regulating Authority alleging or asserting any noncompliance with any Seller Authorizations; and (ii) has not received written notice that any Regulating Authority has taken or is intending to take action to limit, suspend, modify or revoke any Seller Authorizations and, to Seller’s Knowledge, there is no action or proceeding pending or threatened (including any prosecution, injunction, seizure, civil fine, suspension or recall), in each case alleging that such Regulating Authority is considering such action.

5.12 Finders’ Fees. Except for the fees and expenses of SSG Capital Advisors, LLC (“SSG”), the fees and expenses of which will be paid by Seller, there is no investment banker, broker, finder or other intermediary who has been retained by or is authorized to act on behalf of Seller who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement.

5.13 No Other Representations or Warranties. Except for the representations and warranties expressly contained herein, Seller makes no other express or implied representation or warranty. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, THE ACQUIRED ASSETS ARE ASSIGNED, “AS IS,” WITHOUT ANY WARRANTY OF ANY KIND, AND SELLER HEREBY EXPRESSLY DISCLAIMS, TO THE EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL CONDITIONS OR WARRANTIES OF ANY KIND OR NATURE, WHETHER EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTIES OF OR RELATED TO TITLE, NON-INFRINGEMENT, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OR ENFORCEABILITY.

ARTICLE VI.

REPRESENTATIONS AND WARRANTIES OF PURCHASER

Purchaser represents and warrants to Seller that the statements contained in this Article VI are true and correct as of the date of this Agreement.

6.1 Organization and Power. Purchaser is a [corporation] duly organized, validly existing and in good standing under the Laws of the State of [state of organization].

6.2 Authorization. Purchaser has full power and authority to execute and deliver the Transaction Documents and to perform its obligations thereunder. The execution, delivery and performance by Purchaser of the Transaction Documents have been duly and validly authorized and no additional authorization or consent is required in connection therewith.

6.3 Binding Effect. This Agreement has been duly executed and delivered by Purchaser. This Agreement, when executed and delivered by Seller, and the other Transaction Documents when executed and delivered, will constitute the valid and legally binding obligations of Purchaser, enforceable against Purchaser in accordance with their respective terms, subject to bankruptcy, insolvency, reorganization, moratorium and similar Laws of general applicability relating to or affecting creditors' rights and to general equity principles.

6.4 Funding. Purchaser has, without the need to obtain any Third Party debt or equity financing, sufficient and unencumbered funds to consummate the transactions contemplated by this Agreement and to pay the Purchase Price, and Purchaser otherwise has the resources and capabilities (financial and otherwise) to perform its obligations to consummate the transactions contemplated by this Agreement and such performance is not conditioned or contingent in any way upon the receipt of financing from any Person or the availability of funds to Purchaser.

6.5 Adequate Assurances Regarding Assumed Executory Contracts. As of the Closing, Purchaser will be capable of satisfying the conditions contained in sections 365(b)(1)(C) and 365(f) of the Bankruptcy Code with respect to the Assumed Executory Contracts, including without limitation payment of all Cure Costs.

6.6 Finders' Fees. There is no investment banker, broker, finder or other intermediary who has been retained by or is authorized to act on behalf of Purchaser or any Affiliate of Purchaser who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement, except for any fee or commission paid directly by Purchaser and not reducing the Purchase Price in any way.

6.7 Good Faith Purchaser. Purchaser (i) is a "good faith" purchaser, as such term is used in the Bankruptcy Code, and (ii) is entitled to the protections of section 363(m) of the Bankruptcy Code with respect to the transactions contemplated by this Agreement. Purchaser has negotiated and entered into this Agreement in compliance with the Bidding Procedures in compliance with section 363(n) of the Bankruptcy Code, and in good faith and without collusion or fraud of any kind.

6.8 Purchaser Experience. Purchaser is experienced and sophisticated with respect to transactions of the type contemplated by this Agreement. In consultation with experienced counsel and advisors of its choice, Purchaser has conducted its own independent review and analysis of the Acquired Assets, the Assumed Liabilities and the rights and obligations it is acquiring and assuming under the Transaction Documents. Purchaser acknowledges that it and its representatives have been permitted such access to the books and records, contracts and other properties related to the Acquired Assets as it required to complete its review..

6.9 Non-Reliance on Seller Estimates, Projections, Forecasts, Forward-Looking Statements and Business Plans. In connection with the due diligence investigation of Seller by Purchaser and its Affiliates, Purchaser and its Affiliates, have received and may continue to receive after the date hereof from Seller and its Affiliates certain estimates, projections, forecasts and other forward-looking information, as well as certain business plan information, regarding Seller and its business and operations. Purchaser hereby acknowledges that there are uncertainties inherent in attempting to make such estimates, projections, forecasts and other forward-looking statements, as well as in such business plans, with which Purchaser is familiar, that Purchaser is taking full responsibility for making its own evaluation of the adequacy and accuracy of all estimates, projections, forecasts and other forward-looking information, as well as such business plans, so furnished to it (including the reasonableness of the assumptions underlying such estimates, projections, forecasts, forward-looking information or business plans), and that Purchaser will have no claim against Seller, any of its Affiliates, or any other Person, with respect thereto. Accordingly, Purchaser hereby acknowledges and agrees that none of Seller nor any of its Affiliates, nor any other Person, has made or is making any express or implied representation or warranty with respect to such estimates, projections, forecasts, forward-looking statements or business plans (including the reasonableness of the assumptions underlying such estimates, projections, forecasts, forward-looking statements or business plans). Purchaser expressly disclaims that it is relying upon or has relied upon any representations or warranties or other statements or omissions that may have been made by Seller or its Affiliates or any other Person with respect to Seller other than the representations and warranties set forth in this Agreement. Purchaser expressly disclaims any obligation or duty by Seller or its Affiliates to make any disclosures of fact not required to be disclosed pursuant to the specific representations and warranties set forth in this Agreement.

ARTICLE VII.

CERTAIN COVENANTS

7.1 Bankruptcy Sale Process.

(a) Purchaser acknowledges that the Acquired Assets may be subject to competitive bidding and that the Bidding Procedures may be supplemented by other customary procedures consistent with the terms of this Agreement, provided that the Bidding Procedures may not be amended, modified, or supplemented in any respect except as provided for in the Bidding Procedures.

(b) Seller will, as promptly as possible, but in all events in accordance with the Bidding Procedures, file and serve the Initial Notice of Proposed Assumed Executory Contracts, any Supplemental Notice of Proposed Assumed Executory Contracts, and the Final Sale Notice, together with the proposed Sale Order and a copy of the Transaction Documents (with any redactions Seller and Purchaser mutually deem appropriate in accordance with Bankruptcy Rule 9018 and the Bidding Procedures Order), and serve it upon the parties required to be served in accordance with the Bidding Procedures.

(c) Seller will, subject to the provisions of this Agreement and the Bidding Procedures Order, in consultation with Purchaser, use its reasonable best efforts to (x) respond to and resolve all timely objections to the entry of the Sale Order and (y) obtain entry of the Sale Order on or before [●], 2024.

(d) Purchaser will use its reasonable best efforts to assist in obtaining entry of the Sale Order, including furnishing or filing with the Court such affidavits or declarations as Seller may request for the purpose of obtaining entry of the Sale Order.

(e) All motions and other filings by Seller, including any filings regarding notice procedures and all lists of Persons to receive notice, relating to the sale of the Acquired Assets hereunder shall be in form and substance reasonably satisfactory to Purchaser.

(f) Purchaser shall not, without prior written consent of Seller, file, join in, or otherwise support or encourage in any manner whatsoever any motion or other filing relating to the sale of the Acquired Assets hereunder.

(g) In the event that an appeal is taken or a stay pending appeal is requested with respect to the Sale Order, Seller shall promptly notify Purchaser of such appeal or stay request and shall promptly provide to Purchaser a copy of the related notice(s) or order(s). Seller and Purchaser shall use their reasonable best efforts to defend any such appeal or stay request.

(h) Backup Bidder. Sellers and Purchaser agree that, in the event that Purchaser is not the Successful Bidder at the Auction, Purchaser shall act as the Backup Bidder as set forth in the a Bidding Procedures and Bidding Procedures Order, if so named at the Auction; provided that, Purchaser's obligation to act as the Backup Bidder shall terminate on the earlier of (i) ninety (90) days after entry of the Sale Order if the Closing shall not have occurred by such date, and (ii) the date on which Seller consummates an Alternative Transaction. If Purchaser is selected as the Backup Bidder at the conclusion of the Auction, (a) neither such selection itself nor the failure to select the Purchaser as the Successful Bidder shall give rise to a right of Purchaser to terminate this Agreement, and (b) this Agreement shall remain in full force and effect until terminated in accordance with the terms herein.

7.2 Stalking Horse Provisions.⁵

(a) To participate in the bidding process for all or any substantial portion of the Acquired Assets, a Person (other than Purchaser) must submit a bid, in accordance

⁵ NTD: Purchaser should delete Stalking Horse provisions if inapplicable, as necessary.

with the Bidding Procedures, the cash portion of which exceeds the Cash Purchase Price for such assets by no less than the sum of the following: the Break-Up Fee, the maximum amount of the Expense Reimbursement, and \$[●] (such sum, the “Overbid Protection”).

(b) In the event Seller enters into an agreement to consummate or consummates an Alternative Transaction prior to the Outside Date, Seller shall pay Purchaser, in accordance with the Bidding Procedures and by wire transfer to an account designated by Purchaser on the closing date of such Alternative Transaction, an amount equal to \$[●] (the “Break-Up Fee”).

(c) In the event Seller enters into an agreement to consummate or consummates an Alternative Transaction prior to the Outside Date, Seller shall pay Purchaser, in accordance with the Bidding Procedures and by wire transfer to an account designated by Purchaser on the closing date of such Alternative Transaction, reimbursement of all reasonable, documented costs and expenses of Purchaser incurred in connection with Purchaser’s efforts to negotiate and consummate the transactions contemplated by this Agreement (including, without limitation, the fees and expenses of counsel); provided, however, that such reimbursement shall be capped at \$[●] (the “Expense Reimbursement”).

(d) Purchaser shall be entitled to credit bid the amount of the Break-Up Fee and maximum Expense Reimbursement in accordance with section 363(k) of the Bankruptcy Code if Purchaser elects to submit higher bids in the Auction in accordance with the Bidding Procedures.

(e) The Break-Up Fee and Expense Reimbursement shall be paid from any proceeds of an Alternative Transaction, otherwise payable to Seller, provided that if such amounts are not paid from such proceeds, Seller shall remain liable for such amounts.

(f) The Break-Up Fee and Expense Reimbursement (to the extent due and owing) shall be a first-priority administrative expense of Seller’s bankruptcy estate under sections 503(b) and 507(a)(2) of the Bankruptcy Code.

(g) The obligation of Seller to pay, and the payment by Seller of, the Expense Reimbursement (to the extent due and owing), shall in no way limit or otherwise affect the rights of Purchaser to a return of the Deposit, including without limitation the rights of Purchaser under Section 3.4 of this Agreement.

(h) Seller acknowledges and agrees that Purchaser would not have entered into this Agreement but for the provisions in this Section 7.2, and that the provisions of this Section 7.2 are integral to, and shall survive any termination of, this Agreement, other than a termination by Seller under Section 4.6(n).

7.3 Pre-Closing Operating Covenants of Seller.

(a) Until the earlier of Closing or the termination of this Agreement in accordance with Section 4.6, Section 4.7 and Section 4.8, except as expressly provided in this Agreement, or as required by Law, including in connection with the Chapter 11 Cases (it being understood that no provision of this Section 7.3 will require Seller to make any payment to any of

its creditors with respect to any amount owed to such creditors on the Petition Date or which would otherwise violate the Bankruptcy Code), without the consent of Purchaser, Seller shall continue to maintain the Acquired Assets and all books and records on a basis consistent with current practice, and shall continue to make all necessary or appropriate filings and payments with and to Governmental Bodies in connection with the Program in a timely manner, and maintain in effect all existing regulatory approvals required for the ongoing operation of the Program as presently conducted, it being understood that Seller has already taken steps prior to the date of this Agreement to wind down the Business, including suspension of the Program, and it being further understood that Seller shall not be required hereby to make any filing or take any other action with respect to SEC requirements.

(b) Until the earlier of Closing or the termination of this Agreement in accordance with Section 4.6, Section 4.7 and Section 4.8, except as expressly provided in this Agreement, or as required by Law, subject to the limitations of the Bankruptcy Code and the Bankruptcy Rules, without the consent of Purchaser, Seller will not do any of the following, it being understood that Seller has already taken steps prior to the date of this Agreement to wind down the Business:

(i) sell or transfer or create any Encumbrance upon any of the Acquired Assets (other than in the ordinary course of the Business);

(ii) fail to pay any maintenance fees by the due date therefor with respect to any of the Acquired Assets, absent Purchaser's written authorization after good faith consideration, provided that Purchaser reimburse Seller for payment of the portion of such fees attributable to the post-Closing period;

(iii) reject, cancel, terminate, amend, modify, supplement or rescind any Executory Contract or any terms of any Executory Contract without the express written approval of Purchaser, which shall not be unreasonably withheld or delayed, except for the purpose of effecting any changes in applicable Law or implementing regulatory requirements;

(iv) incur any indebtedness for borrowed money.

(v) transfer, sell, assign, abandon, permit to lapse or grant any rights or modify any existing rights to the Acquired Assets, or enter into any settlement regarding the breach or infringement, misappropriation, dilution or other violation of, or challenge the title to, any such Acquired Assets; or

(vi) institute, settle or agree to settle or modify in any manner that is adverse to the Acquired Assets, any litigation, action or other Legal Proceeding before any court or Governmental Body relating to the Acquired Assets and that is or will be an Assumed Liability (provided, however, that nothing herein shall restrict or prevent Seller from instituting, prosecuting, or settling any claims it may have against Purchaser or its Affiliates arising out of or related to this Agreement).

7.4 Access to Information.

(a) Seller agrees that, until the earlier of Closing or the termination of this Agreement in accordance with Section 4.6, Section 4.7 and Section 4.8, Purchaser shall be entitled, through its Representatives, to have such reasonable access to and make such reasonable investigation and examination of the books and records, properties, businesses, assets, accountants, auditors, counsel and operations of Seller as Purchaser's Representatives may reasonably request, provided, however, that Seller shall not be obligated to provide information that it is not permitted to provide under applicable Law. Any such investigations and examinations shall be conducted during regular business hours upon reasonable advance notice and under reasonable circumstances, including Seller's right to have its Representatives accompany Purchaser and its Representatives at the time of any on-site inspection or examination and shall be subject to restrictions under applicable Law. Pursuant to this Section 7.4, Seller shall furnish to Purchaser and its Representatives such financial, operating and property related data and other information as such Persons reasonably request. Seller shall use commercially reasonable efforts to cause its Representatives to reasonably cooperate with Purchaser and Purchaser's Representatives in connection with such investigations and examinations, and Purchaser shall, and use its commercially reasonable efforts to cause its Representatives to, reasonably cooperate with Seller and its Representatives and shall use their reasonable efforts to minimize any disruption to the Business. Purchaser and its Representatives shall be permitted to contact, or engage in discussions or otherwise communicate with Seller's landlords, clients, suppliers and other Persons with which Seller has material commercial dealings, provided, that Purchaser must obtain the prior consent of Seller, which consent shall not be unreasonably withheld or delayed, to initiate such communications and give Seller the opportunity to be present therefor.

(b) No information received pursuant to an investigation made under this Section 7.4 shall be deemed to (i) qualify, modify, amend or otherwise affect any representations, warranties, covenants or other agreements of Seller set forth in this Agreement or any certificate or other instrument delivered to Purchaser in connection with the transactions contemplated hereby, (ii) limit or restrict the remedies available to the parties under applicable Law arising out of a breach of this Agreement or otherwise available at Law or in equity, or (iii) limit or restrict the ability of either party to invoke or rely on the conditions to the obligations of the parties to consummate the transactions contemplated by this Agreement set forth in Article VIII.

7.5 Reasonable Efforts; Further Assurances of Each Party. Until the earlier of Closing or the termination of this Agreement in accordance with Section 4.6, Section 4.7 and Section 4.8, in each case, subject to the limitations of the Bankruptcy Code and Bankruptcy Rules:

(a) each party will use commercially reasonable efforts to take all actions and to do all things necessary, proper or advisable in order to consummate and make effective the transactions contemplated by this Agreement (including satisfaction, but not waiver, of the closing conditions set forth in Article VIII); and

(b) the parties will execute and deliver any documents, instruments or conveyances of any kind and take all other actions which may be reasonably necessary or advisable to carry out the intent of this Agreement and the transactions contemplated herein.

7.6 Regulatory Affairs. Until the earlier of Closing or the termination of this Agreement in accordance with Section 4.6, Section 4.7 and Section 4.8, Seller shall, to the fullest extent permitted by applicable Law, (i) promptly advise Purchaser of the receipt of any communication from the FDA, SEC or any similar state or foreign Governmental Body or other U.S. Governmental Body whether oral, written, electronic or otherwise, (ii) provide Purchaser with a reasonable opportunity to participate in the preparation of any response thereto and the preparation of any other substantive submission or communication to any such Governmental Body and to review any such response, submission or communication prior to the filing or delivery thereof, and (iii) provide Purchaser with the opportunity to participate in any meetings or substantive telephone conversations that Seller or its representatives may have from time to time with any such Governmental Body. Until the earlier of Closing or the termination of this Agreement in accordance with Section 4.6, Section 4.7 and Section 4.8, at Purchaser's request, Seller shall assist Purchaser in obtaining any meetings with, or facilitating communications between, Purchaser and the FDA, SEC or any similar state or foreign Governmental Body or other U.S. Governmental Body.

ARTICLE VIII.

CONDITIONS TO CLOSING

8.1 Conditions Precedent to the Obligations of Seller and Purchaser. The respective obligations of each party to this Agreement to consummate the transactions contemplated herein are subject to the satisfaction or written waiver, on or prior to the Closing Date, of each of the following conditions (any or all of which may be waived in writing by Seller and Purchaser in whole or in part to the extent permitted by applicable Law):

(a) there shall not be in effect any statute, rule, regulation, Law or Order enacted, issued, entered or promulgated by a Governmental Body of competent jurisdiction restraining, enjoining or otherwise prohibiting the consummation of the transactions contemplated hereby;

(b) the Court shall have entered the Bidding Procedures Order and such order shall not have been stayed, reversed, vacated, modified or amended (except as modified or amended in any immaterial respect or with the consent of Purchaser, which consent may be withheld in its sole discretion for material modifications and amendments); and

(c) the Court shall have entered the Sale Order and such order shall not have been stayed, reversed, vacated, modified or amended (except as modified or amended in any immaterial respect or with the consent of Purchaser, which consent may be withheld in its sole discretion for material modifications and amendments).

8.2 Conditions Precedent to the Obligations of Seller. The obligations of Seller to consummate the transactions contemplated by this Agreement are subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions (any or all of which may be waived in writing by Seller in whole or in part to the extent permitted by applicable Law) in addition to those set forth in Section 8.1:

(a) Covenants and Representations. Purchaser shall have performed in all material respects all agreements and covenants required hereby to be performed by Purchaser prior to or at the Closing Date, and the representations and warranties of Purchaser made in Article VI shall be correct and complete in all material respects as of the Closing Date as if made on such date.

(b) Purchase Price. On or prior to the Closing Date, Purchaser shall have satisfied the Purchase Price.

(c) Deliveries. On or prior to the Closing Date, Purchaser shall have delivered to Seller each of the items set forth in Section 4.2 of this Agreement.

8.3 Conditions Precedent to the Obligations of Purchaser. The obligations of Purchaser to consummate the transactions contemplated by this Agreement are subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions (any or all of which may be waived in writing by Purchaser in whole or in part to the extent permitted by applicable Law) in addition to those set forth in Section 8.1:

(a) Covenants and Representations. Except as would not, individually or in the aggregate, be reasonably likely to have a Material Adverse Effect, Seller shall have performed all agreements and covenants required hereby to be performed by Seller prior to or at the Closing Date, and the representations and warranties of Seller in Article V shall be correct and complete as of the Closing Date as if made on such date.

(b) Deliveries. On or prior to the Closing Date, Seller shall have delivered to Purchaser each of the items set forth in Section 4.2 of this Agreement.

(c) Regulatory Approvals. All of the Regulatory Approvals necessary for Purchaser to acquire the Acquired Assets, and assume the Assumed Liabilities, shall have been obtained, and all such Regulatory Approvals shall be in full force and effect.

ARTICLE IX.

MISCELLANEOUS

9.1 Transfer Taxes. Any sales, use, transfer, deed, fixed asset, stamp, documentary stamp or other similar type Taxes and recording charges (each, a "Transfer Tax") which may be payable by reason of the acquisition of the Acquired Assets or the assumption of the Assumed Liabilities under this Agreement or the transactions contemplated herein shall be timely paid by Purchaser. Purchaser and Seller shall cooperate to prepare and timely file any Tax Returns required to be filed in connection with Transfer Taxes described in the immediately preceding sentence.

9.2 Releases. Effective as of and conditioned upon the occurrence of Closing, Purchaser hereby releases and forever discharges Seller and Seller's directors, officers, employees, agents, representatives, successors, assigns, and holders of Claims or interests in Seller's chapter 11 bankruptcy estate, from any and all actions, suits, debts, liens, sums of money, accounts, judgments, claims and demands whatsoever, at law or in equity, either in

contract or in tort, whether known or unknown, on account of, arising out of or relating to any act or omission of any kind or character whatsoever that relates to Seller or this Agreement and the proposed transactions contemplated herein occurring at or prior to the Closing; provided that nothing in this Section 9.2 shall release or discharge any Claim of Purchaser under this Agreement. Notwithstanding any provision of the contrary herein, Purchaser agrees that, in addition to Seller, any other person or entity released and discharged under this section is a third-party beneficiary of this section and shall be entitled to rely on and enforce this section.

9.3 Survival. None of the (a) covenants or agreements to be performed by either Seller or Purchaser prior to the Closing pursuant to this Agreement and (b) representations and warranties by Seller or Purchaser contained in this Agreement shall survive Closing, and neither Seller nor Purchaser shall have liability to the other party after Closing for any breach of any such covenant, agreement, representation or warranty. Except as set forth in the immediately preceding sentence, the covenants and agreements of the parties set forth in this Agreement will survive until fully performed or until such performance is expressly waived in writing by the other party.

9.4 Injunctive Relief. Damages at Law may be an inadequate remedy for the breach by Purchaser or Seller of any of its covenants, promises and agreements contained in this Agreement and, accordingly, each of Purchaser and Seller shall be entitled to injunctive relief with respect to any such breach, including specific performance of such covenants, promises or agreements or an order enjoining a party from any threatened, or from the continuation of any actual, breach of the covenants, promises or agreements contained in this Agreement. The rights of Purchaser and Seller set forth in this Section 9.4 shall be in addition to any other rights which a party may have at Law or in equity pursuant to this Agreement.

9.5 Entire Agreement; Amendments and Waivers. This Agreement (including the Exhibits and Schedules hereto and other documents specifically referred to herein) represents the entire understanding and agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written, of the parties. Any provision of this Agreement may be amended or waived if such amendment or waiver is in writing and signed, in the case of an amendment, by Purchaser and Seller, or in the case of a waiver, by the party against whom the waiver is effective. No failure or delay by either party in exercising any right, power or privilege hereunder will operate as a waiver thereof nor will any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies provided herein will be cumulative and, except as otherwise expressly provided herein, are not exclusive of any rights or remedies provided by applicable Law.

9.6 Counterparts; Electronic Signatures. For the convenience of the parties hereto, this Agreement may be executed in any number of counterparts, each such counterpart being deemed to be an original instrument, and all such counterparts shall together constitute the same agreement. Facsimile signatures or signatures delivered by email in PDF or similar format will be deemed original signatures for purposes of this Agreement.

9.7 Governing Law. This Agreement will be governed by and construed in accordance with the Laws of the State of Delaware without regard to principles of conflicts of Law. The parties hereby submit to the exclusive jurisdiction of the United States Bankruptcy Court for the

District of Delaware and any U.S. federal appellate court therefrom (or, if the United States Bankruptcy Court for the District of Delaware declines to or may not accept authority or jurisdiction over a particular matter, the United States District Court for the District of Delaware; or if the United States District Court for the District of Delaware declines to or may not accept jurisdiction over a particular matter, any state court within Suffolk County of the Commonwealth of Massachusetts) for any actions, suits or proceedings arising out of or relating to this Agreement or the transactions contemplated herein (and each party agrees not to commence any action, suit or proceeding relating thereto except in such courts), and each party further agrees that service of any process, summons, notice or document by U.S. registered mail to its respective address set forth in Section 9.9 shall be effective service of process for any action, suit or proceeding brought against it in any such court.

9.8 Waiver of Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

9.9 Notices. Unless otherwise set forth herein, any notice, request, instruction or other document to be given hereunder by any party to the other parties shall be in writing and shall be deemed duly given (i) upon delivery, when delivered personally, (ii) one (1) day after being sent by overnight courier or when sent by facsimile transmission or email PDF format (with a confirming copy sent by overnight courier), and (iii) three (3) calendar days after being sent by registered or certified mail, postage prepaid, as follows:

If to Seller, to:

InVivo Therapeutics Corporation
1500 District Avenue
Burlington, MA 01803
Attn: Heather Hamel, Chief Legal Officer
Email: hhamel@invivotherapeutics.com

With a copy to:

Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, MA 02109
Attention: George W. Shuster, Jr.
Email: george.shuster@wilmerhale.com

If to Purchaser, to:

[Purchaser]
[ADDRESS]

[ADDRESS]
Attention: [●]
Email: [●]

With a copy to:

[Purchaser's Representative]
[ADDRESS]
[ADDRESS]
Attention: [●]
Email: [●]

or to such other Persons or addresses as may be designated in writing by the party to receive such notice.

9.10 Binding Effect; Assignment. This Agreement will be binding upon and inure to the benefit of the parties and their respective successors and permitted assigns. Except as otherwise expressly stated herein, nothing in this Agreement will create or be deemed to create any Third Party beneficiary rights in any Person or entity not a party to this Agreement. Neither party may assign or delegate its rights or obligations under this Agreement (whether by operation of Law, change of control, or otherwise), either in whole or in part, without the prior written consent of the other party, provided, however, that (a) Purchaser may assign, delegate or transfer any of its rights or obligations under this Agreement to any wholly-owned direct or indirect Subsidiary of Purchaser by sending written notice to, but without the consent of, Seller; provided, further, that such assignment, delegation or transfer shall not relieve Purchaser of any liability or obligation under this Agreement. Any attempted assignment, delegation or transfer in violation of this Section 9.10 shall be void and without effect.

9.11 Third Party Beneficiaries. Except as otherwise expressly stated herein, no Person other than the parties hereto (and any permitted assignee under Section 9.10) shall have any rights or claims under this Agreement.

9.12 Publicity. Neither Seller nor Purchaser will issue any press release or make any public statement regarding the transactions contemplated hereby, without the prior written consent of the other party.

9.13 Severability. If any provision of this Agreement is determined to be invalid or unenforceable, the validity or enforceability of the other provisions of this Agreement as a whole will not be affected; and, in such event, Seller and Purchaser shall negotiate in good faith to change and interpret such provision so as to best accomplish the objectives of such provision within the limits of applicable Law or applicable court decision.

9.14 Non-Recourse. Except as expressly contemplated by this Agreement, no past, present or future director, officer, employee, advisor, lawyer, agent, representative, incorporator, member, partner or equity holder of Seller or Purchaser shall have any liability for (i) any obligations or liabilities of Seller or Purchaser under this Agreement or the certificate of incorporation and by-laws or comparable organizational documents of Seller or Purchaser, or

(ii) any claim based on, in respect of, or by reason of, the transactions contemplated hereby and thereby.

9.15 Time of the Essence. Time is of the essence in the performance of each of the obligations of the parties and with respect to all covenants and conditions to be satisfied by the parties in this Agreement and all documents, acknowledgments and instruments delivered in connection herewith.

9.16 Miscellaneous.

(a) Certain Interpretations. Unless otherwise expressly provided, for purposes of this Agreement, the following rules of interpretation shall apply:

(i) All references in this Agreement to Articles, Sections, Schedules and Exhibits shall be deemed to refer to Articles, Sections, Schedules and Exhibits to this Agreement.

(ii) All Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein. Any capitalized terms used in any Schedule or Exhibit but not otherwise defined therein shall be defined as set forth in this Agreement.

(iii) The Article, Section and paragraph captions herein are for convenience of reference only, do not constitute part of this Agreement and shall not be deemed to limit or otherwise affect any of the provisions hereof.

(iv) The words “include,” “includes” and “including,” when used herein, shall be deemed in each case to be followed by the words “without limitation” (regardless of whether such words or similar words actually appear).

(v) When calculating the period of time before which, within which or following which any act is to be done or step taken pursuant to this Agreement, the date that is the reference date in calculating such period shall be excluded.

(vi) Any reference in this Agreement to \$ shall mean United States Dollars.

(vii) Any reference in this Agreement to gender shall include all genders, and words imparting the singular number only shall include the plural and vice versa.

(viii) The words such as “herein,” “hereinafter,” “hereof,” and “hereunder” refer to this Agreement as a whole and not merely to a subdivision in which such words appear unless the context otherwise requires.

(b) The parties hereto agree that they have been represented by legal counsel during the negotiation and execution of this Agreement and, therefore, waive the application of any Law, regulation, holding or rule of construction providing that ambiguities in

an agreement or other document shall be construed against the party drafting such agreement or document.

(c) This Agreement is the result of the joint efforts of the parties hereto, and each provision hereof has been subject to the mutual consultation, negotiation, and agreement of the parties and there is to be no construction against any party based on any presumption of that party's involvement in the drafting thereof.

(d) Purchaser acknowledges hereby that Seller may not comply with the provisions of any bulk transfer laws of any jurisdiction in connection with the transactions contemplated by this Agreement.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective duly authorized officers as of the date first above written.

SELLER:

**INVIVO THERAPEUTICS HOLDINGS
CORP.**

By: _____

Name:

Title:

-and-

INVIVO THERAPEUTICS CORPORATION

By: _____

Name:

Title:

PURCHASER:

[PURCHASER]

By: _____

Name: [●]

Title: [●]

EXHIBIT A

Acquired Assets

All of the assets relating to the Program as of the Closing Date, including the following:

1. All tangible assets, including, without limitation, (a) all fixtures, furniture, office supplies, and office equipment, (b) all computers, printers, servers, and other information technology equipment, (c) all machinery, tools and tooling, supplies, spare parts, packaging materials, and other operational and manufacturing equipment, (d) all fixtures, (e) (i) any raw materials (including work in process and inventory), finished goods and other product inventory in the possession or control of, or otherwise held by or on behalf of, or owned by Seller (for the avoidance of doubt, the Acquired Assets also include all manufactured product, packaging material, and any other similar assets relating to the Business which have already been paid for by Seller, and any assets that are under manufacture), (f) all signage, advertising materials, marketing materials, literature and manuals, (g) all Documents, and (h) all other tangible personal property, including without limitation all of the assets specifically listed on Exhibit A-[●] hereto.
2. All intangible assets, including, without limitation, (a) all Acquired Avoidance Actions, (b) all claims, prepayments, deposits (including security deposits and equipment deposits), refunds, causes of action, choses in action, rights of recovery, rights of setoff, rights of recoupment, and prepaid items relating to or arising from the Acquired Assets or the Assumed Liabilities; (c) the Acquired Claims; (d) all warranties and similar rights, (e) all certificates, licenses, permits, franchises, rights, approvals, clearances, orders, exemptions, registrations, authorizations, and similar rights issued by any governmental entity or agency, (f) all intangible books, records, files, accounts, ledgers, correspondence, and communications, (g) all rights under contracts, agreements, and instruments that are not Executory Contracts, including, without limitation, all rights under non-disclosure and confidentiality agreements that are not Executory Contracts and all rights under insurance contracts and to insurance proceeds for claims under such insurance contracts arising after the Closing Date (and to insurance proceeds relating to such claims) to the extent that the insurance proceeds are related to other Acquired Assets, (h) all good will, and (i) all other intangible personal property, including without limitation all of the assets specifically listed on Exhibit A-[●] hereto.
3. To the extent not included in the foregoing, all Seller Owned Intellectual Property, including without limitation all of the assets specifically listed on Exhibit A-[●] hereto.
4. Without limiting the generality of the foregoing, all of the assets specifically listed on Annex A-[●] hereto.

For the avoidance of doubt, notwithstanding the foregoing, (1) none of the Excluded Assets are included within the Acquired Assets, and (2) all of the Assumed Executory Contracts are Acquired Assets.

EXHIBIT B

Assumed Executory Contracts

[TBD]⁶

⁶ NTD: This list will include the Specified Licenses.
{1394.001-W0074244.}

EXHIBIT C

Assumed Liabilities

1. Obligations arising after the Closing Date under any Assumed Executory Contract (listed on Exhibit B to this Agreement).

EXHIBIT D

Excluded Assets

1. All Cash and Cash Equivalents of Seller.
2. All checking, savings, and deposit accounts of Seller, and all securities accounts of Seller.
3. All Accounts Receivable.
4. Any real estate rights, including rights under any real estate leases.
5. All royalties or milestone payment rights owed to or held by Seller relating to the patidegib program or otherwise owing to, or having been previously sold by Seller to, HealthCare Royalty Partners III, L.P.
6. All royalties or milestone payment rights owed to or held by Seller relating to the duvelisib program or otherwise owing to, or having been previously sold by Seller to, BVF Partners, L.P.
7. All claims, prepayments, deposits (including security deposits and equipment deposits), refunds, rights of recovery, rights of setoff, rights of recoupment, and prepaid items relating to or arising from the Excluded Assets or the Excluded Liabilities.
8. All benefit, retirement, pension, or similar plans relating to employees of Seller.
9. All (a) rights, claims, or causes of action that Seller may have against any Person with respect to any Excluded Asset or Excluded Liability, (b) Avoidance Actions other than the Acquired Avoidance Actions, (c) estate claims of Seller not constituting Acquired Assets.
10. Any asset of Seller, which would constitute an Acquired Asset (if owned by Seller on the Closing Date) that is conveyed or otherwise disposed of during the period from the date of this Agreement to the Closing Date to the extent such conveyance or other disposal is permitted under, and not prohibited by, Section 7.3 of this Agreement.
11. All losses, loss carry forwards and rights to receive refunds or credits with respect to any and all Taxes of Seller incurred or accrued on or before the Closing Date.
12. All corporate seals, minute books, charter documents, corporate stock record books, original tax and financial records and such other files, books and records of Seller that Seller is required by Law to retain or that exclusively relate to the Excluded Assets and

Excluded Liabilities; provided, however, that Seller shall provide Purchaser with reasonable access to and copies of any such materials.

13. All shares of capital stock or other equity interests of InVivo Therapeutics Holdings Corp. or InVivo Therapeutics Corporation or in any other entity.
14. All insurance providing coverage for or related to current and former directors and officers and the actions and omissions thereof, and all claims and proceeds thereof, and all proceeds of insurance of any type to the extent that such proceeds are the result of claims arising prior to the Closing.

EXHIBIT E

FORM OF BILL OF SALE

THIS BILL OF SALE dated as of [Closing Date], by and among [PURCHASER], a [jurisdiction of organization] [type of entity] (“Purchaser”), and **INVIVO THERAPEUTICS HOLDINGS CORP.**, a Nevada corporation (“Holdings”), and **INVIVO THERAPEUTICS CORPORATION**, a Delaware corporation (“InVivo” and, together with Holdings, “Seller”).

WHEREAS, the parties hereto have entered into an Asset Purchase Agreement dated as of [Date of APA] (the “Purchase Agreement”) providing for the acquisition by Purchaser of certain assets of Seller, and the parties now desire to carry out such transaction by Seller’s execution and delivery to Purchaser of this instrument evidencing the vesting in Purchaser of all of the assets and rights of Seller hereinafter described. Capitalized terms used but not defined herein have the meanings given them in the Purchase Agreement.

NOW, THEREFORE, in consideration of the premises and of other valuable consideration to Seller in hand paid pursuant to the Purchase Agreement, at or before the execution and delivery hereof, the receipt and sufficiency of which by Seller is hereby acknowledged, Seller hereby conveys, grants, sells, transfers, sets over, assigns, remises, releases and delivers unto Purchaser, its successors and assigns forever, effective as of 12:01 a.m. EDT on the date hereof (the “Effective Time”), all of Seller’s right, title and interest in and to the Acquired Assets, free and clear of any Encumbrances, without representation or warranty, express or implied.

PURCHASER HEREBY ACKNOWLEDGES AND AGREES THAT SELLER MAKES NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, EXPRESS OR IMPLIED, WITH RESPECT TO ANY MATTER RELATING TO THE ACQUIRED ASSETS OTHER THAN AS SET FORTH IN THE PURCHASE AGREEMENT. WITHOUT IN ANY WAY LIMITING THE FOREGOING, SELLER HEREBY DISCLAIMS ANY WARRANTY, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE AS TO ANY PORTION OF THE ACQUIRED ASSETS. PURCHASER FURTHER ACKNOWLEDGES THAT PURCHASER HAS CONDUCTED AN INDEPENDENT INSPECTION AND INVESTIGATION OF THE PHYSICAL CONDITION OF THE ACQUIRED ASSETS AND ALL SUCH OTHER MATTERS RELATING TO OR AFFECTING THE ACQUIRED ASSETS AS PURCHASER DEEMED NECESSARY OR APPROPRIATE AND THAT, IN PROCEEDING WITH ITS ACQUISITION OF THE ACQUIRED ASSETS, PURCHASER IS DOING SO BASED SOLELY UPON SUCH INDEPENDENT INSPECTIONS AND INVESTIGATIONS. ACCORDINGLY, PURCHASER WILL ACCEPT THE ACQUIRED ASSETS AT THE CLOSING “AS IS,” “WHERE IS,” AND “WITH ALL FAULTS.”

Seller hereby covenants that, from time to time after the delivery of this instrument, at Purchaser’s request and without further consideration, Seller will do, execute, acknowledge, and deliver, or will cause to be done, executed, acknowledged and delivered, all and every such further acts, deeds, conveyances, transfers, assignments, powers of attorney and assurances as reasonably may be required, and in form and substance reasonably acceptable to Seller, to effectively convey, transfer to and vest in Purchaser, and to put Purchaser in possession of, any of the Acquired Assets.

Nothing in this instrument, express or implied, is intended or shall be construed to confer upon, or give to, any person, firm or corporation other than Purchaser and its successors and assigns, any remedy or claim under or by reason of this instrument or any terms, covenants or condition hereof, and all of the terms, covenants and conditions, promises and agreements in this instrument contained shall be for the sole and exclusive benefit of Purchaser and its successors and assigns.

This instrument is executed by, and shall be binding upon, Seller and its successors and assigns for the uses and purposes above set forth and referred to, effective as of the Effective Time.

This instrument shall be governed by, interpreted under, and construed and enforceable in accordance with, the laws of the State of Delaware, without regard to its conflict of law principle provisions.

To the extent this Bill of Sale is inconsistent with any terms or conditions of the Purchase Agreement, the terms and conditions of the Purchase Agreement shall control.

This instrument may be executed in counterpart signature pages, all of which when so executed and attached hereto shall constitute one and the same original.

[Signature pages follow.]

IN WITNESS WHEREOF, the parties hereto have executed this Bill of Sale or caused this Bill of Sale to be executed on their behalf by a duly authorized officer as of the date first set forth above.

SELLER:

**INVIVO THERAPEUTICS HOLDINGS
CORP.**

By: _____

Name:

Title:

-and-

INVIVO THERAPEUTICS CORPORATION

By: _____

Name:

Title:

PURCHASER:

[PURCHASER]

By: _____

Name: [●]

Title: [●]

EXHIBIT F

FORM OF ASSIGNMENT AND ASSUMPTION AGREEMENT

This **ASSIGNMENT AND ASSUMPTION AGREEMENT** (the “Agreement”) is entered into as of [Closing Date], by and among [PURCHASER], a [jurisdiction of organization] [type of entity] (“Assignee”), and **INVIVO THERAPEUTICS HOLDINGS CORP.**, a Nevada corporation (“Holdings”), and **INVIVO THERAPEUTICS CORPORATION**, a Delaware corporation (“InVivo” and, together with Holdings, “Assignor”).

WITNESSETH:

WHEREAS, Assignor and Assignee entered into that certain Asset Purchase Agreement dated as of [Date of APA] (the “Purchase Agreement”; capitalized terms used but not otherwise defined herein have the meanings given them in the Purchase Agreement); and

WHEREAS, pursuant to the Purchase Agreement, Assignor has agreed to assign certain rights and agreements to Assignee, and Assignee has agreed to assume certain obligations of Assignor, as set forth therein and herein.

NOW, THEREFORE, in consideration of the premises, the mutual covenants set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto mutually covenant and agree as follows:

1. Effective as of 12:01 a.m. EDT on the date hereof, Assignor hereby sells, transfers and assigns (collectively the “Assignment”) to the Assignee, and Assignee hereby assumes and agrees to pay, perform and discharge, each and all of the Assumed Liabilities, as that term is defined in the Purchase Agreement.

2. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.

3. This Agreement shall be governed by, interpreted under, and construed and enforceable in accordance with, the laws of the State of Delaware, without regard to its conflict of law principle provisions and rules.

4. To the extent this Agreement is inconsistent with any terms or conditions in the Purchase Agreement, the Purchase Agreement shall control.

5. This Agreement may be executed in counterpart signature pages, all of which when so executed and attached hereto shall constitute one and the same original.

[Signature pages follow.]

IN WITNESS WHEREOF, the parties hereto have executed this Assignment and Assumption Agreement as of the date first set forth above.

ASSIGNOR:

**INVIVO THERAPEUTICS HOLDINGS
CORP.**

By: _____

Name:

Title:

-and-

INVIVO THERAPEUTICS CORPORATION

By: _____

Name:

Title:

ASSIGNEE:

[PURCHASER]

By: _____
Name: [●]
Title: [●]

EXHIBIT 2

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INVIVO THERAPEUTICS CORPORATION, *et al.*,¹

Debtors.

Chapter 11

Case No. 24-10137 (MFW)

(Jointly Administered)

**NOTICE OF BID DEADLINE, AUCTION, AND SALE HEARING IN CONNECTION
WITH THE SALE OF SUBSTANTIALLY ALL OF THE DEBTORS' ASSETS**

NOTICE IS HEREBY GIVEN, as follows:

1. On February 1, 2024, the above-captioned debtors and debtors-in-possession (the “Debtors”) filed a motion (the “Bid Procedures Motion”) with the United States Bankruptcy Court for the District of Delaware (the “Court”) seeking approval of among other things (i) bid procedures (the “Bid Procedures”) in connection with the sale (the “Sale”) of substantially all of the Debtors’ assets (the “Assets”), (ii) procedures to determine cure amounts and deadlines for objections to certain contracts and leases to be assumed and assigned by the Debtors (the “Cure Procedures”), (iii) the date, time, and place for a sale hearing (the “Sale Hearing”) and for objections to the Sale, and (iv) related relief. On February [___], 2024, the Court entered an order D.I. [●] approving the Bid Procedures Motion, the Bid Procedures and the Contract Procedures (the “Bid Procedures Order”).²

2. All interested parties are invited to submit a Qualified Bid and to make offers to purchase the Assets in accordance with the terms of the Bid Procedures and the Bid Procedures Order. Potential Bidders are encouraged to review the Bid Procedures attached to the Bid Procedures Order carefully and, for further information, are invited to contact the Debtors’ investment banker, SSG Advisors, LLC, Five Tower Bridge, Suite 420, 300 Barr Harbor Drive, West Conshohocken, Pennsylvania 19428, Attn: J. Scott Victor (e-mail: jsvictor@ssgca.com) and Teresa Kohl (tkohl@ssgca.com) (tel.: (610) 940-1094). **The Bid Deadline is March 29, 2024, at 4:00 p.m. (ET).**

3. Consistent with the Bid Procedures Order, in the event the Debtors receive one or more Qualified Bids on or before the Bid Deadline, the Debtors shall conduct the Auction for the purpose of determining the highest or otherwise best bid for the Acquired Assets. **The Auction shall be organized by the Debtors’ professionals and conducted at the offices of Landis Rath**

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number, are: InVivo Therapeutics Corporation (6670) and InVivo Therapeutics Holdings Corp. (8166). The Debtors’ mailing address is 1500 District Avenue, Burlington, MA 01803.

² Capitalized terms not otherwise defined herein shall have the meanings given to such terms in the Bid Procedures Order.

& Cobb LLP, 919 N. Market Street, Suite 1800, Wilmington, Delaware 19801, or by remote audio and/or video link, beginning at 10:00 a.m. (ET) on April 3, 2024 or such other location and time as may be announced prior to the Auction to all Qualified Bidders, the U.S. Trustee and the official committee of unsecured creditors, if any, formed in the Chapter 11 Cases (the “Committee”). The Auction will be recorded and transcribed by an authorized court reporter. The Debtors, their professionals, the U.S. Trustee, the Committee, if any, Qualified Bidders and their respective members and professionals, and creditors and their respective counsel, financial advisors, and/or other authorized representatives may attend the Auction. The only persons or entities who will be permitted to bid at the Auction are the authorized representatives of each Qualified Bidder. The time and place of the Auction may change with notice. The Debtors shall file notice of any such change with the court not later 10:00 a.m. (ET) one (1) day prior to the Auction, and shall serve such notice by email or fax on all creditors who notified Debtors’ counsel of their intention to attend the Auction, in the manner and time set forth in paragraph 5 below, as well as on all bidders and Committee counsel, if any.

4. Any party-in-interest wishing to attend the Auction, whether virtually or in person, may request to attend by contacting, no later than three (3) business days prior to the start of the Auction, Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware 19801, Attn: Matthew B. McGuire, Esq. (e-mail: mcguire@lrclaw.com) and providing their e-mail address and/or fax number, so as to receive notice of any change in the date, time or location of the Auction.

5. At the Sale Hearing on April 5, 2024, at 10:00 a.m. (ET) or such other time as the Court shall determine, the Debtors intend to seek the Court approval of the sale of the Assets to the Successful Bidder at the Auction. In determining the Successful Bidder, in addition to the amount of cash or cash equivalent consideration offered, the Debtors will consider, among other factors, the assumption of liabilities contemplated by each Qualified Bid, certainty of closing, and other factors relating to the value and certainty of the bid. The Sale Hearing will be held before the Honorable Mary F. Walrath, Judge at the United States Bankruptcy Court for the District of Delaware, 824 Market Street, 5th Floor, Courtroom No. 4, Wilmington, Delaware 19801. The Sale Hearing may be adjourned from time-to-time without further notice to creditors or parties in interest other than by announcement of the adjournment in open court or on the Court’s docket.

6. In the event an Auction will occur, no later than 4:00 p.m. (ET) on April 1, 2024, the Debtors will provide e-mail or fax notice containing the identities of all Qualified Bidders (the “Qualified Bidder Notice”) to all Contract Parties who timely submitted a written request for such notice pursuant to the instructions below. The Debtors shall file notice of the identities of the Successful Bidder and the Back-Up Bidder (and, if the Successful Bidder or the Back-Up Bidder is a special purpose entity, the identity of the entity or entities that are the primary equity holders, or otherwise control, the special purpose entity), and the amount of the Successful Bid and Back-Up Bid with the Court by the earlier of (a) five (5) business hours after the close of the Auction or (b) noon of the day after the close of the Auction. At that same time, the Debtors shall serve notice of the foregoing information (the “Successful Bidder Notice”) by email or fax to all Contract Parties and creditors who have timely requested notice of such information. To receive a copy of the Qualified Bidder Notice and the Successful Bidder Notice, a Contract Party must submit a written request in writing to Debtors’ counsel, Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware, Attn: Matthew B. McGuire, Esq. (e-mail: mcguire@lrclaw.com)

and provide Debtors' counsel with their email addresses or fax numbers by no later than the Bid Deadline.

7. At the Sale Hearing, the Court may enter such orders as it deems appropriate under applicable law and as required by the circumstances and equities of these Chapter 11 Cases, and the Debtors, subject to the terms of the Successful Bidder's asset purchase agreement, may seek entry of an order which provides, except with respect to any Assumed Liabilities, all persons and entities, including, but not limited to, all debt security holders, equity security holders, governmental, tax and regulatory authorities, lenders, trade creditors, litigation claimants and other creditors, holding liens, claims, encumbrances or interests of any kind or nature whatsoever against or in all or any portion of the Assets (whether legal or equitable, secured or unsecured, matured or unmatured, contingent or non-contingent, liquidated or unliquidated or subordinate), arising under or out of in connection with, or in any way relating to the Debtors, the Assets, the operation of the Debtors' business prior to the Closing Date or the transfer of the Assets to the Buyer, that all such persons are forever prohibited and permanently enjoined from (i) commencing or continuing in any manner any action or other proceeding, the employment of process, or any act (whether in law or equity, in any judicial, administrative, arbitral, or other proceeding) to collect or recover any interest; (ii) enforcing, attaching, collecting, or recovering in any manner any judgment, award, decree, or order with respect to an interest, (iii) creating, perfecting, or enforcing any interest, or (iv) asserting any right of subrogation of any kind with respect to an interest, in each case as against the Successful Bidder or its designee, any of their respective affiliates or subsidiaries, or any of their respective representatives, or any of their respective property or assets, including the Assets.

8. The Debtors proposes that, to be timely and otherwise eligible for consideration by the Court, objections, if any, to the Sale of the Assets or to entry of the form of Sale Order, ("Sale Objections"), or the assumption and assignment of executory contracts and unexpired leases pursuant to the terms of the agreement reached between the Debtors and the Successful Bidder ("Contract Objections") shall be in writing, shall conform to the Federal Rules of Bankruptcy Procedure and the Local Rules of the Bankruptcy Court for the District of Delaware, shall set forth the name of the objecting party, the nature and amount of any claims or interests held or asserted against the Debtors' estates or properties, the basis for the objection and the specific grounds therefor, and shall be filed with the Court and be served upon: (i) counsel for the Debtors, Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware 19801 (Attn: Matthew B. McGuire. (e-mail: mcguire@lrclaw.com) and Joshua B. Brooks, Esq. (e-mail: brooks@lrclaw.com)); and Wilmer Cutler Pickering Hale and Dorr LLP, 7 World Trade Center, 250 Greenwich Street, New York, New York, 10007 (Attn: George Shuster, Esq. (e-mail: george.shuster@wilmerhale.com) and Benjamin Loveland, Esq. (e-mail: benjamin.loveland@wilmerhale.com)); (ii) counsel to the Committee, if any; and (iii) the Office of the United States Trustee, 844 King Street, Suite 2207, Wilmington, Delaware 19801 (Attn: Joseph Cudia, Esq. (email: Joseph.Cudia@usdoj.gov)) (collectively, the "Sale Objection Parties") **so that such Contract and Sale Objections are received by no later than 4:00 p.m. (ET) on March 29, 2024.**

9. In the event (a) an Auction is conducted, the deadline for objections related to the conduct of the Auction itself shall be at the Sale Hearing; (b) the form of Sale Order approving such Successful Bidder's asset purchase agreement; and (c) the proposed asset purchase agreement between the Debtors and such Successful Bidder shall be at the Sale Hearing.

10. Contract Parties shall be able to assert an objection at or before the Sale Hearing to the assignment of executory contracts and unexpired leases to such Successful Bidder solely on the grounds that the proposed assignment does not comply with 11 U.S.C. § 365(b)(1)(C), with any such objection that is not resolved prior to or at the Sale Hearing to be heard at a later-scheduled hearing as the Court deems appropriate.

11. You may obtain a copy of the Motion, the Bid Procedures, the Bid Procedures Order, the form of Sale Order, and the Notice of Sale Hearing by sending a written request to the Debtor⁵'s undersigned counsel.

Dated: _____, 2024 **LANDIS RATH & COBB LLP**
Wilmington, Delaware

/s/

Matthew B. McGuire (No. 4366)
Joshua B. Brooks (No. 6765)
919 Market Street, Suite 1800
Wilmington, Delaware 19801
Telephone: (302) 467-4400
Facsimile: (302) 467-4450
Email: mcguire@lrclaw.com
brooks@lrclaw.com

*Counsel to the Debtors and
Debtors-In-Possession*

EXHIBIT 3

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INVIVO THERAPEUTICS CORPORATION, *et al.*,¹

Debtors.

Chapter 11

Case No. 24-10137 (MFW)

(Jointly Administered)

**NOTICE OF DEBTORS INTENT TO ASSUME AND ASSIGN CERTAIN UNEXPIRED
LEASES AND EXECUTORY CONTRACTS AND FIXING OF CURE AMOUNTS**

NOTICE IS HEREBY GIVEN, as follows:

1. On February [], 2024, the United States Bankruptcy Court for the District of Delaware (the “Court”) entered an order (the “Bid Procedures Order”)² approving among other things (i) bid procedures (the “Bid Procedures”) in connection with the sale of substantially all of the Debtors’ assets (the “Assets”) and (ii) procedures to determine cure amounts and deadlines for objections to certain contracts and leases to be assumed and assigned by the Debtors (the “Contract Procedures”).

2. At a hearing on April 5, 2024, at 10:00 a.m. (ET) or such other time as the Court shall determine (the “Sale Hearing”), the Debtors intend to seek approval of the sale of the Assets (the “Sale”) to such party as determined pursuant to the Bid Procedures to have submitted the highest or otherwise best bid for the Assets (the “Successful Bidder”). The Sale Hearing shall be before the Honorable Mary F. Walrath, Judge at the United States Bankruptcy Court for the District of Delaware, 824 Market Street, 5th Floor, Courtroom No. 4, Wilmington, Delaware 19801. The Sale Hearing may be adjourned, from time to time, without further notice to creditors or parties in interest other than by announcement of the adjournment in open court or on the Court’s docket.

3. The Debtors seek to have the Sale be free and clear of all liens, claims, encumbrances, defenses (including, without limitation, rights of setoff) and interests, including, without limitation, security interests of whatever kind or nature, mortgages, conditional sales or title retention agreements, pledges, deeds of trust, hypothecations, liens, encumbrances, assignments, preferences, debts, easements, charges, suits, licenses, options, rights-of-recovery, judgments, orders and decrees of any court or foreign or domestic governmental entity, taxes (including foreign, state and local taxes), licenses, covenants, restrictions, indentures, instruments, leases, options, off-sets, claims for reimbursement, contribution, indemnity or exoneration, successor, product, environmental, tax, labor, ERISA, CERCLA, alter ego and other liabilities, causes of action, contract rights and claims, to the fullest extent of the law, in each case, of any

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number, are: InVivo Therapeutics Corporation (6670) and InVivo Therapeutics Holdings Corp. (8166). The Debtors’ mailing address is 1500 District Avenue, Burlington, MA 01803.

² Capitalized terms not otherwise defined herein shall have the meanings given to such terms in the Bid Procedures Order and/or the Bid Procedures Motion

kind or nature (including, without limitation, all “claims” as defined in section 101(5) of the Bankruptcy Code), known or unknown, whether pre-petition or post-petition, secured or unsecured, choate or inchoate, filed or unfiled, scheduled or unscheduled, perfected or unperfected, liquidated or unliquidated, noticed or unnoticed, recorded or unrecorded, contingent or noncontingent, material or non-material, statutory or non-statutory, matured or unmatured, legal or equitable to the maximum extent permitted by Bankruptcy Code section 363.

4. At the Sale Hearing, the Court may enter such orders as it deems appropriate under applicable law and as required by the circumstances and equities of these Chapter 11 Cases, and the Debtors, subject to the terms of the Successful Bidders’ asset purchase agreement, may seek entry of an order which provides, all persons and entities, including, but not limited to, all debt security holders, equity security holders, governmental, tax and regulatory authorities, lenders, trade creditors, litigation claimants and other creditors, holding liens, claims, encumbrances or interests of any kind or nature whatsoever against or in all or any portion of the Assets (whether legal or equitable, secured or unsecured, matured or unmatured, contingent or non-contingent, liquidated or unliquidated or subordinate), arising under or out of, in connection with, or in any way relating to the Debtors, the Assets, the operation of the Debtors’ business prior to the Closing Date or the transfer of the Assets to the Successful Bidder, shall be forever prohibited and permanently enjoined from (i) commencing or continuing in any manner any action or other proceeding, the employment of process, or any act (whether in law or equity, in any judicial, administrative, arbitral, or other proceeding) to collect or recover any interest; (ii) enforcing, attaching, collecting, or recovering in any manner any judgment, award, decree, or order with respect to an interest, (iii) creating, perfecting, or enforcing any interest, or (iv) asserting any right of subrogation of any kind with respect to an interest, in each case as against the Successful Bidder or its designee, any of their respective affiliates or subsidiaries, or any of their respective representatives, or any of their respective property or assets, including the Assets.

5. Pursuant to the Bid Procedures Order and the Contract Procedures approved therein, the Debtors intend to seek approval to assume and assign certain unexpired leases and executory contracts, pursuant to Bankruptcy Code section 365 (collectively, the “Contracts”) to the Successful Bidder. You have been identified as a party to a Contract (a “Contract Party”) that the Debtors *may* seek to assume and assign. The Contract with respect to which you have been identified as a non-Debtor party is set forth on **Exhibit 1** annexed hereto. The Debtors assert that no consent of any Contract Party is required for the assumption or assignment of any Contract, regardless of the applicable terms of the Contract, by operation of Bankruptcy Code section 365.

6. The Debtors believe that any and all defaults (other than the filing of these Chapter 11 Cases), actual pecuniary losses and any amounts due under the Contract can be cured and satisfied in full by the payment of the cure amounts (the “Cure Amounts”), which are also set forth on **Exhibit 1**; provided, however, the Debtors may adjust the Cure Amount with respect to any Contract on **Exhibit 1** as necessary and in accordance with the Bid Procedures. **The inclusion of a Contract on Exhibit 1 hereto is not, and should not be deemed to be, an agreement or acknowledgement by the Debtors that such Contract is an executory contract or unexpired lease under Bankruptcy Code section 365 or that such Contract will be assumed and assigned by the Debtors; the Successful Bidder has the right up to the Closing to determine whether or not to have your Contract assigned.**

7. Any party objecting to (i) any of the Cure Amounts set forth on **Exhibit 1** hereto, and/or (ii) the proposed assumption and assignment of any Contract in connection with the Sale, including, without limitation, the Debtors' ability to assign the Contract without the Contract Party's consent, and/or (iii) the adequate assurance of future performance to be provided by the Successful Bidder, as applicable, must file with the Court and serve an objection (a "Contract Objection") in writing, setting forth with specificity any and all obligations that the objecting party asserts must be cured or satisfied in respect to the Contract, and/or any and all objections to the potential assumption and assignment of such Contract, together with all documentation supporting such cure claim or objection, upon: (i) counsel for the Debtors, Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware 19801 (Attn: Matthew B. McGuire, Esq. (e-mail: mcguire@lrclaw.com) and Joshua B. Brooks (e-mail: brooks@lrclaw.com)); and Wilmer Cutler Pickering Hale and Dorr LLP, 7 World Trade Center, 250 Greenwich Street, New York, New York, 10007 (Attn: George Shuster, Esq. (e-mail: george.shuster@wilmerhale.com) and Benjamin Loveland, Esq. (e-mail: benjamin.loveland@wilmerhale.com)); (ii) counsel to the Committee, if any; and (iii) the Office of the United States Trustee, 844 King Street, Suite 2207, Wilmington, Delaware 19801 (Attn: Joseph Cudia, Esq. (email: Joseph.Cudia@usdoj.gov)) **so as to be received before 4:00 p.m. (ET) on March 29, 2024** (the "Contract Objection Deadline"); provided, however, that if the Debtors amend the Cure Notice to add a contract or lease, the Contract Party shall have until the earlier of (a) fourteen 14 days after service of the Cure Notice, and (b) the Sale Hearing to submit a Contract Objection (the "Amended Contract Objection Deadline"); provided further, that if the Debtors amend the Cure Notice to reduce the Cure Amount of a Contract, except where such reduction was upon mutual agreement of the parties, the Contract Party shall have until fourteen (14) days after service of the amended Cure Notice to object to the Cure Amount; and provided further, that Contract Parties shall be able to assert an objection at or before the Sale Hearing to the assignment of executory contracts and unexpired leases to such Successful Bidder solely on the grounds that the proposed assignment does not comply with 11 U.S.C. § 365(b)(1)(C), with any such objection that is not resolved prior to or at the Sale Hearing to be heard at a later- scheduled hearing as the Court deems appropriate.³

8. In the event an Auction will occur, no later than 4:00 p.m. (ET) on April 1, 2024, the Debtors shall provide e-mail or fax notice containing the identities of all Qualified Bidders (the "Qualified Bidder Notice") to all Contract Parties who timely submitted a written request for such notice pursuant to the instructions below. The Debtors shall file notice of the identities of the Successful Bidder and the Back-Up Bidder (and, if the Successful Bidder or Back-Up Bidder is a special purpose entity, the identity of the entity or entities that are the primary equity holders, or otherwise control, the special purpose entity), and the amount of the Successful Bid and Back-Up Bid with the Court by the earlier of (a) five (5) business hours after the close of the Auction or (b) noon on the day after the close of the Auction. At that same time, the Debtors shall serve notice of the foregoing information (the "Successful Bidder Notice") by email or fax to all Contract Parties and creditors who have timely requested notice of such information. To receive a copy of the Qualified Bidder Notice and the Successful Bidder Notice, a Contract Party must submit a written request in writing to Debtors' counsel, Landis Rath & Cobb LLP, 919 Market Street, Suite

³ Bankruptcy Code section 365(b)(1)(C) provides: "If there has been a default in an executory contract or unexpired lease of the debtor, the trustee may not assume such contract or lease unless, at the time of assumption of such contract or lease, the trustee provides adequate assurance of future performance under such contract or lease."

1800, Wilmington, Delaware, Attn: Matthew B. McGuire, Esq. (e-mail: mcguire@lrclaw.com) and provide Debtors' counsel with their email addresses or fax numbers by no later than the Bid Deadline.

9. Where a Contract Party to a Contract files an objection meeting the requirements of paragraph 6 herein, objecting to the assumption by the Debtors and assignment to the Successful Bidder of such Contract and/or asserting a cure amount higher than the proposed Cure Amount listed on this notice, the Debtors, the Contract Party and the Successful Bidder shall meet and confer in good faith to attempt to resolve any such objection without Court intervention. In the event the Contract Objection is not resolved, such Contract Objection will be heard at the Sale Hearing or thereafter. To the extent it is determined that the Cure Amount exceeds the amount set forth on **Exhibit 1** hereto, the Successful Bidder may determine not to have such Contract assumed and assigned to it.

10. If no Cure Amount is due, or no other amount is due or owing under the Contract, and the Contract Party to such agreement does not otherwise object to the Debtors' assumption, sale and assignment of such agreement, no further action needs to be taken on the part of that Contract Party.

11. Unless an objection to the assumption and assignment of a Contract is filed and served before the Objection Deadline (or the Amended Contract Objection Deadline, as applicable), all Contract Parties shall be (i) forever barred from objecting to the proposed Cure Amounts and from asserting any additional cure or other amounts (other than as may be asserted in an Additional Cure Notice), and the Debtors and the Successful Bidder shall be entitled to rely solely upon the proposed Cure Amounts set forth in the Cure Notices; (ii) deemed to have consented to the assumption and assignment of the Contracts; (iii) forever barred and estopped from asserting or claiming against the Debtors or the Successful Bidder that any additional amounts are due or other defaults exist (other than as may be asserted in an Additional Cure Notice), that conditions to assignment must be satisfied under such Contracts, including, without limitation, any consent rights, or that there is any objection or defense to the assumption and assignment of such Contracts, including without limitation adequate assurance of future performance; (iv) precluded from objecting to the Cure Amount (if any) and the assumption and assignment; and (v) barred and estopped from asserting or claiming that their Contract contains an enforceable consent right; provided, however, that a counterparty to an Assumed Executory Contract shall not be barred from seeking additional amounts on account of any defaults occurring between the service of the Cure Notice and the assumption of the Contract.

12. The Debtors' decision to assume and assign a Contract is subject to the Successful Bidder's, as applicable, designation in accordance with the Contract Procedures and the Court's approval of and consummation of the Sale. Absent consummation of the Sale, a Contract shall not be deemed assumed and assigned and shall in all respects be subject to further administration under the Bankruptcy Code. The designation of any agreement as a Contract shall not constitute or be deemed to be a determination or admission by the Debtors or the Successful Bidder that such document is, in fact, an executory contract or unexpired lease within the meaning of the Bankruptcy Code (all rights with respect thereto being expressly reserved including, for the avoidance of doubt, the Debtors' right to change the designation of any agreement as an executory

contract or unexpired lease under Bankruptcy Code section 365 at any time prior to the Closing Date).

Dated: _____, 2024
Wilmington, Delaware

LANDIS RATH & COBB LLP

/s/ _____

Matthew B. McGuire (No. 4366)

Joshua B. Brooks (No. 6765)

919 Market Street, Suite 1800

Wilmington, Delaware 19801

Telephone: (302) 467-4400

Facsimile: (302) 467-4450

Email: mcguire@lrclaw.com

brooks@lrclaw.com

*Counsel to the Debtors and
Debtors-In-Possession*

EXHIBIT 4

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INVIVO THERAPEUTICS CORPORATION, *et al.*,¹

Debtors.

Chapter 11

Case No. 24-10137 (MFW)

(Jointly Administered)

NOTICE OF DEBTORS INTENT TO ASSUME

**AND ASSIGN CERTAIN ADDITIONAL LEASES AND EXECUTORY
CONTRACTS AND FIXING OF ADDITIONAL CURE AMOUNTS**

NOTICE IS HEREBY GIVEN, as follows:

1. On February [], 2024, the United States Bankruptcy Court for the District of Delaware (the “Court”) entered an order (the “Bid Procedures Order”)² approving among other things (i) bid procedures (the “Bid Procedures”) in connection with the sale of substantially all of the Debtors’ assets (the “Assets”) and (ii) procedures to determine cure amounts and deadlines for objections to certain contracts and leases to be assumed and assigned by the Debtors (the “Contract Procedures”).

2. Pursuant to the Bid Procedures Order and the Contract Procedures approved therein, the non-Debtor parties to the Contracts (the “Contract Parties”) had until 4:00 p.m. (ET) on March 29, 2024, to object (a “Contract Objection”) to (i) the Cure Amounts listed by the Debtors (other than the Additional Cure Amounts (defined below)) and to propose alternative cure amounts; and/or (ii) the proposed assumption and assignment of the Contracts in connection with the Sale, including, without limitation, the Debtors’ ability to assign the Contracts without the Contract Parties⁵ consent or the adequate assurance of future performance to be provided.

3. At a hearing on April 5, 2024, at 10:00 a.m. (ET) or such other time as the Court shall determine (the “Sale Hearing”), the Debtors intend to seek approval of the sale of the Assets (the “Sale”) to such party as determined pursuant to the Bid Procedures to have submitted the highest or otherwise best bid for the Assets (the “Successful Bidder”). The Sale Hearing shall be before the Honorable Mary F. Walrath, Judge at the United States Bankruptcy Court for the District of Delaware, 824 Market Street, 5th Floor, Courtroom No. 4, Wilmington, Delaware 19801. The Sale Hearing may be adjourned, from time to time, without further notice to creditors or parties in interest other than by announcement of the adjournment in open court or on the Court’s docket.

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number, are: InVivo Therapeutics Corporation (6670) and InVivo Therapeutics Holdings Corp. (8166). The Debtors’ mailing address is 1500 District Avenue, Burlington, MA 01803.

² Capitalized terms not otherwise defined herein shall have the meanings given to such terms in the Bid Procedures Order and/or the Bid Procedures Motion.

4. The Debtors seek to have the Sale be free and clear of all liens, claims, encumbrances, defenses (including, without limitation, rights of setoff) and interests, including, without limitation, security interests of whatever kind or nature, mortgages, conditional sales or title retention agreements, pledges, deeds of trust, hypothecations, liens, encumbrances, assignments, preferences, debts, easements, charges, suits, licenses, options, rights-of-recovery, judgments, orders and decrees of any court or foreign or domestic governmental entity, taxes (including foreign, state and local taxes), licenses, covenants, restrictions, indentures, instruments, leases, options, off-sets, claims for reimbursement, contribution, indemnity or exoneration, successor, product, environmental, tax, labor, ERISA, CERCLA, alter ego and other liabilities, causes of action, contract rights and claims, to the fullest extent of the law, in each case, of any kind or nature (including, without limitation, all “claims” as defined in section 101(5) of the Bankruptcy Code), known or unknown, whether pre-petition or post-petition, secured or unsecured, choate or inchoate, filed or unfiled, scheduled or unscheduled, perfected or unperfected, liquidated or unliquidated, noticed or unnoticed, recorded or unrecorded, contingent or noncontingent, material or non-material, statutory or non-statutory, matured or unmatured, legal or equitable to the maximum extent permitted by Bankruptcy Code section 363.

5. On [], 2024, the Debtors filed the *Notice of Debtors’ Intent to Assume and Assign Certain Unexpired Leases and Executory Contracts and Fixing of Cure Amounts* (the “Initial Cure Notice”). Through this notice, the Debtors hereby supplement the Initial Cure Notice to either add Contract(s) inadvertently omitted from the Initial Cure Notice or to list the additional Cure Amounts (the “Additional Cure Amounts”) the Debtors believe are owed with respect to such Contract(s). You have been identified as a party to a Contract the Debtors *may* seek to assume and assign that is listed on the supplemental Contract list attached hereto as Exhibit 1 (each an “Additional Assumed Contract”).

6. Any objections to the Additional Cure Amounts (such objection being the only permissible grounds for objection) must be filed with the Court and served on: (i) counsel for the Debtors, Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware 19801 (Attn: Matthew B. McGuire, Esq. (e-mail: mcguire@lrclaw.com) and Joshua B. Brooks (e-mail: brooks@lrclaw.com)); and Wilmer Cutler Pickering Hale and Dorr LLP, 7 World Trade Center, 250 Greenwich Street, New York, New York, 10007 (Attn: George Shuster, Esq. (e-mail: george.shuster@wilmerhale.com) and Benjamin Loveland, Esq. (e-mail: benjamin.loveland@wilmerhale.com)); (ii) counsel to the Committee, if any; and (iii) the Office of the United States Trustee, 844 King Street, Suite 2207, Wilmington, Delaware 19801 (Attn: Joseph Cudia, Esq. (email: Joseph.Cudia@usdoj.gov)); so as to actually be received by **4:00 p.m. (ET) on or before the earlier of (a) the date that is fourteen (14) days after service of the additional cure notice or (b) the Sale Hearing** (the “Additional Cure Deadline”), which deadline may be extended in the sole discretion of the Debtors and the Successful Bidder.

7. If no objection to the Additional Cure Amounts is filed by the Additional Cure Deadline, the Court will enter an order (an “Additional Assumption Order”) authorizing the assumption and assignment of the Additional Assumed Contract effective as of the date of this notice. In the event an objection is filed by the Additional Cure Deadline, and the parties cannot consensually agree on the Additional Cure Amounts, the Debtors will seek expedited determination of the objection by the Court on the first available hearing date.

8. If no Additional Cure Amount is due or you agree with the Additional Cure Amount set forth on **Exhibit 1**, no further action needs to be taken and the Court will enter an order authorizing the assumption by the Debtors and assignment to the Successful Bidder of the contracts listed on **Exhibit 1**.

Dated: _____ 2024
Wilmington, Delaware

LANDIS RATH & COBB LLP

/s/ _____
Matthew B. McGuire (No. 4366)
Joshua B. Brooks (No. 6765)
919 Market Street, Suite 1800
Wilmington, Delaware 19801
Telephone: (302) 467-4400
Facsimile: (302) 467-4450
Email: mcguire@lrclaw.com
brooks@lrclaw.com

*Counsel to the Debtors and
Debtors-In-Possession*

EXHIBIT B

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INVIVO THERAPEUTICS CORPORATION, *et al.*,¹

Debtors.

Chapter 11

Case No. 24-10137 (MFW)

(Jointly Administered)

Ref. No. ~~—~~[18](#)

ORDER: (A) APPROVING BID PROCEDURES RELATING TO THE SALE OF SUBSTANTIALLY ALL OF THE DEBTORS' ASSETS, (B) APPROVING STALKING HORSE BID PROTECTIONS, (C) SCHEDULING A HEARING TO CONSIDER THE SALE, (D) APPROVING THE FORM AND MANNER OF NOTICE OF SALE BY AUCTION, (E) ESTABLISHING NOTICE AND PROCEDURES FOR THE ASSUMPTION AND ASSIGNMENT OF CONTRACTS AND LEASES, AND (F) GRANTING RELATED RELIEF

Upon the Motion² filed by the above-captioned debtors and debtors-in-possession (together, the “Debtor”), pursuant to sections 105(a), 363, 365, 503 and 507 of title 11 of the United States Code, 11 U.S.C. §§ 101, *et seq.* (the “Bankruptcy Code”), and Rules 2002, 6003, 6004, 6006, 9007 and 9008 of the Federal Rules of Bankruptcy Procedure (the “Bankruptcy Rules”), and rule 6004-1 of the Local Rules of Bankruptcy Practice and Procedure of the United States Bankruptcy Court for the District of Delaware (the “Local Rules”), for entry of an order (the “Order”), (i) approving the procedures (the “Bid Procedures”) substantially in the form attached hereto as Exhibit 1, with respect to the proposed sale (the “Sale”) of substantially all of the Debtors’ assets (the “Assets”), (ii) scheduling a hearing on the Sale (the “Sale Hearing”) and setting objection and bidding deadlines with respect to the Sale, (iii) approving the form and manner of notice of the Sale and the auction (the “Auction”) for the Assets, a copy of which is attached hereto as Exhibit 2 (the “Sale Notice”), (iv) establishing procedures to determine cure

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number, are: InVivo Therapeutics Corporation (6670) and InVivo Therapeutics Holdings Corp. (8166). The Debtors’ mailing address is 1500 District Avenue, Burlington, MA 01803.

² Capitalized terms used but not defined herein shall have the same meanings given to such terms as in the Motion.

amounts and deadlines for objections to the assumption and assignment of executory contracts and unexpired leases as set forth in the Motion (collectively, the “Contract Procedures”); and (v) granting related relief; and it appearing that the notice of the Motion provided is appropriate and sufficient under the circumstances and that no other or further notice need be given; and it appearing that the relief requested is in the best interests of the Debtors’ estates, their creditors and other parties in interest; and after due deliberation and good and sufficient cause appearing therefor:

THE COURT HEREBY FINDS AND CONCLUDES THAT:³

A. This Court has jurisdiction over this matter and over the properties of the Debtors and their estates pursuant to 28 U.S.C. §§ 157 and 1334. This proceeding is a core proceeding pursuant to 28 U.S.C. § 157. Venue is proper in this district and in this Court pursuant to 28 U.S.C. §§ 1408 and 1409.

B. The statutory and rule-based predicates for the relief requested in the Motion are Bankruptcy Code sections 105(a), 363, 365, 503 and 507, Bankruptcy Rules 2002, 6003, 6004, 6006, 9007, 9008 and Local Rule 6004-1.

C. Notice of the Motion having been given as set forth in the Motion is sufficient in light of the circumstances and the nature of the relief requested in the Motion and no other or further notice is necessary or required, except as otherwise set forth herein.

D. The Debtors have articulated good and sufficient reasons for this Court to grant the relief requested in the Motion regarding the Sale process, including, without limitation: (i) approving the Bid Procedures; (ii) approving the Stalking Horse Bid Protections; (iii) scheduling

³ The findings and conclusions set forth herein constitute the Court’s findings of fact and conclusions of law pursuant to Bankruptcy Rule 7052, made applicable to this proceeding pursuant to Bankruptcy Rule 9014. To the extent that any of the following findings of fact constitute conclusions of law, they are adopted as such. To the extent any of the following conclusions of law constitute findings of fact, they are adopted as such.

the Auction and the Sale Hearing; (iv) approving the Sale Notice; and (v) approving the Cure Notice and Contract Procedures.

E. The Debtors have demonstrated a sound business justification for authorizing [them to offer](#) the Stalking Horse Bid Protections [to any potential Stalking Horse Bidder](#).

F. The Bid Procedures were proposed ~~and negotiated~~ in good faith by the Debtors, and are fair, reasonable and appropriate under the circumstances, and are properly designed to maximize the recovery from any sale of the Assets.

G. The form and scope of the Sale Notice attached hereto as Exhibit 2 is appropriate and reasonably calculated to provide all interested parties with timely and proper notice of the Sale, the Sale Hearing and the Auction and no other and further notice is required.

H. The Contract Procedures and the notices related thereto, including the Cure Notice attached hereto as Exhibit 3 and the Additional Cure Notice attached as Exhibit 4 are appropriate and reasonably calculated to provide all Contract Parties with proper notice of the potential assumption and assignment of Contracts or unexpired leases and any Cure Amounts relating thereto and no further or other notice is required.

I. The entry of this Order is in the best interests of the Debtors, their estates, their creditors, and other parties in interest; and it is therefore:

ORDERED, ADJUDGED AND DECREED THAT:

1. The relief requested in the Motion is GRANTED as set forth herein.
2. The Bid Procedures and Contract Procedures are approved in all respects and the relief requested in the Motion as it pertains to the Bid Procedures and Contract Procedures, is granted.
3. All objections to the relief requested in the Motion with respect to the Bid Procedures or the Contract Procedures that have not been withdrawn, waived, or settled as

announced to the Court at the hearing on the Motion or as reflected in this Order or by stipulation or withdrawal filed with the Court, are overruled.

4. The Bid Procedures attached hereto as Exhibit 1 are hereby approved and fully incorporated into this Order, and shall apply with respect to the Auction and the proposed Sale of the Assets.

5. The Debtors are authorized to take any and all actions necessary or appropriate, consistent with the terms of this Order, to implement the Bid Procedures.

6. The Stalking Horse ~~Bid Protections~~Procedures are approved as set forth herein:

- a. To the extent the Debtors designate a Stalking Horse Bidder with respect to any of the assets, the Debtors shall promptly upon execution of a Stalking Horse Agreement (and in no event more than one (1) calendar day following such execution) file with the Court and serve upon the U.S. Trustee, the Committee (if any), and those parties who have filed the appropriate notice pursuant to Bankruptcy Rule 2002 requesting notice of all pleadings filed in the Chapter 11 Cases, and cause to be published on the website maintained by the Debtors' claims and noticing agent in these Chapter 11 Cases, located at the Debtors' claims agent's website at <https://www.kccllc.net/invivo>, a notice that contains information about the Stalking Horse Bidder (and if the Stalking Horse Bidder is a newly formed entity, then the Stalking Horse Bidder's parent company or sponsor), the Stalking Horse Bid, attaches the proposed Stalking Horse Agreement, states whether the Stalking Horse Bidder has any connection to the Debtors other those that arise from the Stalking Horse Bid, and describes any Stalking Horse Bid Protections proposed to be afforded to the Stalking Horse Bidder (as defined herein) (the "Notice of Stalking Horse Bidder"):
- b. Any objections (each, a "Stalking Horse Objection") to the designation of a Stalking Horse Bidder, including any Stalking Horse Bid Protections pursuant to the terms and provisions of a Stalking Horse Agreement, must (i) be in writing; (ii) state the name and address of the objecting party and the amount and nature of the Claim or Interest of such party; (iii) state with particularity the basis and nature of any objection; (iv) conform to the Bankruptcy Rules and the Local Rules; and (v) be filed with the Court and served upon the Sale Notice Parties within ~~five~~seven (7) calendar days after the filing of the relevant Notice of Stalking Horse Bidder. ~~If a timely Stalking Horse Objection is filed and served in accordance with the preceding paragraph, the proposed Stalking Horse Bid Protections will not~~

~~be deemed approved until either the Stalking Horse Objection is resolved by agreement of the objecting party and the Debtors or by order of the Court.~~ If no timely Stalking Horse Objection is filed and served with respect to ~~an applicable~~the Stalking Horse ~~Agreement in accordance with the Bid Procedures, the Stalking Horse Bid Protections shall be deemed approved without further order of the Court~~Bid, upon the expiration of the objection deadline, the Debtors will submit the proposed order approving the Stalking Horse Bidder and the Stalking Horse Bid to the Court, which may enter such order without a hearing, including with respect to any Bid Protections set forth in the Stalking Horse Supplement. For the avoidance of doubt, no determination is made in this Order with regard to authorizing any Bid Protections.

7. Pursuant to the Bid Procedures, the Debtors may designate one or more Stalking Horse Bidders on or before March 26, 2024 at 4:00 p.m. (ET).

8. The Debtors shall have the right to determine at the Auction that any Qualified Bid shall be the Back-Up Bid.

9. Pursuant to the Bid Procedures, a Potential Bidder that desires to make a bid shall deliver written copies of its bid to the parties identified in the Bid Procedures no later than 4:00 p.m. (ET) on March 29, 2024, (the "Bid Deadline") and shall comply with all other requirements set forth in the Bid Procedures in making such a bid for the Assets.

10. To the extent the Debtors receive at least two Qualified Bids, the Debtors shall conduct the Auction commencing at 10:00 a.m. (ET) on April 3, 2024, at the offices of Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware 19801, or by remote audio and/or video link.

11. If the Debtors do not receive a Qualified Bid, the Debtors will not hold the Auction. No later than 4:00 p.m. (ET) on April 1, 2024, the Debtors shall notify all Qualified Bidders and counsel to the Committee, if any, whether the Auction will occur.

12. Upon conclusion of the bidding at any Auction, the Auction shall be closed, and the Debtors, in consultation with the Committee, if any, shall (i) review each Qualified Bid on

the basis of financial and contractual terms and the factors relevant to the Sale process and the contract assumption process, including, without limitation, those factors affecting the speed and certainty of consummating the proposed Sale and the amount of the cash (or cash equivalents) consideration and (ii) identify the highest or otherwise best offer for the Assets (the “Successful Bid” and the entity submitting such Successful Bid, the “Successful Bidder”), the Back-Up Bid and the Back-Up Bidder and advise the Qualified Bidders of such determinations. The Debtors shall file with the Court notice of such determinations by the earlier of (a) five (5) business hours after the close of the auction or (b) noon of the day after the close of the auction. If the Successful Bidder or the Back-Up Bidder is a special purpose entity, the notice shall also identify the entity or entities that are the primary equity holders, or otherwise control, the special purpose entity.

13. The Debtors, in their reasonable business judgment, in consultation with the Committee, if any, may (a) determine which Qualified Bid, if any, is the highest or otherwise best offer; and (b) reject, at any time before entry of an order of the Court approving a Qualified Bid, any bid that is (i) inadequate or insufficient; (ii) not in conformity with the requirements of the Bankruptcy Code, the Bid Procedures, or the terms and conditions of the Sale; or (iii) contrary to the best interests of the Debtors, their estates, their creditors, or other stakeholders.

14. The Debtors’ presentation of a particular Qualified Bid to the Court for approval does not constitute the Debtors’ acceptance of such Qualified Bid. Other than as expressly set forth in the Bid Procedures Order, the Debtors will be deemed to have accepted a bid only when the bid has been approved by the Court at the Sale Hearing.

15. After the Successful Bid, the next highest or otherwise best offer, as determined by the Debtors, in consultation with the Committee, if any, (the “Back-Up Bid”) shall remain

open, and the entity submitting such Back-Up Bid (the “Back-Up Bidder”) shall be required to fully perform under such Back-Up Bid, until the consummation of a Sale Transaction with the Successful Bidder. In the event the Successful Bidder fails to consummate the Sale as a result of the Successful Bidder’s default or breach under the applicable purchase agreement in accordance with the terms of such purchase agreement by the closing date contemplated in such purchase agreement, the Debtors shall be, among other things, free to enter into a new purchase agreement with the Back-Up Bidder at the purchase price contemplated in the Back-Up Bid. Following the approval of the Sale of the Assets to the Successful Bidder at the Sale Hearing, if such Successful Bidder fails to consummate the approved Sale within thirty (30) days after entry of an Order approving such Sale, the Debtors shall be authorized, in consultation with the Committee, if any, but not required, to deem the Back-Up Bid, as disclosed at the Sale Hearing, the Successful Bid, and the Debtors may consummate the Sale to the Back-Up Bidder without further order of the Court.

16. The Contract Procedures, setting forth, among other things, the procedures for determining the Cure Amounts and the deadline for objecting to the Cure Amounts and/or the proposed assumption and assignment of executory contracts and unexpired leases, as provided in the Motion, are hereby approved in their entirety. Notice of the Contract Procedures in the form attached hereto as Exhibit 3 and service of such notice of the Contract Procedures to the Contract Parties, are appropriate and sufficient under the circumstances, and no other or further notice of the Contract Procedures need to be given.

17. The Court shall conduct the Sale Hearing commencing on April 5, 2024 at 10:00 a.m. (ET), at which time the Court will consider approval of the Sale to the Successful Bidder and entry of the Sale Order.

18. Objections to approval of the Sale and entry of the Sale Order, including the sale of the Assets free and clear of all Encumbrances pursuant to Bankruptcy Code section 363(f), with such Encumbrances to attach to the Sale Proceeds (if any) (a “Sale Objection”), must be in writing and filed with the Court and served on (i) counsel for the Debtors, Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware 19801 (Attn: Matthew B. McGuire, Esq. (e-mail: mcguire@lrclaw.com) and Joshua B. Brooks, Esq. (e-mail: brooks@lrclaw.com)); and Wilmer Cutler Pickering Hale and Dorr LLP, 7 World Trade Center, 250 Greenwich Street, New York, New York, 10007 (Attn: George Shuster, Esq. (e-mail: george.shuster@wilmerhale.com) and Benjamin Loveland, Esq. (e-mail: benjamin.loveland@wilmerhale.com)); (ii) counsel to the Committee, if any; and (iii) the Office of the United States Trustee, 844 King Street, Suite 2207, Wilmington, Delaware 19801 (Attn: Joseph Cudia, Esq. (email: Joseph.Cudia@usdoj.gov)), so as to be received by such parties prior to 4:00 p.m. (ET) on March 29, 2024 (the “Sale Objection Deadline”).

19. Amounts listed by the Debtors and to propose alternative Cure Amounts, and/or (b) the proposed assumption and assignment of the Contracts in connection with the Sale, including, without limitation, the Debtors’ ability to assign the Contracts without the Contract Parties’ consent (a “Contract Objection”), must be in writing and filed with the Court and served on (i) counsel for the Debtors, Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware 19801 (Attn: Matthew B. McGuire, Esq. (e-mail: mcguire@lrclaw.com) and Joshua B. Brooks, Esq. (e-mail: brooks@lrclaw.com)); and Wilmer Cutler Pickering Hale and Dorr LLP, 7 World Trade Center, 250 Greenwich Street, New York, New York, 10007 (Attn: George Shuster, Esq. (e-mail: george.shuster@wilmerhale.com) and Benjamin Loveland, Esq. (e-mail: benjamin.loveland@wilmerhale.com)); (ii) counsel to the Committee, if any; and

(iii) the Office of the United States Trustee, 844 King Street, Suite 2207, Wilmington, Delaware 19801 (Attn: Joseph Cudia, Esq. (email: Joseph.Cudia@usdoj.gov)), so as to be received by such parties prior to 4:00 p.m. (ET) on the date that is fourteen (14) days following service of the Cure Notice but no later than March 29, 2024 (the “Contract Objection Deadline”); provided, however, that objections to the adequate assurance of future performance to be provided by the Successful Bidder (or any designee thereof) may be made at the Sale Hearing or at another date set by the Court; provided, however, that if the Debtors amend the Cure Notice to add a contract or lease, the non-Debtor party to the added contract or lease shall have until the earlier of (i) fourteen (14) days after service of notice of adding a contract or lease; or (ii) the Sale Hearing to submit a Contract Objection with respect to the contract or lease added by the Debtors’ amendment (the “Amended Contract Objection Deadline”); provided further, that if the Debtors amend the Cure Notice to reduce the Cure Amount of a Contract or lease, except where such reduction was upon mutual agreement of the parties, the non-Debtor party to the Contract or lease with the reduced Cure Amount shall have until the Amended Contract Objection Deadline to object to the Cure Amount; and provided further, that in the event the Auction results in a Successful Bidder, the Contract Parties shall have until the Amended Contract Objection Deadline to object to the assignment of executory contracts and unexpired leases to such Successful Bidder, other than to the Cure Amount which shall be subject to the Contract Objection Deadline, with any such objection being heard at the Sale Hearing or at a later-scheduled hearing as the Court deems appropriate.

20. Unless a Contract Objection is filed and served before the Contract Objection Deadline or the Amended Contract Objection Deadline, as applicable, all Contract Parties shall be (i) forever barred from objecting to the proposed Cure Amounts and from asserting any

additional cure or other amounts (other than as may be asserted in an Additional Cure Notice), and the Debtors and the Successful Bidder shall be entitled to rely solely upon the proposed Cure Amounts set forth in the Cure Notices; (ii) deemed to have consented to the assumption and assignment, (iii) forever barred and estopped from asserting or claiming against the Debtors or the Successful Bidder, as applicable, that any additional amounts are due or other defaults exist (other than as may be asserted in an Additional Cure Notice), that conditions to assignment must be satisfied under such Contracts, including without limitation adequate assurance of future performance; (iv) precluded from objecting to the Cure Amount (if any) and the assumption and assignment; and (v) barred and estopped from asserting or claiming that their Contract contains an enforceable consent right; provided, however, that a counterparty to an Assumed Executory Contract shall not be barred from seeking additional amounts on account of any defaults occurring between the service of the Cure Notice and the assumption of the Contract.

21. The Debtors, the Contract Party, and the Successful Bidder may consensually resolve any Contract Objection prior to the Sale Hearing. In the event a Contract Objection is not resolved, such Contract Objection will be heard at the Sale Hearing or thereafter, or the Successful Bidder may designate such Contract as a Contract that will not be assumed and assigned to the Successful Bidder, in which case such Contract shall not be assumed and shall remain property of the Debtors' estates, subject to any further orders of the Court.

22. The Debtors are hereby authorized to share certain of the Contracts that contain confidentiality restrictions with Qualified Bidders subject to the terms of the non-disclosure agreement by and between the Debtors and each Qualified Bidder, provided that each such Qualified Bidder requesting access to such confidential contracts enters into a non-disclosure agreement with the Debtors, in a form acceptable to the Debtors.

23. All Qualified Bidders are deemed to have submitted to the exclusive jurisdiction of the Court with respect to all matters between and among any Qualified Bidder and the Debtors related to the Auction and the Sale.

24. The Sale Notice attached hereto as Exhibit 2 is approved. The Sale Notice provides all parties in interest good and sufficient notice of the relief sought in the Motion, including, but not limited to, the Auction, the Bid Deadline, the Bid Procedures, the Sale Hearing, and the Sale.

25. Within two (2) business days of the entry of the Bid Procedures Order, the Debtors shall serve by first class mail, postage prepaid, copies of: (i) this Order and (ii) the Sale Notice upon the following entities: (a) the Office of the United States Trustee for the District of Delaware; (b) counsel to the Committee, if any, or if none is formed, the creditors holding the twenty (20) largest unsecured claims as set forth on the list filed with the Debtors' petitions; (c) all taxing authorities having jurisdiction over any of the Assets subject to the Sale, including the Internal Revenue Service; (d) the Environmental Protection Agency; (e) the U.S. Securities Exchange Commission; (f) the state/local environmental agencies in the jurisdictions where the Debtors own or lease real property; (g) all parties that have requested notice pursuant to Bankruptcy Rule 2002 as of the date prior to the date of entry of the Bid Procedures Order; (h) all persons or entities known to the Debtors that have or have asserted a lien on, or security interest in, all or any portion of the Assets; (i) all of the Debtors' known creditors; (j) the Food and Drug Administration; and (k) all potential bidders previously identified or otherwise known to the Debtors (collectively, the "Sale Notice Parties"). The Debtors are also authorized and directed to publish the Sale Notice in the national edition of either the *Wall Street Journal National Edition* or *USA Today* or similar publication.

26. The Cure Notice attached hereto as Exhibit 3 provides proper notice to all parties in interest and is approved. The Debtors shall serve the Cure Notice on all Contract Parties by first class mail not less than fourteen days prior to the Sale Objection Deadline.

27. The Additional Cure Notice attached hereto as Exhibit 4 provides proper notice to all parties in interest and is approved. The Debtors shall serve the Additional Cure Notice pursuant to the additional assumption procedures as provided in the Motion.

28. All of the dates set forth on the attached Schedule 1 are hereby approved.

29. This Order shall constitute findings of fact and conclusions of law and shall take effect immediately upon execution hereof.

30. Notwithstanding the possible applicability of Bankruptcy Rule 6003 or 6004(h) or otherwise, the terms and conditions of this Order shall be immediately effective and enforceable upon its entry, and no automatic stay of execution shall apply to this Order.

31. This Court shall retain jurisdiction over any matters related to or arising from the implementation of this Order and the Bid Procedures.

Dated: _____, 2024
Wilmington, Delaware

United States Bankruptcy Judge

SCHEDULE 1

Deadline for Debtors to Serve Notice of Sale Hearing and Notice of Entry of Bid Procedures Order	Within two (2) business days after entry of the Bid Procedures Order
Deadline for Debtors to Serve Cure Notices	Not less than fourteen (14) days prior to the Sale Objection Deadline
Deadline for Debtors to designate Stalking Horse Bidder	March 26, 2024 at 4:00 p.m. (ET)
Bid Deadline	March 29, 2024 at 4:00 p.m. (ET)
Deadline to Object to Cure Amounts	4:00 p.m. (ET) on the date that is fourteen (14) days after service of the Cure Notice
Deadline to Object to Assumption and Assignment of Contracts and Leases to Successful Bidder	4:00 p.m. (ET) on the date that is fourteen (14) days after service of the Cure Notice
Amended Contract Objection Deadline	The earlier of (a) 4:00 p.m. on the date that is fourteen (14) days after service of notice of adding a contract or lease or (b) the Sale Hearing
Sale Objection Deadline	March 29, 2024 at 4:00 p.m. (ET)
Auction, if necessary	April 3, 2024 at 10:00 a.m. (ET)
Deadline of Debtors to File and Serve Notice of Successful Bidder and Amount of Bid	Within 1 day after the close of the Auction
Sale Hearing	April 5, 2024 at 10:00 a.m. (ET)

EXHIBIT 1

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INVIVO THERAPEUTICS CORPORATION, *et al.*,¹

Debtors.

Chapter 11

Case No. 24-10137 (MFW)

~~(Joint Administration Pending)~~ Jointly Administered

BID PROCEDURES

Overview

On February 1, 2024, InVivo Therapeutics Holdings Corp. and InVivo Therapeutics Corporation, as debtors and debtors in possession (together, the “Debtors”), filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Court”).

On February [], 2024, the Court entered an order [D.I.] (the “Bid Procedures Order”)² which, among other things, authorized the Debtors to solicit bids and approved these procedures (the “Bid Procedures”) for the consideration of the highest or otherwise best bid for all or a portion of the Debtors’ assets on the terms and conditions set forth herein (a “Sale Transaction”).

The Bid Procedures describe, among other things: (i) the procedures for bidders to submit bids for the Debtors’ assets; (ii) the manner in which bidders and bids become Qualified Bidders and Qualified Bids; (iii) the process for negotiating the bids received; (iv) the conduct of the Auction if the Debtors receive Qualified Bids; (v) the procedure for the ultimate selection of any Successful Bidder; and (vi) the process for approval of a Sale Transaction at the Sale Hearing (as defined herein).

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number, are: InVivo Therapeutics Corporation (6670) and InVivo Therapeutics Holdings Corp. (8166). The Debtors’ mailing address is 1500 District Avenue, Burlington, MA 01803.

² Capitalized terms used but not otherwise defined in these Procedures shall have the meanings ascribed to such terms in the Order and the *Motion of Debtors for Entry of Orders: (a)(I) Approving Bid Procedures Relating to the Sale of Substantially All of the Debtors’ Assets, (II) Approving Stalking Horse Bid Protections, (III) Scheduling a Hearing to Consider the Sale, (IV) Approving the Form and Manner of Notice of Sale by Auction, (V) Establishing Notice and Procedures for the Assumption and Assignment of Contracts and Leases, and (VI) Granting Related Relief; and (B)(I) Approving Asset Purchase Agreement and Authorizing the Sale of Certain Assets of the Debtors Outside the Ordinary Course of Business, (II) Authorizing the Sale of Assets Free and Clear of All Liens, Claims, Encumbrances and Interests, (III) Authorizing the Assumption and Assignment of Certain Executory Contracts and Unexpired Leases, and (IV) Granting Related Relief* [D.I. -18] (the “Motion”).

The Debtors reserve the right, subject to the exercise of their reasonable business judgment, to modify or terminate these Bid Procedures, to waive terms and conditions set forth herein, to extend any of the deadlines or other dates set forth herein, to adjourn the Auction and/or Sale Hearing, and/or to terminate discussions with any and all prospective bidders at any time and without specifying the reasons therefor, in each case, to the extent not materially inconsistent with these Bid Procedures and/or the Bid Procedures Order.

Summary of Key Dates

Key Event	Deadline
Deadline to designate Stalking Horse Bidder	March 26, 2024 at 4:00 p.m. (ET)
Deadline to submit Bids	March 29, 2024 at 4:00 p.m. (ET)
Deadline to file objections to (i) Sale Transaction, and (ii) Cure Costs	March 29, 2024 at 4:00 p.m. (ET)
Deadline for Debtors to notify Bidders of status as Qualified Bidders	April 1, 2024
Auction, if necessary, to be conducted at the offices of Landis Rath & Cobb LLP, 919 N. Market Street, Suite 1800, Wilmington DE 19801 or by remote audio and/or video link	April 3, 2024 at 10:00 a.m. (ET)
Deadline of Debtors to File and Serve Notice of Successful Bidder and Amount of Bid	Within 1 <u>Earlier of (a) five (5) business hours after close of the Auction or (b) noon of the day after the close of the Auction</u>
Deadline to file objections to Adequate Assurance of future performance	At the Sale Hearing
Sale Hearing	April 5, 2024 (subject to the Court's availability)

Assets to be Sold

The Debtors intend to offer substantially all of their assets for Sale. Parties may submit bids for the purchase and sale of any and all of the Debtors' assets, in accordance with the terms and conditions set forth herein.

Due Diligence

The Debtors have posted copies of all material documents related to the Debtors' assets to the Debtors' confidential electronic data room (the "Data Room"). To access the Data Room, a party must submit to the Debtors' advisors:

1. an executed confidentiality agreement in form and substance reasonably satisfactory to the Debtors (unless such party is already a party to an existing confidentiality agreement with the Debtors that is acceptable to the Debtors for this due diligence process, in which case such agreement shall govern); and
2. sufficient information, as reasonably requested by the Debtors, to allow the Debtors to determine that the interested party ~~(i) has the financial wherewithal to consummate a Sale Transaction, and (ii)~~ intends to access the Data Room for a purpose consistent with these Bid Procedures.

An interested party that meets the aforementioned requirements to the satisfaction of the Debtors shall be a "Potential Bidder." As soon as practicable, the Debtors will provide such Potential Bidder access to the Data Room; provided, however, that, such access may be terminated by the Debtors in their reasonable discretion at any time for any reason whatsoever, including that a Potential Bidder does not become a Qualified Bidder, violates these Bid Procedures or these Bid Procedures are terminated.

Each Potential Bidder shall comply with all reasonable requests for information and due diligence access by the Debtors or their advisors regarding the ability of such Potential Bidder to consummate a Sale Transaction.

Until the Bid Deadline, the Debtors will provide any Potential Bidder with reasonable access to the Data Room and any additional information requested by Potential Bidders (subject to any restrictions pursuant to applicable law) that the Debtors believe to be reasonable and appropriate under the circumstances. All additional due diligence requests shall be directed to the Debtors' investment bankers, SSG Advisors, LLC, Attn: J. Scott Victor (jsvictor@ssgca.com) and Teresa Kohl (tkohl@ssgca.com). Unless prohibited by law or otherwise determined by the Debtors, the availability of additional due diligence to a Potential Bidder will cease if (i) the Potential Bidder does not become a Qualified Bidder, (ii) these Bid Procedures are terminated, or (iii) the Potential Bidder breaches any obligations under its confidentiality agreement.

Neither the Debtors nor any of their representatives shall be obligated to furnish any information of any kind whatsoever relating to the Debtors' assets to any person or entity who (i) is not a Potential Bidder, (ii) does not comply with the participation requirements set forth herein, or (iii) in the case of competitively sensitive information, is a competitor of the Debtors.

Designation of Stalking Horse Bidders

Designation of Stalking Horse Bidders. The Debtors, in consultation with any official committee of unsecured creditors appointed in the Chapter 11 Cases (the "Committee"), may designate one or more Stalking Horse Bidders and enter into Stalking Horse Agreements with

such Stalking Horse Bidders. The Debtors may designate one or more Stalking Horse Bidders on or before March 26, 2024 at 4:00 p.m. (ET). To the extent the Debtors designate a Stalking Horse Bidder with respect to any of the assets, the Debtors shall promptly upon execution of a Stalking Horse Agreement (and in no event more than one (1) calendar day following such execution) file with the Court and serve upon the U.S. Trustee, the Committee (if any), and those parties who have filed the appropriate notice pursuant to Bankruptcy Rule 2002 requesting notice of all pleadings in these Chapter 11 Cases, and cause to be published on the website maintained by the Debtors' claims and noticing agent in ~~this~~these Chapter 11 ~~Case~~Cases, located at Debtors' claims agent's website at [https:// www.kccllc.net/invivo](https://www.kccllc.net/invivo) a notice that contains information about the Stalking Horse Bidder (and if the Stalking Horse Bidder is a newly formed entity, then the Stalking Horse Bidder's parent company or sponsor), the Stalking Horse Bid, attaches the proposed Stalking Horse Agreement, states whether the Stalking Horse Bidder has any connection to the Debtors other than those that arise from the Stalking Horse Bid, and describes any Stalking Horse Bid Protections proposed to be afforded to the Stalking Horse Bidder (as defined herein) (the "Notice of Stalking Horse Bidder").

Stalking Horse Bid Protections. The Debtors, in consultation with any Committee, may (i) establish initial overbid minimum and subsequent bidding increment requirements; (ii) offer each Stalking Horse Bidder a break-up fee and/or expense reimbursement in an amount agreed to by the Debtors (a "Termination Payment"); (iii) provide that, if the Stalking Horse Bidder bids on certain assets at the Auction, the Stalking Horse Bidder will be entitled to a credit in the amount of its Termination Payment against the increased purchase price for the assets; and (iv) provide other appropriate and customary protections to a Stalking Horse Bidder (the Termination Payment and the other bid protection described in this paragraph collectively are referred to as the "Stalking Horse Bid Protections").

Objections to Designation of Stalking Horse Bidders. Any objections (each, a "Stalking Horse Objection") to the designation of a Stalking Horse Bidder, including any Stalking Horse Bid Protections pursuant to the terms and provisions of a Stalking Horse Agreement, must (i) be in writing; (ii) state the name and address of the objecting party and the amount and nature of the Claim or Interest of such party; (iii) state with particularity the basis and nature of any objection; (iv) conform to the Bankruptcy Rules and the Local Rules; and (v) be served upon the Notice Parties³ within ~~five~~seven (~~5~~7) calendar days after the filing of the relevant Notice of Stalking Horse Bidder. ~~If a timely Stalking Horse Objection is filed and served in accordance with the preceding paragraph, the proposed Stalking Horse Bid Protections will not be deemed approved until either the Stalking Horse Objection is resolved by agreement of the objecting party and the Debtors or by order of the Court.~~ If no timely Stalking Horse Objection is filed and served with respect to ~~an applicable~~the Stalking Horse ~~Agreement in accordance with the Bid Procedures, the Stalking Horse Bid Protections shall be deemed approved without further order of the Court upon the Bid, upon~~ expiration of the objection deadline, the Debtors will submit a proposed order approving the Stalking Horse Bidder and the Stalking Horse Bid to the Court, which may enter such order without a hearing, including with respect to any Stalking Horse Bid Protections.

For all purposes under the Bid Procedures, any Stalking Horse Bidder approved as such pursuant to these Bid Procedures and the Bid Procedures Order shall be considered a Qualified

³ Notice Parties means: (a) the Debtors; (b) the Committee; (c) the Office of the United States Trustee; and (d) all parties who have appeared in these Chapter 11 Cases pursuant to Bankruptcy Rule 2002.

Bidder, and the applicable Stalking Horse Bid shall be considered a Qualified Bid. In the event that the applicable Stalking Horse Bid is the only Qualified Bid received by the Debtors in respect of the applicable assets by the Bid Deadline, the Debtors may cancel the Auction.

Bid Deadline

A Potential Bidder that desires to make a bid on any of the Debtors' assets shall deliver electronic copies of its bid so as to be received no later than March 29, 2024 at 4:00 p.m. (ET) (the "**Bid Deadline**"); provided that, the Debtors may extend the Bid Deadline without further order of the Court subject to providing notice to all Potential Bidders and any Stalking Horse Bidders. The submission of a bid by the Bid Deadline shall constitute a binding and irrevocable offer to acquire the assets specified in such bid. Any party that does not submit a bid by the Bid Deadline will not be allowed to (i) submit any offer after the Bid Deadline or (ii) participate in any Auction. Bids should be submitted by email to the following Debtor representatives:

SSG Advisors LLC	J. Scott Victor	jsvictor@ssgca.com
	Teresa Kohl	tkohl@ssgca.com
Wilmer Cutler Pickering Hale and Dorr LLP	George W. Shuster Jr.	george.shuster@wilmerhale.com
	Benjamin Loveland	benjamin.loveland@wilmerhale.com
Landis Rath & Cobb LLP	Mathew B. McGuire	m McGuire@lrclaw.com
	Joshua B. Brooks	brooks@lrclaw.com

Form and Content of Qualified Bid

A bid is a signed document from a Potential Bidder received by the Bid Deadline that identifies the purchaser by its legal name and any other party that will be participating in connection with the bid, and includes the material terms of the offer to purchase a portion of or substantially all of the Debtors' assets (a "**Bid**"). To constitute a "**Qualified Bid**" a Bid must include, at a minimum, the following:

- i. **Acquired Assets.** Each Bid must clearly identify, in writing and as applicable, the particular assets the Potential Bidder seeks to acquire from the Debtors, including any contracts and leases of the Debtors that would be assumed and assigned in connection with a proposed Sale Transaction.⁴ For the avoidance of doubt, a Qualified Bid may include a Bid for less than all or substantially all of the Debtors' assets.
- ii. **Purchase Price; Form of Consideration; Cash Requirements; Assumed Liabilities.** Each Bid must clearly set forth, as applicable:

⁴ Specifically, each Bid should indicate its preferred method of addressing the BHC and MIT in-licenses, whether assumption and assignment, renegotiation with the licensors, or other method.

- (A) Purchase Price. Each Bid must clearly identify the purchase price to be paid (the “Purchase Price”), and whether the Bid is based on an all-cash offer or consists of certain non-cash components, including, without limitation and/or the assumption of liabilities;
 - (B) Cash Requirements. Each Bid must provide sufficient cash consideration for the payment of any applicable Termination Payment in cash in full;
 - (C) Assumed Liabilities. Each Bid must clearly identify, in writing and as applicable, the particular liabilities, if any, including executory contracts, the Bidder seeks to assume. For the avoidance of doubt, a Qualified Bid may include a bid for less than all or substantially all of the Debtors’ liabilities; and
- iii. Proposed APA. Each Bid must include an executed asset purchase agreement (the “Proposed APA”) for the assets included in such Bid, together with a redline comparing the Proposed APA to the form APA attached hereto as Exhibit A.
 - iv. Unconditional Offer. A statement that the Bid is formal, binding, and unconditional, is not subject to any further due diligence or financing contingency, and is irrevocable until the Debtors notify the Potential Bidder that such Bid is not a Successful Bid or a Back-Up Bid, or until the first business day after the close of a Sale Transaction.
 - v. Proof of Financial Ability to Perform. Each Bid must contain such financial and other information that allows the Debtors to make a reasonable determination as to the Potential Bidder’s financial and other capabilities to consummate a Sale Transaction including, without limitation, such financial and other information setting forth adequate assurance of future performance in satisfaction of the requirements under section 365(f)(2)(B) of the Bankruptcy Code, and the Potential Bidder’s willingness to perform under any contracts that are assumed and assigned to such party. Without limiting the foregoing, such information must include current financial statements or similar financial information certified to be true and correct as of the date thereof, proof of financing commitments if needed to consummate the transaction (not subject to, in the Debtors’ discretion, any unreasonable conditions), contact information for verification of such information, including any financing sources, and any other information reasonably requested by the Debtors necessary to demonstrate that such Potential Bidder has the ability to consummate a Sale Transaction in a timely manner.
 - vi. Designation of Contracts and Leases. Each Bid must identify with particularity each and every executory contract and unexpired lease, the assumption and assignment of which is a condition to closing a Sale Transaction;⁵ **provided, however,** that the Bid may allow for the Potential Bidder to remove executory contracts and unexpired leases from the list of contracts to be assumed and assigned any time prior to the closing of a Sale Transaction; **provided, further,**

⁵ See FN 4 above.

however, that to the extent the Debtors identify any additional executory contracts or unexpired leases after the Bid is submitted, the Bid may allow for the Potential Bidder to add such executory contracts and unexpired leases to the list of contracts to be assumed and assigned any time from and after the Bid is submitted.

- vii. **Required Approvals**. A statement or evidence (1) of the Potential Bidder's plan and ability to obtain all requisite governmental, regulatory, or other third-party approvals; and (2) that the Bid is reasonably likely to be consummated, if selected as the Successful Bid, within a time frame required by the Bid Procedures Order and otherwise acceptable to the Debtors.
- viii. **Authorization**. Each Bid must include evidence of corporate authorization and approval from the Potential Bidder's board of directors (or comparable governing body) with respect to the submission, execution, and delivery of a Bid, participation in the Auction, and closing of the transactions contemplated by the Potential Bidder's Proposed APA in accordance with the terms of the Bid and these Bid Procedures.
- ix. **No Entitlement to Expense Reimbursement or Other Amounts**. With the exception of any Stalking Horse Bid, expressly state that the Bid does not entitle the Potential Bidder to any break-up fee, termination fee, expense reimbursement or similar type of payment or reimbursement, and a waiver of any substantial contribution administrative expense claims under section 503(b) of the Bankruptcy Code related to the bidding process.
- x. **Joint Bids**. The Debtors may approve joint Bids in their reasonable discretion on a case-by-case basis.
- xi. **Representations and Warranties**. Each Bid must include the following representations and warranties:
 - (A) a statement that the Potential Bidder has had an opportunity to conduct any and all due diligence regarding the applicable assets prior to submitting its Bid;
 - (B) a statement that the Potential Bidder has relied solely upon its own independent review, investigation, and/or inspection of any relevant documents and the assets in making its Bid and did not rely on any written or oral statements, representations, promises, warranties, or guaranties whatsoever, whether express or implied, by operation of law or otherwise, regarding the assets or the completeness of any information provided in connection therewith, except as expressly stated in the representations and warranties contained in the Potential Bidder's Proposed APA ultimately accepted and executed by the Debtors;

- (C) a statement that the Potential Bidder agrees to serve as Back-Up Bidder, if its Bid is selected as the next or highest or next best bid after the Successful Bid with respect to the applicable assets;
 - (D) a statement that the Potential Bidder has not engaged in any collusion with respect to the submission of its Bid; and
 - (E) a statement that the Potential Bidder agrees to be bound by the terms of the Bid Procedures.
- xii. A Potential Bidder must also accompany its Bid with:
- (A) a cash deposit in the amount of ten percent (10%) of the Purchase Price (a “Good Faith Deposit”);
 - (B) the contact information of the specific person(s) whom the Debtors or their advisors should contact in the event that the Debtors have any questions or wishes to discuss the Bid submitted by the Potential Bidder;
 - (C) a covenant to cooperate with the Debtors to provide pertinent factual information regarding the Potential Bidder’s operations reasonably required to analyze issues arising with respect to any applicable regulatory requirements; and
 - (D) if the value of a Bid includes additional non-cash components, a detailed analysis of the value of any additional non-cash component of the Bid and backup documentation to support such value.

Good Faith Deposit

A Good Faith Deposit must be deposited, prior to the Bid Deadline, with an escrow agent selected by the Debtors (the “Escrow Agent”) pursuant to an escrow agreement to be provided by the Debtors. To the extent a Qualified Bid is modified before, during, or after the Auction, the Debtors reserve the right to require that such Qualified Bidder adjust its Good Faith Deposit so that it equals ten percent (10%) of the Purchase Price. If a Qualified Bidder is required to adjust its Good Faith Deposit, its status as a Qualified Bidder shall be suspended pending satisfaction of such adjustment.

Review of Bids; Designation of Qualified Bids

The Debtors, in consultation with the Committee, if any, will evaluate Bids that are timely submitted and may engage in negotiations with Potential Bidders who submitted Bids as the Debtors deem appropriate in the exercise of their business judgment, based upon the Debtors’ evaluation of the content of each Bid.

A Bid received for assets that is determined by the Debtors (in consultation with the Committee) to meet the requirements set forth herein will be considered a “Qualified Bid” and

any bidder that submits a Qualified Bid (including any Stalking Horse Bid) will be considered a “Qualified Bidder.”

By no later than April 1, 2024 (the “Qualified Bid Deadline”), the Debtors shall determine, in their reasonable judgment (after consultation with the Committee, if any) which of the Bids received by the Bid Deadline qualify as a Qualified Bid. The Debtors shall notify each Bidder who submits a Qualified Bid of its status as a Qualified Bidder by the Qualified Bid Deadline.

In evaluating the Bids, the Debtors may take into consideration the following non-binding factors:

1. the amount of the purchase price and/or other non-cash consideration, as applicable, set forth in the Bid;
2. the assets included in or excluded from the Bid, including any executory contracts or leases proposed to be assumed;
3. the value to be provided to the Debtors under the Bid, including the net economic effect upon the Debtors’ estates, taking into account any Stalking Horse Bidder’s rights to any Termination Payment;
4. any benefit to the Debtors’ bankruptcy estates from any assumption of liabilities or waiver of liabilities;
5. the transaction structure and execution risk, including conditions to, timing of, and certainty of closing; termination provisions; availability of financing and financial wherewithal to meet all commitments; and required governmental or other approvals;
6. the impact on employees and employee claims against the Debtors;
7. the impact on trade creditors; and
8. any other factor the Debtors may reasonably deem relevant consistent with their fiduciary duties.

The Debtors reserve the right to work with any Potential Bidder in advance of the Auction to cure any deficiencies in a Bid that is not initially deemed a Qualified Bid. The Debtors may amend or waive the conditions precedent to being a Qualified Bidder at any time, in their reasonable business judgment and in a manner consistent with their fiduciary duties and applicable law (as reasonably determined in good faith by the Debtors in consultation with their legal counsel).

The Debtors may accept a single Bid or multiple partial Bids for non-overlapping assets such that, if taken together, such multiple partial bids would otherwise meet the standards for a single Qualified Bid as to any assets or combinations of assets that the Debtors determine to auction (in which event those multiple bidders shall be treated as a single Qualified Bidder for purposes of the Auction).

Without the written consent of the Debtors, a Qualified Bidder may not modify, amend, or withdraw its Qualified Bid, except for proposed amendments to increase the Purchase Price or otherwise improve the terms of the Qualified Bid for the Debtors during the period that such

Qualified Bid remains binding as specified herein; provided that, any Qualified Bid may be improved at the Auction as set forth in these Bid Procedures.

The Debtors shall make a determination regarding the following:

- (A) the assets and/or any combination of assets to be auctioned by the Debtors; and
- (B) which Bids have been determined to be Qualified Bids and the applicable assets relating to such Qualified Bids.

Failure to Receive Qualified Bids ~~Far~~For Substantially Similar Assets

If no Qualified Bid (other than the applicable Stalking Horse Bid, if any) is received by the Qualified Bid Deadline, the Debtors will not conduct the Auction, and shall file a notice with the Court indicating that no Auction will be held. The Debtors shall also publish such notice on the website of its claims and noticing agent, [https:// www.kccllc.net/invivo](https://www.kccllc.net/invivo).

Auction Procedures

If the Debtors receive two or more Qualified Bids for substantially the same assets, the Debtors may, in their business judgment, conduct the Auction in person or by remote audio and/or video link on April 3, 2024, beginning at 10:00 a.m. (ET) at the offices of Landis Rath & Cobb LLP, 919 N. Market Street, Wilmington, DE 19801. Only a Qualified Bidder will be eligible to participate at the Auction, subject to such limitations as the Debtors may impose in good faith. In addition, [the U.S. Trustee and](#) professionals and/or other representatives of the Debtors, Committee, and any creditors or equity holders of the Debtors shall be permitted to attend and observe the Auction. Each Qualified Bidder shall be required to confirm, both before and after the Auction, that it has not engaged in any collusion with respect to the submission of any bid, the bidding, or the Auction.

The Debtors, in consultation with the Committee, if any, may adopt rules for the Auction at any time that the Debtors reasonably determine to be appropriate to promote a value-maximizing auction. Any rules developed by the Debtors will provide that all bids in the Auction will be made and received on an open basis, and all other bidders participating in the Auction will be entitled to be present for all bidding with the understanding that the true identity of each bidder placing a bid at the Auction will be fully disclosed to all other bidders participating in the Auction and that all material terms of a bid submitted in response to any successive bids made at the Auction will be disclosed to all other bidders. Each Qualified Bidder will be permitted what the Debtors reasonably determine to be an appropriate amount of time to respond to the previous bid at the Auction. The Auction will be conducted openly and shall be transcribed or recorded.

The Debtors may, in their discretion and in consultation with the Committee, if any, identify the highest or otherwise best Qualified Bid as the successful bid (a “Successful Bid” and the bidder submitting such bid, a “Successful Bidder”). The Debtors may also identify a Qualified Bidder that submitted the next highest or otherwise best Qualified Bid as a back-up bid (a “Back-Up Bid” and the bidder submitting such bid, a “Backup Bidder”). A Back-Up Bid shall remain open and irrevocable until the earliest to occur of (i) consummation of a Sale Transaction

with the Successful Bidder and (ii) the release of such Back-Up Bid by the Debtors in writing (such date, the “Back-Up Bid Expiration Date”). If a Sale Transaction with a Successful Bidder is terminated prior to the Back-Up Bid Expiration Date, the Back-Up Bidder shall be deemed a Successful Bidder and shall be obligated to consummate the Back-Up Bid as if it were a Successful Bid. Provided, however, that the Debtors are not required to accept any bid or designate a Successful Bidder or Back-Up Bidder.

Within one day after the Auction, a Successful Bidder shall submit to the Debtors fully executed documentation memorializing the terms of a Successful Bid. A Successful Bid may not be assigned to any party without the consent of the Debtors.

At any time before entry of an order approving an applicable Sale Transaction envisioned by a Qualified Bid, the Debtors reserve the right to and may reject such Qualified Bid if such Qualified Bid, in the Debtors’ judgment (after consultation with the Committee, if any), is: (i) inadequate or insufficient; (ii) not in conformity with the requirements of the Bankruptcy Code, these Bid Procedures, or the terms and conditions of the applicable Sale Transaction; or (iii) contrary to the best interests of the Debtors and their estates.

Post-Auction Process

~~Within one~~ By the earlier of (a) five (5) business hours of the close of the Auction or (b) noon of the day after the ~~conclusion~~ close of the Auction, or as soon as reasonably practicable thereafter, the Debtors shall file with the Court a notice of a Successful Bid, Successful Bidder, Back-Up Bid, and Back-Up Bidder. Unless otherwise required pursuant to the Debtors’ fiduciary duties, the Debtors shall not consider any bids submitted after the conclusion of the Auction.

Within seven (7) days after the Auction, the Debtors shall direct the Escrow Agent to return the deposit of any bidder, who is not declared a Successful Bidder or Back-Up Bidder. Within five (5) days after the Back-Up Bid Expiration Date, the Debtors shall direct the Escrow Agent to return the deposit of a Back-Up Bidder. Upon the authorized return of any such deposit, the bid of such Potential Bidder, Qualified Bidder or Back-Up Bidder, as applicable, shall be deemed revoked and no longer enforceable.

A Successful Bidder’s deposit shall be applied against the cash portion of the purchase price of such bidder’s Successful Bid upon the consummation of a Sale Transaction.

In addition to the foregoing, the deposit of a Qualified Bidder will be forfeited to the Debtors if (i) the Qualified Bidder attempts to modify, amend, or withdraw its Qualified Bid, except as permitted herein, during the time the Qualified Bid remains binding and irrevocable or (ii) the Qualified Bidder is selected as a Successful Bidder or Back-Up Bidder and refuses or fails to enter into the required definitive documentation or to consummate a Sale Transaction according to these Bid Procedures.

Notices Regarding Assumption and Assignment

The Debtors shall provide all notices regarding the proposed assumption and assignment of contracts and leases in accordance with the Assumption and Assignment Procedures included in the Bid Procedures Order.

Sale Hearing

If the Debtors elect to proceed with a Sale Transaction, the Debtors will seek the entry of an order authorizing and approving the Sale Transaction at a hearing before the Court on April 5, 2024, or at a date otherwise designated by the Court (the “Sale Hearing”). The Debtors, in the exercise of their business judgment, may adjourn the Sale Hearing without notice or with limited and shortened notice to parties, including by (i) an announcement of such adjournment at the Sale Hearing or at the Auction or (ii) the filing of a notice of adjournment with the Court prior to the commencement of the Sale Hearing.

Objections to a Sale Transaction, including any objection to the sale of the Debtors’ assets free and clear of liens, claims, encumbrances, and other interests pursuant to section 363(f) of the Bankruptcy Code (each, a “Sale Objection”), shall (i) be in writing; (ii) state the name and address of the objecting party and the amount and nature of the Claim or Interest of such party; (iii) state with particularity the basis and nature of any objection, and provide proposed language that, if accepted and incorporated by the Debtors, would obviate such objection; (iv) conform to the Bankruptcy Rules and the Local Rules; (v) be filed with the Court; and (vi) be served upon the Notice Parties (as defined in the in the Bid Procedures Order) by March 29, 2024 at 4:00 p.m. (ET) (the “Sale Objection Deadline”); provided that, the Debtors may extend the Sale Objection Deadline, as the Debtors deem appropriate in the exercise of their reasonable business judgment. If a timely Sale Objection cannot otherwise be resolved by the parties, such objection shall be heard by the Court at the Sale Hearing.

A Successful Bidder shall appear at the Sale Hearing and be prepared to have a representative(s) testify in support of the Successful Bid and such Successful Bidder’s ability to close in a timely manner and provide adequate assurance of its future performance under any and all executory contracts and unexpired leases to be assumed and/or assigned as part of the proposed transaction.

Any party who fails to file with the Court and serve on the Objection Notice Parties a Sale Objection by the Sale Objection Deadline may be forever barred from asserting, at the Sale Hearing or thereafter, any Sale Objection to the relief requested in the Motion with regard to a Successful Bidder, or to the consummation and performance of a Sale Transaction, contemplated by an asset purchase agreement between the Debtors and a Successful Bidder, including the transfer of assets to a Successful Bidder, free and clear of all liens, claims, encumbrances, and other interests pursuant to section 363(f) of the Bankruptcy Code. Failure to object shall constitute consent for the purposes of section 363(f)(2) of the Bankruptcy Code.

Consent to Jurisdiction and Authority as Condition to Bidding

All bidders that participate in the bidding process shall be deemed to have (i) consented to the core jurisdiction of the Court to enter any order or orders, which shall be binding in all respects, in any way related to these Bid Procedures, the bid process, the Auction, the Sale Hearing, or the construction and enforcement of any agreement or any other document relating to an applicable Sale Transaction; (ii) waived any right to a jury trial in connection with any disputes relating to these Bid Procedures, the bid process, the Auction, the Sale Hearing, or the construction and enforcement of any agreement or any other document relating to a Sale

Transaction; and (iii) consented to the entry of a final order or judgment in any way related to these Bid Procedures, the bid process, the Auction, the Sale Hearing, or the construction and enforcement of any agreement or any other document relating to an applicable Sale Transaction if it is determined that the Court would lack Article III jurisdiction to enter such a final order or judgment absent the consent of the parties.

Reservation of Rights

The Debtors reserve the right to, in their reasonable business judgment, in a manner consistent with their fiduciary duties and applicable law to modify these Bid Procedures; waive terms and conditions set forth herein with respect to all Potential Bidders; extend the deadlines set forth herein; announce at the Auction modified or additional procedures for conducting the Auction; alter the assumptions set forth herein; and provide reasonable accommodations to any Stalking Horse Bidder with respect to such terms, conditions, and deadlines of the bidding and Auction process to promote further bids on any assets, in each case, to the extent not materially inconsistent with these Bid Procedures and the Bid Procedures Order. The Debtors shall not be obligated to consummate or pursue any transaction with respect to any asset.

EXHIBIT A

ASSET PURCHASE AGREEMENT

BY AND BETWEEN

[PURCHASER],

as Purchaser,

and

INVIVO THERAPEUTICS HOLDINGS CORP.

and

INVIVO THERAPEUTICS CORPORATION,

collectively, as Seller

Dated as of [●], 2024

THIS DOCUMENT DOES NOT INDICATE ANY DECISION TO SELL ANY ASSETS, OR TO TAKE ANY OTHER ACTION DESCRIBED HEREIN. THIS DOCUMENT IS NOT INTENDED TO CREATE, NOR WILL IT BE DEEMED TO CREATE, A LEGALLY BINDING OR ENFORCEABLE OFFER, ACCEPTANCE OF AN OFFER, OR AGREEMENT, OF ANY TYPE OR NATURE, UNLESS AND UNTIL AGREED TO AND EXECUTED BY ALL PARTIES.

TABLE OF CONTENTS

	<u>Page</u>
ARTICLE I.	
DEFINITIONS AND EFFECTIVENESS.....	1
1.1 Certain Definitions	1
ARTICLE II.	
ACQUISITION AND TRANSFER OF ASSETS; ASSUMPTION OF LIABILITIES	11
2.1 Transfer of Assets.....	11
2.2 Excluded Assets.....	12
2.3 Assumed Liabilities.....	12
2.4 Excluded Liabilities.....	12
2.5 Assumed Executory Contracts	12
2.6 Waiver and Release of Acquired Avoidance Actions.....	12
2.7 Liens Attach to Sale Proceeds.....	13
ARTICLE III.	
CONSIDERATION	13
3.1 Consideration.....	13
3.2 Payment of Purchase Price at Closing	13
3.3 Assumed Liabilities.....	13
3.4 Deposit.....	13
3.5 Allocation of Consideration	13
ARTICLE IV.	
CLOSING AND TERMINATION	14
4.1 Closing.....	14
4.2 Conveyances at Closing	14
4.3 Additional Deliveries	14
4.4 Transaction Expenses	15
4.5 Prorations.....	15
4.6 Termination of Agreement	15
4.7 Procedure Upon Termination	16
4.8 Effect of Termination	17

ARTICLE V.

REPRESENTATIONS AND WARRANTIES OF SELLER17

5.1 Organization and Power17

5.2 Corporate Authorization.....17

5.3 Binding Effect17

5.4 Ownership of Acquired Assets.....17

5.5 Taxes.....18

5.6 Real Property18

5.7 Intellectual Property18

5.8 Litigation19

5.9 Environmental Matters19

5.10 Compliance With Laws19

5.11 Permits; Regulatory Matters.....20

5.12 Labor Matters **Error! Bookmark not defined.**

5.13 Finders’ Fees20

5.14 No Other Representations or Warranties20

ARTICLE VI.

REPRESENTATIONS AND WARRANTIES OF PURCHASER21

6.1 Organization and Power21

6.2 Authorization21

6.3 Binding Effect21

6.4 Funding.....21

6.5 Adequate Assurances Regarding Assumed Executory Contracts.....21

6.6 Finders’ Fees21

6.7 Good Faith Purchaser21

6.8 Purchaser Experience22

6.9 Non-Reliance on Seller Estimates, Projections, Forecasts, Forward-
Looking Statements and Business Plans22

ARTICLE VII.

CERTAIN COVENANTS22

7.1 Bankruptcy Sale Process.22

7.2 Stalking Horse Provisions.23

7.3 Pre-Closing Operating Covenants of Seller.24

7.4 Access to Information26
 7.5 Reasonable Efforts; Further Assurances of Each Party26
 7.6 Regulatory Affairs27

ARTICLE VIII.

CONDITIONS TO CLOSING27
 8.1 Conditions Precedent to the Obligations of Seller and Purchaser27
 8.2 Conditions Precedent to the Obligations of Seller27
 8.3 Conditions Precedent to the Obligations of Purchaser28

ARTICLE IX.

MISCELLANEOUS28
 9.1 Transfer Taxes28
 9.2 Releases28
 9.3 Survival29
 9.4 Injunctive Relief29
 9.5 Entire Agreement; Amendments and Waivers29
 9.6 Counterparts; Electronic Signatures29
 9.7 Governing Law29
 9.8 Waiver of Jury Trial30
 9.9 Notices30
 9.10 Binding Effect; Assignment31
 9.11 Third Party Beneficiaries31
 9.12 Publicity31
 9.13 Severability31
 9.14 Non-Recourse31
 9.15 Time of the Essence32
 9.16 Miscellaneous32

EXHIBITS

Exhibit A Acquired Assets
 Exhibit B Assumed Executory Contracts
 Exhibit C Assumed Liabilities
 Exhibit D Excluded Assets
 Exhibit E Bill of Sale
 Exhibit F Form of Assignment and Assumption Agreement

SCHEDULES

Schedule 4.5 Prorations Exceptions

ASSET PURCHASE AGREEMENT

This **ASSET PURCHASE AGREEMENT** (this “Agreement”), dated as of [●], 2024, is made and entered into by and among [PURCHASER], a [jurisdiction of organization] [type of entity] (“Purchaser”), and **INVIVO THERAPEUTICS HOLDINGS CORP.**, a Nevada corporation (“Holdings”), and **INVIVO THERAPEUTICS CORPORATION**, a Delaware corporation (“InVivo” and, together with Holdings, “Seller”). Certain capitalized terms used herein are defined in Article I.

RECITALS

WHEREAS, Seller is a research and research and clinical-stage biomaterials and biotechnology company with a focus on the development of its investigational Neuro-Spinal Scaffold implant (the “NSS Implant”) for the treatment of spinal cord injuries (the “Business”);

WHEREAS, Seller commenced a case (the “Chapter 11 Case”) under chapter 11 of title 11 of the United States Code, 11 U.S.C. § 101 et seq. (the “Bankruptcy Code”), in the United States Bankruptcy Court for the District of Delaware (the “Court”);

WHEREAS, Purchaser desires to acquire certain assets of Seller identified herein, and Seller desires to sell, convey, assign, and transfer to Purchaser such assets, pursuant to the terms and conditions of this Agreement;

WHEREAS, it is intended that the Acquired Assets (defined below) will be sold and purchased pursuant to the terms of this Agreement in a sale authorized by the Court pursuant to section 363 of the Bankruptcy Code; and

WHEREAS, in connection with such a sale, it is intended that the Court shall approve the assumption and assignment of certain Executory Contracts (defined below) under section 365 of the Bankruptcy Code.

NOW, THEREFORE, in consideration of the foregoing and the mutual representations, warranties, covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, Purchaser and Seller hereby agree as follows:

ARTICLE I.

DEFINITIONS AND EFFECTIVENESS

1.1 Certain Definitions. For purposes of this Agreement, the following terms used in this Agreement shall have the respective meanings assigned to them below:

(a) “Accounts Receivable” means (i) any and all accounts receivable, trade accounts and other amounts (including overdue accounts receivable, refunds, rebates, and other credits) owed to Seller relating to, or arising in connection with the operation and conduct of, the Business prior to the Closing and any other similar rights of Seller to payment from third parties arising prior to the Closing and the full benefit of all security for such accounts or rights to

payment; (ii) all other accounts or notes receivable of Seller as of the Closing and the full benefit of all security for such accounts or notes receivable; and (iii) any and all claims, remedies or other rights relating to any of the foregoing, together with any interest or unpaid financing charges accrued thereon, in each case that have not been satisfied or discharged prior to the close of business on the day immediately preceding the Closing or have not been written off or sent to collection prior to the close of business on the day immediately preceding the Closing (it being understood that the receipt of a check prior to the close of business on the day immediately preceding the Closing Date shall constitute satisfaction or discharge of the applicable account or note receivable to the extent of the payment represented thereby).

(b) “Acquired Assets” means the assets of Seller related to the Program, as set forth on Exhibit A hereto.

(c) “Acquired Avoidance Actions” means any and all Avoidance Actions against any vendor, customer, or other counterparty of the Business, including without limitation the Persons listed on Annex A-[●] to Exhibit A.

(d) “Acquired Claims” [RESERVED].¹

(e) “Affiliate” means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, such Person, and the term “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through ownership of voting securities, by contract or otherwise.

(f) “Alternative Transaction” means a sale, transfer or other disposition of all or any substantial portion of the Acquired Assets to any Person or Persons other than Purchaser, in any transaction or series of transactions.

(g) “Assumed Executory Contracts” means the Executory Contracts to be assumed and assigned to Purchaser pursuant to section 365 of the Bankruptcy Code in accordance with the Bidding Procedures, as set forth on Exhibit B hereto.

(h) “Assumed Liabilities” means only those liabilities expressly set forth on Exhibit C hereto.²

(i) “Auction” shall have the meaning set forth in the Bidding Procedures.

(j) “Avoidance Action” means any and all claims, rights and causes of action of Seller arising under chapter 5 of the Bankruptcy Code or similar federal, state or local laws.

¹ NTD: Treatment of Acquired Claims to be proposed by Purchaser.

² NTD: Seller would expect any Purchaser to assume royalty obligations in respect of the Specified Licenses.

(k) “Backup Bidder” shall have the meaning set forth in the Bidding Procedures.

(l) “Bankruptcy Matters” means (a) the amount, extent, or type of Cash and Cash Equivalents of Seller or any other Excluded Assets, or any Excluded Liabilities; (b) any failure, in and of itself, of Seller to meet any projections, budgets, plans or forecasts of revenues, earnings or other financial performance measures or operating statistics filed with the Court; or (c) the announcement, commencement, or continuation of the Chapter 11 Cases or any action approved by the Court in the Chapter 11 Case.

(m) “Bankruptcy Rules” means the Federal Rules of Bankruptcy Procedure.

(n) “Bidding Procedures” means the procedures governing the submission, evaluation and qualification of competing bids for the Acquired Assets, and the auction among qualified bidders for the purchase of the Acquired Assets, as described in the Bidding Procedures Order.

(o) “Bidding Procedures Motion” means a motion filed by Seller, reasonably satisfactory in form and substance to Seller, seeking approval of (i) the sale process described in the Sale Motion and the Bidding Procedures, and (ii) the Stalking Horse Provisions.

(p) “Bidding Procedures Order” means an Order of the Court, reasonably satisfactory in form and substance to Seller, approving the sale process described in the Sale Motion and the Bidding Procedures, including, without limitation, the Stalking Horse Provisions.

(q) “Break-Up Fee” shall have the meaning set forth in Section 7.2.

(r) “Business Day” means any day other than a Saturday, Sunday or a legal holiday on which banking institutions in the State of Delaware are not required to open.

(s) “Cash and Cash Equivalents” means all of Seller’s cash (including petty cash but excluding any checks that remain uncashed or uncleared prior to the close of business on the Closing Date), checking account balances, marketable securities, certificates of deposits, time deposits, bankers’ acceptances, commercial paper and government securities and other cash equivalents.

(t) “Cash Purchase Price” means an amount in cash equal to \$[●], subject to adjustment as provided in Section 3.2 and Section 4.5.

(u) “Claim” has the meaning set forth in section 101(5) of the Bankruptcy Code.

(v) “Contract” means any written or oral contract, lease, purchase order, service order, sales order, or instrument or other agreement, arrangement or commitment that is binding upon a Person or its property, and any amendments, modifications or supplements thereto.

(w) “Copyright” means all copyrights, including copyrights in software and in the content contained on any Web site, artwork (including editable jpeg images), packaging material, patient information leaflets, promotional material, advertising material, and those which are registered, applied for registration or used, whether registrable or not, by Seller, and rights to sue for past infringement thereof.

(x) “Cure Costs” means, for any Assumed Executory Contract, the amount required to be paid under section 365 of the Bankruptcy Code to effectuate the assumption and assignment of such Assumed Executory Contract by Seller to Purchaser (giving effect to any mutual agreement with the contract counterparty to such Assumed Executory Contract).

(y) “Deposit” means the good-faith deposit in the amount of \$[●].³

(z) “Deposit Escrow Agent” means the Person serving from time to time as escrow agent under the Deposit Escrow Agreement, provided that counsel to Seller may serve as the Deposit Escrow Agent.

(aa) “Deposit Escrow Agreement” means the escrow agreement being entered into by Seller and Purchaser or their representatives as of the date of this Agreement, reasonably satisfactory in form and substance to Seller and Purchaser, pursuant to which the Deposit Escrow Agent will hold the Deposit, provided that email confirmation of escrow terms from counsel to Seller may serve as the Deposit Escrow Agreement if counsel to Seller serves as the Deposit Escrow Agent.

(bb) “Documents” means all of Seller’s written files, documents, instruments, papers, books, reports, records, tapes, microfilms, photographs, letters, budgets, forecasts, plans, operating records, safety and environmental reports, data, studies and documents, Tax Returns, ledgers, journals, title policies, customer lists, regulatory filings, operating data and plans, research material, technical documentation (design specifications, engineering information, test results, maintenance schedules, functional requirements, operating instructions, logic manuals, processes, flow charts, etc.), user documentation (installation guides, user manuals, training materials, release notes, working papers, etc.), marketing documentation (sales brochures, flyers, pamphlets, web pages, etc.), and other similar materials related to, used in, or held for use in connection with the Program or any of the Acquired Assets, in each case whether or not in electronic form.

(cc) “Encumbrance” means any lien, interest, encumbrance, Claim, right, demand, charge, mortgage, deed of trust, option, pledge, security interest or similar interest, title defect, hypothecation, easement, right of way, restrictive covenant, condition, restriction, encroachment, rights of first refusal, preemptive right, judgment, conditional sale or other title retention agreements and other imposition, imperfection or defect of title or restriction on transfer or use of any nature whatsoever, whether secured or unsecured, choate or inchoate, filed or unfiled, scheduled or unscheduled, recorded or unrecorded, contingent or non-contingent, material or non-

³ NTD: This amount should be 10% of the value of the purchase price.

material, known or unknown; provided, however that the term “Encumbrance” does not include the Assumed Liabilities.

(dd) “Environmental Law” means any applicable law, regulation, order, decree or permit requirement of any governmental jurisdiction relating to: (a) the protection, investigation or restoration of the environment, human health and safety, or natural resources, (b) the handling, use, storage, treatment, transport, disposal, release or threatened release of any Hazardous Substance or (c) noise, odor or wetlands protection.

(ee) “Excluded Assets” means those assets and properties of Seller that are not Acquired Assets including, without limitation, the assets set forth on Exhibit D hereto.

(ff) “Excluded Liabilities” means those Encumbrances or Liabilities of Seller or related to the Acquired Assets or any other assets of Seller, whether actual or contingent, accrued or unaccrued, matured or unmatured, liquidated or unliquidated, or known or unknown, that are not the Assumed Liabilities set forth on Exhibit C hereto.

(gg) “Executory Contracts” means all executory contracts (including licenses) and unexpired leases related to the Business in effect as of the date hereof to which Seller is a party.

(hh) “Expense Reimbursement” shall have the meaning set forth in Section 7.2.

(ii) “FDA” means the United States Food and Drug Administration.

(jj) “Final Order” means an Order or judgment of the Court or any other court of competent jurisdiction entered by the Clerk of the Court or such other court on the docket in Seller’s Chapter 11 Cases or the docket of such other court, which has not been modified, amended, reversed, vacated or stayed and as to which (a) the time to appeal, petition for *certiorari*, or move for a new trial, reargument or rehearing has expired and as to which no appeal, petition for *certiorari* or motion for new trial, reargument or rehearing shall then be pending or (b) if an appeal, writ of *certiorari*, new trial, reargument or rehearing thereof has been sought, such Order or judgment of the Court or other court of competent jurisdiction shall have been affirmed by the highest court to which such Order was appealed, or *certiorari* shall have been denied, or a new trial, reargument or rehearing shall have been denied or resulted in no modification of such Order, and the time to take any further appeal, petition for *certiorari* or move for a new trial, reargument or rehearing shall have expired, as a result of which such Order shall have become final in accordance with Rule 8002 of the Bankruptcy Rules; provided, however, that the possibility that a motion under Rule 60 of the Federal Rules of Civil Procedure, or any analogous rule under the Bankruptcy Rules, may be filed relating to such Order, shall not cause such Order not to be a Final Order.

(kk) “Final Sale Notice” means a notice distributed in accordance with the Bidding Procedures regarding the transactions contemplated by this Agreement and the Sale Order.

(ll) “GAAP” means United States generally accepted accounting principles.

(mm) “Governmental Body” means any government, quasi-governmental entity, or other governmental or regulatory body, agency or political subdivision thereof of any nature, whether foreign, federal, state, provincial or local, or any ministry agency, branch, department, official, entity, instrumentality or authority thereof, or any court or arbitrator (public or private) or any judicial, quasi-judicial or administrative body, or any regulatory body of applicable jurisdiction, including any Regulating Authority.

(nn) “Hazardous Substance” means: (a) any substance that is regulated or which falls within the definition of a “hazardous substance,” “hazardous waste” or “hazardous material” pursuant to any Environmental Law or (b) any petroleum product or by-product, asbestos-containing material, polychlorinated biphenyls, radioactive materials or radon.

(oo) “Initial Notice of Proposed Assumed Executory Contracts” means a notice filed by Seller with the Court in accordance with the Bidding Procedures identifying the Executory Contracts Purchaser intends, as of the date of such notice, to assume as of the Closing Date.

(pp) “Intellectual Property” means all of the following anywhere in the world and all legal rights, title or interest in the following arising under Law: (i) all Patents and applications for Patents and all related reissues, reexaminations, divisions, renewals, extensions, provisionals, continuations and continuations-in-part, including any future applications or filings of the foregoing; (ii) all Copyrights, Copyright registrations and Copyright applications, copyrightable works and all other corresponding rights; (iii) all mask works, mask work registrations and mask work applications and all other corresponding rights; (iv) all advertising material, trade dress and trade names, logos, Internet addresses and domain names, Trademarks and service marks and related registrations and applications, including any intent to use applications, supplemental registrations and any renewals or extensions, all other indicia of commercial source or origin and all goodwill associated with any of the foregoing; (v) all inventions (whether patentable or unpatentable and whether or not reduced to practice), know how, technology, technical data, trade secrets, confidential business information, manufacturing and production processes and techniques, research and development information, clinical trial data and information, safety data and pharmacovigilance data, financial, marketing and business data, pricing and cost information, business and marketing plans, advertising and promotional materials, customer, distributor, reseller and supplier lists and information, correspondence, records, and other documentation, and other proprietary information of every kind; (vi) all computer software (including source and object code), firmware, development tools, algorithms, files, records, technical drawings and related documentation, data and manuals; (vii) all databases and data collections; (viii) all licenses and permits to the extent transferable; (ix) all rights pertaining to the foregoing, including those arising under international treaties and convention rights, (x) all rights and powers to assert, defend and recover title to any of the foregoing, (xi) all rights to assert, defend, sue, and recover damages for any past, present and future infringement, misuse, misappropriation, impairment, unauthorized use or other violation of any rights in or to any of the foregoing, (xii) all proceeds, income, royalties, damages and payments now and/or hereafter due

and payable under and/or in respect of all of the foregoing (including with respect to past, present or future infringement or violation thereof), (xiii) all administrative rights arising from the foregoing, including the right to prosecute applications and oppose, interfere with or challenge the applications of others, the rights to obtain renewals, continuations, divisions, and extensions of legal protection pertaining to any of the foregoing, and (xiv) all other intellectual property rights irrespective of not being registered or applied for registration.

(qq) “Laws” (and each, a “Law”) means all federal, state, provincial, local or foreign laws, statutes, common law, rules, codes, regulations, restrictions, ordinances, Orders, decrees, approvals, directives, judgments, rulings, injunctions, writs and awards of, or issued, promulgated, enforced or entered by, any and all Governmental Bodies, or court of competent jurisdiction, or other legal requirement or rule of law, including common law.

(rr) “Legal Proceeding” means any judicial, administrative or arbitral actions, suits, proceedings (public or private) or claims or any proceedings by or before a Governmental Body.

(ss) “Liability” means, as to any Person, any debt, adverse claim, liability, duty, responsibility, obligation, commitment, assessment, cost, expense, loss, expenditure, charge, fee, penalty, fine, contribution or premium of any kind or nature whatsoever of such Person, whether known or unknown, asserted or unasserted, absolute or contingent, direct or indirect, accrued or unaccrued, liquidated or unliquidated, or due or to become due, including all costs and expenses relating thereto.

(tt) “Material Adverse Effect” means any effect that is materially adverse to the value of the Acquired Assets; provided, however, that (x) any decrease in value of the Acquired Assets that is less than twenty-five percent (25%) shall not be deemed material for purposes of this definition, and (y) no effect (by itself or when aggregated or taken together with any and all other effects) directly or indirectly resulting from, arising out of, attributable to, or related to any of the following shall be deemed to be or constitute a “Material Adverse Effect,” and no effect (by itself or when aggregated or taken together with any and all other such effects) directly or indirectly resulting from, arising out of, attributable to, or related to any of the following shall be taken into account when determining whether a “Material Adverse Effect” has occurred or may, would or could occur: (a) general economic conditions (or changes in such conditions) in the United States or any other country or region in the world, or conditions in the global economy generally; (b) conditions (or changes in such conditions) in the securities markets, credit markets, currency markets or other financial markets in the United States or any other country or region in the world, including (i) changes in interest rates in the United States or any other country or region in the world and changes in exchange rates for the currencies of any countries and (ii) any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market operating in the United States or any other country or region in the world; (c) conditions (or changes in such conditions) in the industries in which Seller conducts business; (d) political conditions (or changes in such conditions) in the United States or any other country or region in the world or acts of war, sabotage or terrorism (including any escalation or general worsening of any such acts of war, sabotage or terrorism) in the United States or any other country or region in the world; (e) earthquakes, hurricanes,

tsunamis, tornadoes, floods, mudslides, wild fires or other natural disasters, weather conditions and other force majeure events in the United States or any other country or region in the world; (f) any global or national health concern, epidemic, disease outbreak, pandemic (whether or not declared as such by any Governmental Body and including the “Coronavirus” or “COVID-19”) or any Law issued by a Governmental Body requiring business closures, quarantine or “sheltering-in-place” or similar restrictions that arise out of such health concern, epidemic, disease outbreak or pandemic (including the “Coronavirus” or “COVID-19”) or any change in such Law following the date of this Agreement; (g) the announcement of this Agreement or the pendency or consummation of the transactions contemplated thereby, including (i) the identity of Purchaser, (ii) the loss or departure of officers or other employees of Seller, (iii) the termination or potential termination of (or the failure or potential failure to renew or enter into) any contracts with suppliers, distributors or other business partners, whether as a direct or indirect result of the loss or departure of officers or employees of Seller or otherwise, and (iv) any other negative development (or potential negative development) in the relationships of Seller with any of its suppliers, distributors or other business partners; (h) any actions taken or failure to take action, in each case, to which Purchaser has approved, consented to or requested; or compliance with the terms of, or the taking of any action required or contemplated by, this Agreement; or the failure to take any action prohibited by this Agreement; (i) changes or developments in law or other legal or regulatory conditions (including rules, regulations, administrative policies, actions, requests, recommendations, determinations, statements, positions, and decisions of the FDA), or the interpretation thereof, or changes in GAAP or other accounting standards (or the interpretation thereof), or that result from any action taken for the purpose of complying with any of the foregoing; (j) any product or product candidate of Seller, including any change, event, circumstance or development relating to the potential or actual use or sale of any such product or product candidate, the suspension, recall, rejection, refusal of, request to refile or any delay in obtaining or making any regulatory application or filing relating to any such product or product candidate or any clinical trial in respect thereof, any other negative actions, requests, recommendations, determinations, statements, positions, or decisions of the FDA or any other Governmental Body relating to any such product or product candidate or any clinical trial in respect thereof, any other competitive or regulatory development affecting any such product or product candidate, or the failure to conduct successful clinical trials on a timely basis for any such product candidate; (l) any product or product candidate of any Person (other than Seller), including the entry into the market of any product potentially or actually competitive with any product or product candidate of Seller; (l) any clinical trials or studies undertaken by any Person and any date resulting therefrom or other results thereof, and any negative publicity or unfavorable media attention resulting therefrom; (m) any fees or expenses incurred in connection with the transactions contemplated by this Agreement; (n) changes in Seller’s stock price or the trading volume of Seller’s stock, or any failure by Seller to meet any public estimates or expectations of Seller’s revenue, earnings or other financial performance or results of operations for any period, or any failure by Seller to meet any internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations (but not, in each case, the underlying cause of such changes or failures, unless such changes or failures would otherwise be excepted from this definition), or any cessation, suspension, or other limitation on the listing or trading of Seller’s stock; (o) any legal proceedings made or brought by any of the current or former stockholders of Seller (on their own behalf or on

behalf of Seller) against Seller, Purchaser, or any of their directors or officers, including legal proceedings arising out of or in connection with any other transactions contemplated by or this Agreement; or (p) any Bankruptcy Matters.

(uu) “Order” means any order, writ, judgment, injunction, decree, stipulation, determination, decision, verdict, ruling, subpoena, or award entered by or with any Governmental Body (whether temporary, preliminary or permanent).

(vv) “Overbid Protection” shall have the meaning set forth in Section 7.2(a) of this Agreement.

(ww) “Patents” means all patents and industrial designs, including any continuations, divisionals, continuations-in-part, renewals, reissues and applications for any of the foregoing, and rights to pursue future applications and filings for any of the foregoing and to rights to sue for past infringement thereof.

(xx) “Permits” means all licenses, permits (including environmental, construction and operation permits), provider numbers, franchises, certificates, approvals, consents, waivers, clearances, exemptions, classifications, registrations, orders and other similar documents and authorizations issued by any Governmental Body and/or any self-regulatory body or organization to or for the benefit of Seller and used, or held for use, in connection with the operation of the Business or applicable to ownership of the Acquired Assets or assumption of the Assumed Liabilities.

(yy) “Person” means an individual, corporation, partnership, limited liability company, unlimited liability company, joint venture, association, trust, unincorporated organization, labor union, estate, Governmental Body or other entity or group.

(zz) “Petition Date” means the date Seller commences its Chapter 11 Cases under chapter 11 of the Bankruptcy Code in the Court.

(aaa) “Program” means Seller’s NSS Implant development program, including all rights to the NSS Implant and all indications thereof and improvements thereon as of the date of this Agreement.

(bbb) “Regulatory Approvals” means any consents, waivers, approvals, Orders, Permits or authorizations of any Governmental Body required in connection with the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereunder.

(ccc) “Representatives” means, with respect to any Person, such Person’s directors, managers, officers, employees, investment bankers, attorneys, accountants and other advisors or representatives.

(ddd) “Sale” means the transactions contemplated by this Agreement whereby Purchaser purchases the Acquired Assets free and clear of all Encumbrances in accordance with section 363 of the Bankruptcy Code.

(eee) “Sale Hearing” means the hearing before the Court to approve this Agreement and seeking entry of the Sale Order.

(fff) “Sale Motion” means a motion filed by Seller, reasonably satisfactory in form and substance to Seller and Purchaser, (a) seeking approval of this Agreement and the transactions contemplated herein, including the sale of Seller’s assets, free and clear of all Encumbrances and the assumption and assignment of all Assumed Executory Contracts, to Purchaser, and (b) seeking an order containing, without limitation, a finding that Purchaser has acted in good faith and is entitled to the protections of section 363(m) of the Bankruptcy Code.

(ggg) “Sale Order” means an Order of the Court, reasonably satisfactory in form and substance to Seller and Purchaser, (a) approving this Agreement and the transactions contemplated herein, including, without limitation, the sale of the Acquired Assets free and clear of all Encumbrances, and the assumption and assignment of all Assumed Executory Contracts, to Purchaser, and (b) including, without limitation, a finding that Purchaser has acted in good faith and is entitled to the protections of section 363(m) of the Bankruptcy Code.

(hhh) “SEC” means the United States Securities and Exchange Commission.

(iii) “Seller’s Knowledge” means the actual knowledge as of the date hereof (without any duty to inquire or investigate) of the individuals identified on Schedule [●].

(jjj) “Seller Owned Intellectual Property” means any Intellectual Property owned by Seller that is material to the Business as currently conducted.

(kkk) “Seller SEC Reports” means all registration statements, forms, reports and other documents filed by Seller with the SEC since January 1, 2022 or that Seller may file after the date hereof until the Closing (including exhibits and all other information incorporated therein).

(lll) “Specified Licenses” means [●].⁴

(mmm) “Stalking Horse Provisions” means the provisions described in Section 7.2 of this Agreement.

(nnn) “Subsidiary” means, with respect to any Person, (a) any other Person that directly, or indirectly through one or more intermediaries, is controlled by such Person; or (b) any other Person where a majority of its equity interests are held, directly, or indirectly through one or more intermediaries, by such Person. For purposes of this definition, “control” (including, with correlative meaning, the terms “controlling” and “controlled”) means the possession, directly

⁴ NTD: This concept is intended to capture any licenses the assumption of which is a Purchaser condition to the sale. Note that Seller expects any Purchaser to address the process and expense of any license consents or modifications that may be required to transfer any license rights or related assets to Purchaser.

or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through ownership of voting securities, by contract or otherwise.

(ooo) “Successful Bidder” shall have the meaning set forth in the Bidding Procedures.

(ppp) “Supplemental Notice of Proposed Assumed Executory Contracts” means a notice filed by Seller with the Court in accordance with the Bidding Procedures identifying the Executory Contracts Purchaser intends, as of the date of such notice, to assume as of the Closing Date and that were not listed on the Initial Notice of Proposed Assumed Executory Contracts.

(qqq) “Tax” and “Taxes” mean any and all taxes, charges, fees, tariffs, duties, impositions, levies or other assessments, imposed by any Laws or Governmental Body, and including any interest, penalties or additional amounts attributable to, imposed upon, or with respect thereto.

(rrr) “Tax Return” means any return, report, information return, declaration, claim for refund or other document (including any schedule or related or supporting information) supplied or required to be supplied to any Governmental Body with respect to Taxes, including attachments thereto and amendments thereof.

(sss) “Third Party” means any Person that is not a party hereto or an Affiliate of a party hereto.

(ttt) “Trademarks” means trademarks, trade names, service marks, designs, logos, brand names, emblems, signs or insignia, slogans, Internet addresses and domain names, other similar designations of source or origin and general intangibles of like nature, together with the registrations and applications for registrations pertaining to any of the foregoing, any derivations of any of the foregoing, all goodwill associated therewith, and rights to sue for past infringement thereof.

(uuu) “Transaction Documents” means this Agreement and any and all other instruments required to effectuate the transactions contemplated by this Agreement.

ARTICLE II.

ACQUISITION AND TRANSFER OF ASSETS; ASSUMPTION OF LIABILITIES

2.1 Transfer of Assets. Subject to approval of the Court, and upon the terms and subject to the conditions and provisions contained herein, at the Closing, Seller shall sell, convey, transfer, assign and deliver to Purchaser, and Purchaser shall acquire and accept from Seller, all of Seller’s right, title, and interest in the Acquired Assets, free and clear of all Encumbrances, subject to Section 2.3 below. Notwithstanding anything to the contrary contained in this Agreement, Purchaser may, by notice to Seller, at any time on or before the Closing Date, in its sole discretion, alter or amend Exhibit A to this Agreement by removing an Acquired Asset.

2.2 Excluded Assets. Notwithstanding anything to the contrary in this Agreement, the Acquired Assets shall not include, and Seller shall retain, all of its rights, title and interest in and to, and shall not sell, convey, transfer, assign or deliver to Purchaser, any of the Excluded Assets.

2.3 Assumed Liabilities. At the Closing, Purchaser shall assume and have sole responsibility for the Assumed Liabilities.

2.4 Excluded Liabilities. For the avoidance of doubt, notwithstanding any other terms, provisions and conditions of this Agreement, Purchaser shall not assume, or otherwise be responsible or liable for, the Excluded Liabilities.

2.5 Assumed Executory Contracts. To the maximum extent permitted by the Bankruptcy Code and in accordance with the Bidding Procedures, each Assumed Executory Contract shall be assumed and assigned to Purchaser pursuant to section 365 of the Bankruptcy Code as of the later of: (a) for any Assumed Executory Contract listed on the Initial Notice of Proposed Assumed Executory Contracts, (1) if no objection is filed by the Closing Date, the Closing Date, or (2) if an objection is filed by the Closing Date, the date such assumption and assignment is approved by an Order of the Court, and (b) for any Assumed Executory Contract listed on a Supplemental Notice of Proposed Assumed Executory Contracts, (1) if no objection is filed by the date specified in such Supplemental Notice of Proposed Assumed Executory Contracts, such date, or (2) if an objection is filed by the date specified in such Supplemental Notice of Proposed Assumed Executory Contracts, the date such assumption and assignment is approved by an Order of the Court.

(a) On or before the Closing Date, Purchaser may, at any time and for any reason, in its sole discretion, elect to remove any Executory Contract from Exhibit B, in which case such Executory Contract shall not be an Assumed Executory Contract, and, at the request of Purchaser on or prior to the Closing Date, Seller shall reject such Executory Contract as soon as practicable following the Closing Date. On or before the date on which the Sale Order is entered, Purchaser may, at any time and for any reason, in its sole discretion, elect to add to Exhibit B any Executory Contract not previously listed thereon, and such Executory Contract shall be an Assumed Executory Contract.

(b) Purchaser shall be responsible and liable for, and shall pay, all Cure Costs.

(c) Seller shall provide Purchaser with no less than five (5) Business Days' prior written notice of the filing of any motion to reject any Executory Contract not designated as an Assumed Executory Contract on Exhibit B as of the date of this Agreement.

2.6 Waiver and Release of Acquired Avoidance Actions. Without limiting the provisions of Section 9.2 hereof, Purchaser shall be deemed to have waived and released all of the Acquired Avoidance Actions immediately following the Closing, and Purchaser shall not take any action to pursue or enforce any of the Acquired Avoidance Actions. Notwithstanding any provision of the contrary herein, Purchaser agrees that, in addition to Seller, any defendant in any Acquired Avoidance Action is a third-party beneficiary of this section and shall be entitled to rely on and enforce this section.

2.7 Liens Attach to Sale Proceeds. Any liens on the Acquired Assets existing as of the Closing Date will attach to the proceeds from the sale of the Acquired Assets according to such liens' relative priorities.

ARTICLE III.

CONSIDERATION

3.1 Consideration. The aggregate consideration (collectively, the "Purchase Price") to be paid for the acquisition of the Acquired Assets shall consist of the following, which shall be payable in accordance with the terms and conditions set forth in this Article III and Article IV: (i) the Cash Purchase Price; *plus* (ii) assumption of the Assumed Liabilities set forth on Exhibit C; *plus* (iii) any Cure Costs.

3.2 Payment of Purchase Price at Closing. The Purchase Price as described in Section 3.1 shall be satisfied at the Closing, subject to the terms and conditions contained in this Article III and Article IV.

3.3 Assumed Liabilities. Purchaser shall assume the Assumed Liabilities pursuant to the assignment and assumption agreement substantially in the form attached hereto as Exhibit F (the "Assignment and Assumption Agreement").

3.4 Deposit. Purchaser has provided the Deposit in good faith to the Deposit Escrow Agent to be held in trust in a non-interest-bearing account pursuant to the terms and conditions of the Deposit Escrow Agreement. If the Closing occurs, the Deposit shall be paid to Seller and applied against the Cash Purchase Price at the Closing. If the Closing does not occur, then the Deposit shall be disbursed as follows: (i) in the event of a termination of this Agreement by Seller pursuant to Section 4.6(n), Seller shall be entitled to retain the Deposit as liquidated damages; (ii) in the event of a termination of this Agreement for any reason other than by Seller pursuant to Section 4.6(n), the Deposit shall be returned to Purchaser; or (iii) in the event of a termination of this Agreement and the Deposit has not been disbursed in accordance with clauses (i) or (ii) of this Section 3.4, then the Deposit shall be disbursed as any court of competent jurisdiction may direct.

3.5 Allocation of Consideration. Within thirty (30) calendar days after the Closing Date, Purchaser shall deliver to Seller an allocation of the Purchase Price among the Acquired Assets (the "Allocation"). Such Allocation shall become part of this Agreement for all purposes. Seller and Purchaser agree to report, pursuant to section 1060 of the Internal Revenue Code of 1986 and the regulations promulgated thereunder, if and when required, the Allocation of the Purchase Price, as adjusted, in a manner entirely consistent with such Allocation in the preparation and filing of all Tax Returns (including IRS form 8594). Neither Seller nor Purchaser shall take any action that would call into question the bona fide nature of such Allocation; and neither party shall take any position for Tax purposes which is inconsistent with such Allocation, unless required to do so under applicable law. Notwithstanding the foregoing, the Allocation shall not be binding upon any person or entity that is not a party to this Agreement.

ARTICLE IV.

CLOSING AND TERMINATION

4.1 Closing. Provided that the conditions to closing set forth herein have been satisfied or, if waiveable, have been waived in accordance herewith, the closing of the transactions contemplated herein (the “Closing”) shall be held via e-mail or such other place as agreed to between Purchaser and Seller, within three (3) calendar days following the first day that all such conditions have been satisfied or, if waiveable, waived, on a Business Day mutually agreeable to Purchaser and Seller. The date on which the Closing occurs in accordance with the previous sentence is referred to as the “Closing Date”. Unless otherwise agreed by the parties in writing, the Closing shall be deemed effective and all right, title and interest of Seller in the Acquired Assets to be acquired by Purchaser hereunder shall be considered to have passed to Purchaser and the assumption of all of the Assumed Liabilities shall be considered to have occurred as of 12:01 a.m. Eastern Time on the Closing Date.

4.2 Conveyances at Closing. At the Closing, Seller and Purchaser shall take the following actions:

(a) Purchaser shall pay to or as directed by Seller, by wire transfer in immediately available funds, the Cash Purchase Price as set forth in Section 3.1, as adjusted (without duplication) pursuant to Section 3.2, Section 3.4, and Section 4.5;

(b) Seller shall deliver or make available to Purchaser possession of the Acquired Assets;

(c) Seller and Purchaser shall execute and deliver to one another a duly executed bill of sale with respect to the Acquired Assets, substantially in the form attached hereto as Exhibit E (the “Bill of Sale”);

(d) Seller shall provide to Purchaser all such other duly executed instruments as Purchaser may reasonably require to effectuate the transfer, assignment and conveyance of the Acquired Assets;

(e) Seller and Purchaser shall execute and deliver to one another the Assignment and Assumption Agreement with respect to the Assumed Liabilities; and

(f) Seller shall provide Purchaser with executed written consents, in form and substance reasonably satisfactory to Purchaser, from each licensor of a Specified License, consenting to the assignment to Purchaser of each corresponding Specified License, unless the Court or another court of competent jurisdiction has entered a Final Order that such consent is not required; provided, however, that any Cure Costs in respect of any Specified License shall be borne by Purchaser and all liabilities in respect of any Specified License shall be Assumed Liabilities.

4.3 Additional Deliveries. After the Closing Date, Seller shall deliver to Purchaser such other instruments and documents, and shall take such other actions, as shall be reasonably requested by Purchaser to vest in Purchaser all of Seller’s right, title and interest in and to the Acquired Assets and otherwise to effectuate the transactions described herein.

4.4 Transaction Expenses. Except as expressly provided herein in respect of the Expense Reimbursement (to the extent due and owing), each party shall bear its own costs and expenses, including attorney, accountant and other consultant fees, in connection with the execution and negotiation of this Agreement and the Transaction Documents and the consummation of the transactions contemplated by this Agreement.

4.5 Prorations. To the extent there are obligations in respect of the Acquired Assets that arose during or relate to the period up to and including the Closing Date (“Pre-Closing Obligations”) and obligations that arose during or relate to the period following the Closing Date, including any and all real or personal property tax obligations (“Post-Closing Obligations”), Purchaser and Seller shall allocate such obligations between themselves on a ratable basis that fairly reflects the portions (up to 100%) of such obligations that are Pre-Closing Obligations and that shall be paid by Seller, and the portions (up to 100%) of such obligations that are Post-Closing Obligations and that shall be paid by Purchaser. To the extent that any net amount is owing to Purchaser or Seller, as the case may be under this Section 4.5 as of the Closing, the Purchase Price shall be decreased or increased, as the case may be, to the extent such prorations are identified as of the Closing, and to the extent such prorations cannot or are not identified until after the Closing, then any net amount owing to Seller or Purchaser shall be paid by the party owing such amount. Any net amount owing to Purchaser under this Section 4.5, shall be an administrative expense of Seller’s bankruptcy estate under section 503(b) and section 507(a)(2) of the Bankruptcy Code. Notwithstanding the foregoing, this Section 4.5 shall not apply to the items listed on Schedule 4.5, which items shall be paid by Seller and/or Purchaser as indicated thereon.

4.6 Termination of Agreement. This Agreement may be terminated at any time prior to the Closing as follows:

- (a) by the mutual written consent of Seller and Purchaser;
- (b) by Purchaser or Seller, if the Petition Date has not occurred on or before [●], 2024.
- (c) by Purchaser or Seller, upon entry into an agreement to consummate (subject to Purchaser’s obligation to serve as a Backup Bidder pursuant to Section 7.1(h)), or the consummation of, an Alternative Transaction, provided, however, that upon a termination pursuant to this Section 4.6(c), Seller shall perform its obligations under Section 4.8 and Section 7.2;
- (d) by Purchaser or Seller, if the Closing shall not have been consummated prior to [●], 2024 (the “Outside Date”); provided, that if the Closing shall not have occurred on or before the Outside Date due to a material breach of any representations, warranties, covenants or agreements contained in this Agreement by Purchaser or Seller, then Purchaser (if Purchaser is in breach) or Seller (if Seller is in breach), respectively, may not terminate this Agreement pursuant to this Section 4.6(d); provided further, that if Purchaser is selected as the Backup Bidder at the conclusion of the Auction, Purchaser shall not be permitted to terminate this Agreement until the earlier of (i) ninety (90) days after entry of the Sale Order if the Closing shall not have occurred by such date, and (ii) the date on which Seller consummates an Alternative Transaction;

(e) by Purchaser, if the Auction has not been held on or before [●], 2024, unless Seller determines in accordance with the Bidding Procedures not to conduct any Auction;

(f) by Purchaser or Seller, if there shall be any Law that makes consummation of the transactions contemplated hereby illegal or otherwise prohibited, or there shall be in effect a final non-appealable order of a Governmental Body of competent jurisdiction restraining, enjoining or otherwise prohibiting the consummation of the transactions contemplated hereby; it being agreed that the parties hereto shall promptly appeal any such adverse determination which is appealable (and pursue such appeal with reasonable diligence);

(g) by Purchaser or Seller, if the Chapter 11 Cases are dismissed or converted to cases under chapter 7 of the Bankruptcy Code, or if a chapter 11 trustee or examiner with expanded powers is appointed, provided, however, that no party shall have such a termination right if it has sought, consented to, or otherwise supported such dismissal or conversion;

(h) by Purchaser, if the Court enters an order granting stay relief to any third party with respect to any material portion of the Acquired Assets, if such stay relief allows such third party to exercise control over, or reduce the value to Purchaser of, the Acquired Assets;

(i) by Purchaser, if there occurs a Material Adverse Effect;

(j) by Purchaser or Seller, if the Sale Order shall not have been entered on or before [●], 2024 (subject to Purchaser's obligation to serve as a Backup Bidder pursuant to Section 7.1(h));

(k) by Purchaser, if the Court enters an Order denying any motion or other filing filed by Seller relating to the sale of the Acquired Assets hereunder;

(l) by Purchaser or Seller, if the Bidding Procedures Order or Sale Order is stayed, reversed, vacated, modified or amended (except as modified or amended in any immaterial respect or with the consent of Purchaser, which consent may be withheld in its sole discretion for material modifications and amendments);

(m) by Seller, if Purchaser fails to satisfy any of its material obligations at Closing;

(n) by Purchaser, if the Auction is conducted and Purchaser is not named by Seller as the Successful Bidder or the Backup Bidder at the conclusion of the Auction; or

(o) by Purchaser, if Seller is in breach of any of its material obligations hereunder and, to the extent such breach is reasonably capable of cure within such period, such breach has not been cured by Seller within fifteen (15) calendar days after written notification by Purchaser.

4.7 Procedure Upon Termination. In the event of a termination of this Agreement pursuant to Section 4.6, (a) written notice thereof shall be given promptly by the terminating party

to the other party hereto, specifying the provision hereof pursuant to which such termination is made, (b) this Agreement shall thereupon terminate and become void and of no further force and effect, and (c) the consummation of the transactions contemplated by this Agreement shall be abandoned without further action of the parties hereto. If this Agreement is terminated as provided herein, each party shall return all documents, work papers and other material of any other party relating to the transactions contemplated hereby, whether so obtained before or after the execution hereof, to the party furnishing the same.

4.8 Effect of Termination. In the event that this Agreement is validly terminated pursuant to Section 4.6, each of the parties shall be relieved of its duties and obligations arising under this Agreement effective as of the date of such termination and such termination shall be without Liability to Purchaser or Seller; provided, however, that Section 4.6, Section 4.7, Section 7.2 (other than in the case of a termination Seller under Section 4.6(n)), and this Section 4.8 shall survive any such termination and shall be enforceable hereunder. In no event shall any termination of this Agreement relieve any party hereto of any Liability for any willful breach of this Agreement by such party. Upon termination of this Agreement, (a) the Deposit shall be delivered to any applicable party as provided in Section 3.4 and (b) Purchaser shall be entitled to the Stalking Horse Provisions to the extent set forth in Section 7.2.

ARTICLE V.

REPRESENTATIONS AND WARRANTIES OF SELLER

Seller represents and warrants to Purchaser that the statements contained in this Article V are true and correct as of the date of this Agreement, except as disclosed in the Seller SEC Reports filed or furnished prior to the date of this Agreement or in filings made by Seller in the Chapter 11 Cases prior to the date of this Agreement.

5.1 Organization and Power. Seller is a corporation duly organized, validly existing and in good standing under the Laws of the State of Nevada. Seller has all requisite corporate power and authority to own the Acquired Assets.

5.2 Corporate Authorization. Subject to entry of the Sale Order, Seller has full corporate power and authority to execute and deliver any and all Transaction Documents and to perform the obligations thereunder. Subject to entry of the Sale Order, the execution, delivery and performance of Seller of the Transaction Documents have been duly and validly authorized and no additional corporate authorization or consent is required in connection therewith.

5.3 Binding Effect. Subject to entry of the Sale Order, this Agreement has been duly executed and delivered by Seller. This Agreement, when executed and delivered by Purchaser, and the other Transaction Documents when executed and delivered, will, upon the entry of the Sale Order, constitute the valid and legally binding obligations of Seller, enforceable against Seller in accordance with their respective terms.

5.4 Ownership of Acquired Assets. Seller owns (or, in the case of Intellectual Property licensed by Seller from a Third Party, including Specified Licenses, has license rights to) all Acquired Assets and, subject to entry of the Sale Order, has the right to transfer all of its right,

title, and interest in the Acquired Assets to Purchaser, in each case, effective at Closing and free and clear of any Encumbrances.

5.5 Taxes. Except for matters that, individually or in the aggregate, are not reasonably likely to have a Material Adverse Effect:

(a) Seller has filed all Tax Returns that it was required to file, and all such Tax Returns were correct and complete. Seller has paid (or caused to be paid) on a timely basis all Taxes due and owing by Seller, other than Taxes that are being contested in good faith through appropriate proceedings and for which the most recent financial statements contained in the Seller SEC Reports reflect an adequate reserve in accordance with GAAP.

(b) As of the date of this Agreement, no examination or audit of any Tax Return of Seller by any Governmental Body is currently in progress or has been proposed in writing. There are no liens for Taxes on any of the assets or properties of Seller.

(c) Seller does not have any liability for any Taxes of any Person (other than Seller) (i) under Treasury Regulation Section 1.1502-6 (or any similar provision of Tax law in any jurisdiction) or as a transferee or successor, or (ii) pursuant to any Tax sharing or Tax indemnification agreement or other similar agreement (other than pursuant to commercial agreements or arrangements that are not primarily related to Taxes).

(d) Seller has not entered into any “listed transaction” within the meaning of Treasury Regulation Section 1.6011-4(b)(2).

5.6 Real Property.

(a) Seller does not own any real property.

(b) Other than general office space leased on a month-to-month basis, Seller does not lease, sublease, or license from any Third Party any real property material to the conduct of the Business as currently conducted.

5.7 Intellectual Property.

(a) To Seller’s Knowledge, Seller owns, licenses, sublicenses or otherwise possesses legally enforceable rights to use all Intellectual Property held by Seller for use in the conduct of the Business as currently conducted (in each case excluding generally commercially available, off-the-shelf software programs), except where the absence of which, individually or in the aggregate, is not reasonably likely to have a Material Adverse Effect, subject, in the case of the Specified Licenses, to the rights of the licensors in respect of the Specified Licenses.

(b) To Seller’s Knowledge, all issued Patents and registrations for Trademarks and Copyrights included in the Seller Owned Intellectual Property are subsisting and have not expired or been cancelled.

(c) To Seller's Knowledge, the conduct of the Program as currently conducted, does not infringe, violate or constitute a misappropriation of any Intellectual Property of any Third Party, except for such infringements, violations and misappropriations that, individually or in the aggregate, are not reasonably likely to have a Material Adverse Effect. Between January 1, 2022 and the date of this Agreement, Seller has not received any written claim or notice from any Person (i) alleging any such infringement, violation or misappropriation or (ii) advising that such Person is challenging or threatening to challenge the ownership, use, validity or enforceability of any Seller Owned Intellectual Property, except, in each case in clauses (i) and (ii), for any such infringement, violation, misappropriation or challenge that is not reasonably likely to have a Material Adverse Effect.

(d) To Seller's Knowledge, Seller has implemented commercially reasonable measures to maintain the confidentiality of the Seller Owned Intellectual Property of a nature that Seller intends to keep confidential.

(e) To Seller's Knowledge, Seller is not in default under any Specified License in any manner that would allow the licensor under any Specified License to terminate such Specified License or otherwise limit or terminate the rights of Seller under such Specified License.

(f) To Seller's Knowledge, no third party is infringing, violating or misappropriating any of the Seller Owned Intellectual Property, except for infringements, violations or misappropriations that, individually or in the aggregate, are not reasonably likely to have a Material Adverse Effect.

5.8 Litigation. As of the date of this Agreement, there is no action, suit, proceeding, claim, arbitration or investigation pending and of which Seller has been notified or, to Seller's Knowledge, threatened against Seller, in each case that, individually or in the aggregate, is reasonably likely to have a Material Adverse Effect. As of the date of this Agreement, there are no judgments, orders or decrees outstanding against Seller that, individually or in the aggregate, are reasonably likely to have a Material Adverse Effect.

5.9 Environmental Matters.

(a) Except for matters that, individually or in the aggregate, are not reasonably likely to have a Material Adverse Effect: (i) Seller is not in violation of any Environmental Law; and (ii) Seller has all permits, licenses and other authorizations required under any Environmental Law and Seller is in compliance with such permits, licenses and other authorizations.

(b) The only representations and warranties of Seller in this Agreement as to any environmental matters or any other obligation or liability with respect to Hazardous Substances or materials of environmental concern are those contained in this Section 5.10. Without limiting the generality of the foregoing, the representations and warranties contained in Sections 5.11 and 5.11 do not relate to environmental matters.

5.10 Compliance With Laws. Seller is, and since January 1, 2022 has been, in compliance with, and is not in violation of, any applicable statute, law or regulation with respect to the conduct of the Program, or the ownership or operation of its properties or assets,

except for failures to comply or violations that, individually or in the aggregate, are not reasonably likely to have a Material Adverse Effect.

5.11 Permits; Regulatory Matters.

(a) Seller or its agents and representatives have all Permits required to conduct the Program as currently conducted, including all such Permits required by the FDA, and any other federal, state or foreign agencies or bodies with material regulatory authority over the Business (together with the FDA, the “Regulating Authorities”), except for such Permits the absence of which, individually or in the aggregate, are not reasonably likely to have a Material Adverse Effect (the “Seller Authorizations”).

(b) Except for matters that, individually or in the aggregate, are not reasonably likely to have a Material Adverse Effect, since January 1, 2022 or that have been disclosed in writing to Purchaser or in Seller’s public filings with the SEC, Seller: (i) has not received any written notice or correspondence from any Regulating Authority alleging or asserting any noncompliance with any Seller Authorizations; and (ii) has not received written notice that any Regulating Authority has taken or is intending to take action to limit, suspend, modify or revoke any Seller Authorizations and, to Seller’s Knowledge, there is no action or proceeding pending or threatened (including any prosecution, injunction, seizure, civil fine, suspension or recall), in each case alleging that such Regulating Authority is considering such action.

5.12 Finders’ Fees. Except for the fees and expenses of SSG Capital Advisors, LLC (“SSG”), the fees and expenses of which will be paid by Seller, there is no investment banker, broker, finder or other intermediary who has been retained by or is authorized to act on behalf of Seller who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement.

5.13 No Other Representations or Warranties. Except for the representations and warranties expressly contained herein, Seller makes no other express or implied representation or warranty. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, THE ACQUIRED ASSETS ARE ASSIGNED, “AS IS,” WITHOUT ANY WARRANTY OF ANY KIND, AND SELLER HEREBY EXPRESSLY DISCLAIMS, TO THE EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL CONDITIONS OR WARRANTIES OF ANY KIND OR NATURE, WHETHER EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTIES OF OR RELATED TO TITLE, NON-INFRINGEMENT, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OR ENFORCEABILITY.

ARTICLE VI.

REPRESENTATIONS AND WARRANTIES OF PURCHASER

Purchaser represents and warrants to Seller that the statements contained in this Article VI are true and correct as of the date of this Agreement.

6.1 Organization and Power. Purchaser is a [corporation] duly organized, validly existing and in good standing under the Laws of the State of [state of organization].

6.2 Authorization. Purchaser has full power and authority to execute and deliver the Transaction Documents and to perform its obligations thereunder. The execution, delivery and performance by Purchaser of the Transaction Documents have been duly and validly authorized and no additional authorization or consent is required in connection therewith.

6.3 Binding Effect. This Agreement has been duly executed and delivered by Purchaser. This Agreement, when executed and delivered by Seller, and the other Transaction Documents when executed and delivered, will constitute the valid and legally binding obligations of Purchaser, enforceable against Purchaser in accordance with their respective terms, subject to bankruptcy, insolvency, reorganization, moratorium and similar Laws of general applicability relating to or affecting creditors' rights and to general equity principles.

6.4 Funding. Purchaser has, without the need to obtain any Third Party debt or equity financing, sufficient and unencumbered funds to consummate the transactions contemplated by this Agreement and to pay the Purchase Price, and Purchaser otherwise has the resources and capabilities (financial and otherwise) to perform its obligations to consummate the transactions contemplated by this Agreement and such performance is not conditioned or contingent in any way upon the receipt of financing from any Person or the availability of funds to Purchaser.

6.5 Adequate Assurances Regarding Assumed Executory Contracts. As of the Closing, Purchaser will be capable of satisfying the conditions contained in sections 365(b)(1)(C) and 365(f) of the Bankruptcy Code with respect to the Assumed Executory Contracts, including without limitation payment of all Cure Costs.

6.6 Finders' Fees. There is no investment banker, broker, finder or other intermediary who has been retained by or is authorized to act on behalf of Purchaser or any Affiliate of Purchaser who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement, except for any fee or commission paid directly by Purchaser and not reducing the Purchase Price in any way.

6.7 Good Faith Purchaser. Purchaser (i) is a "good faith" purchaser, as such term is used in the Bankruptcy Code, and (ii) is entitled to the protections of section 363(m) of the Bankruptcy Code with respect to the transactions contemplated by this Agreement. Purchaser has negotiated and entered into this Agreement in compliance with the Bidding Procedures in compliance with section 363(n) of the Bankruptcy Code, and in good faith and without collusion or fraud of any kind.

6.8 Purchaser Experience. Purchaser is experienced and sophisticated with respect to transactions of the type contemplated by this Agreement. In consultation with experienced counsel and advisors of its choice, Purchaser has conducted its own independent review and analysis of the Acquired Assets, the Assumed Liabilities and the rights and obligations it is acquiring and assuming under the Transaction Documents. Purchaser acknowledges that it and its representatives have been permitted such access to the books and records, contracts and other properties related to the Acquired Assets as it required to complete its review..

6.9 Non-Reliance on Seller Estimates, Projections, Forecasts, Forward-Looking Statements and Business Plans. In connection with the due diligence investigation of Seller by Purchaser and its Affiliates, Purchaser and its Affiliates, have received and may continue to receive after the date hereof from Seller and its Affiliates certain estimates, projections, forecasts and other forward-looking information, as well as certain business plan information, regarding Seller and its business and operations. Purchaser hereby acknowledges that there are uncertainties inherent in attempting to make such estimates, projections, forecasts and other forward-looking statements, as well as in such business plans, with which Purchaser is familiar, that Purchaser is taking full responsibility for making its own evaluation of the adequacy and accuracy of all estimates, projections, forecasts and other forward-looking information, as well as such business plans, so furnished to it (including the reasonableness of the assumptions underlying such estimates, projections, forecasts, forward-looking information or business plans), and that Purchaser will have no claim against Seller, any of its Affiliates, or any other Person, with respect thereto. Accordingly, Purchaser hereby acknowledges and agrees that none of Seller nor any of its Affiliates, nor any other Person, has made or is making any express or implied representation or warranty with respect to such estimates, projections, forecasts, forward-looking statements or business plans (including the reasonableness of the assumptions underlying such estimates, projections, forecasts, forward-looking statements or business plans). Purchaser expressly disclaims that it is relying upon or has relied upon any representations or warranties or other statements or omissions that may have been made by Seller or its Affiliates or any other Person with respect to Seller other than the representations and warranties set forth in this Agreement. Purchaser expressly disclaims any obligation or duty by Seller or its Affiliates to make any disclosures of fact not required to be disclosed pursuant to the specific representations and warranties set forth in this Agreement.

ARTICLE VII.

CERTAIN COVENANTS

7.1 Bankruptcy Sale Process.

(a) Purchaser acknowledges that the Acquired Assets may be subject to competitive bidding and that the Bidding Procedures may be supplemented by other customary procedures consistent with the terms of this Agreement, provided that the Bidding Procedures may not be amended, modified, or supplemented in any respect except as provided for in the Bidding Procedures.

(b) Seller will, as promptly as possible, but in all events in accordance with the Bidding Procedures, file and serve the Initial Notice of Proposed Assumed Executory Contracts, any Supplemental Notice of Proposed Assumed Executory Contracts, and the Final Sale Notice, together with the proposed Sale Order and a copy of the Transaction Documents (with any redactions Seller and Purchaser mutually deem appropriate in accordance with Bankruptcy Rule 9018 and the Bidding Procedures Order), and serve it upon the parties required to be served in accordance with the Bidding Procedures.

(c) Seller will, subject to the provisions of this Agreement and the Bidding Procedures Order, in consultation with Purchaser, use its reasonable best efforts to (x) respond to and resolve all timely objections to the entry of the Sale Order and (y) obtain entry of the Sale Order on or before [●], 2024.

(d) Purchaser will use its reasonable best efforts to assist in obtaining entry of the Sale Order, including furnishing or filing with the Court such affidavits or declarations as Seller may request for the purpose of obtaining entry of the Sale Order.

(e) All motions and other filings by Seller, including any filings regarding notice procedures and all lists of Persons to receive notice, relating to the sale of the Acquired Assets hereunder shall be in form and substance reasonably satisfactory to Purchaser.

(f) Purchaser shall not, without prior written consent of Seller, file, join in, or otherwise support or encourage in any manner whatsoever any motion or other filing relating to the sale of the Acquired Assets hereunder.

(g) In the event that an appeal is taken or a stay pending appeal is requested with respect to the Sale Order, Seller shall promptly notify Purchaser of such appeal or stay request and shall promptly provide to Purchaser a copy of the related notice(s) or order(s). Seller and Purchaser shall use their reasonable best efforts to defend any such appeal or stay request.

(h) Backup Bidder. Sellers and Purchaser agree that, in the event that Purchaser is not the Successful Bidder at the Auction, Purchaser shall act as the Backup Bidder as set forth in the a Bidding Procedures and Bidding Procedures Order, if so named at the Auction; provided that, Purchaser's obligation to act as the Backup Bidder shall terminate on the earlier of (i) ninety (90) days after entry of the Sale Order if the Closing shall not have occurred by such date, and (ii) the date on which Seller consummates an Alternative Transaction. If Purchaser is selected as the Backup Bidder at the conclusion of the Auction, (a) neither such selection itself nor the failure to select the Purchaser as the Successful Bidder shall give rise to a right of Purchaser to terminate this Agreement, and (b) this Agreement shall remain in full force and effect until terminated in accordance with the terms herein.

7.2 Stalking Horse Provisions.⁵

(a) To participate in the bidding process for all or any substantial portion of the Acquired Assets, a Person (other than Purchaser) must submit a bid, in accordance

⁵ NTD: Purchaser should delete Stalking Horse provisions if inapplicable, as necessary.

with the Bidding Procedures, the cash portion of which exceeds the Cash Purchase Price for such assets by no less than the sum of the following: the Break-Up Fee, the maximum amount of the Expense Reimbursement, and \$[●] (such sum, the “Overbid Protection”).

(b) In the event Seller enters into an agreement to consummate or consummates an Alternative Transaction prior to the Outside Date, Seller shall pay Purchaser, in accordance with the Bidding Procedures and by wire transfer to an account designated by Purchaser on the closing date of such Alternative Transaction, an amount equal to \$[●] (the “Break-Up Fee”).

(c) In the event Seller enters into an agreement to consummate or consummates an Alternative Transaction prior to the Outside Date, Seller shall pay Purchaser, in accordance with the Bidding Procedures and by wire transfer to an account designated by Purchaser on the closing date of such Alternative Transaction, reimbursement of all reasonable, documented costs and expenses of Purchaser incurred in connection with Purchaser’s efforts to negotiate and consummate the transactions contemplated by this Agreement (including, without limitation, the fees and expenses of counsel); provided, however, that such reimbursement shall be capped at \$[●] (the “Expense Reimbursement”).

(d) Purchaser shall be entitled to credit bid the amount of the Break-Up Fee and maximum Expense Reimbursement in accordance with section 363(k) of the Bankruptcy Code if Purchaser elects to submit higher bids in the Auction in accordance with the Bidding Procedures.

(e) The Break-Up Fee and Expense Reimbursement shall be paid from any proceeds of an Alternative Transaction, otherwise payable to Seller, provided that if such amounts are not paid from such proceeds, Seller shall remain liable for such amounts.

(f) The Break-Up Fee and Expense Reimbursement (to the extent due and owing) shall be a first-priority administrative expense of Seller’s bankruptcy estate under sections 503(b) and 507(a)(2) of the Bankruptcy Code.

(g) The obligation of Seller to pay, and the payment by Seller of, the Expense Reimbursement (to the extent due and owing), shall in no way limit or otherwise affect the rights of Purchaser to a return of the Deposit, including without limitation the rights of Purchaser under Section 3.4 of this Agreement.

(h) Seller acknowledges and agrees that Purchaser would not have entered into this Agreement but for the provisions in this Section 7.2, and that the provisions of this Section 7.2 are integral to, and shall survive any termination of, this Agreement, other than a termination by Seller under Section 4.6(n).

7.3 Pre-Closing Operating Covenants of Seller.

(a) Until the earlier of Closing or the termination of this Agreement in accordance with Section 4.6, Section 4.7 and Section 4.8, except as expressly provided in this Agreement, or as required by Law, including in connection with the Chapter 11 Cases (it being understood that no provision of this Section 7.3 will require Seller to make any payment to any of

its creditors with respect to any amount owed to such creditors on the Petition Date or which would otherwise violate the Bankruptcy Code), without the consent of Purchaser, Seller shall continue to maintain the Acquired Assets and all books and records on a basis consistent with current practice, and shall continue to make all necessary or appropriate filings and payments with and to Governmental Bodies in connection with the Program in a timely manner, and maintain in effect all existing regulatory approvals required for the ongoing operation of the Program as presently conducted, it being understood that Seller has already taken steps prior to the date of this Agreement to wind down the Business, including suspension of the Program, and it being further understood that Seller shall not be required hereby to make any filing or take any other action with respect to SEC requirements.

(b) Until the earlier of Closing or the termination of this Agreement in accordance with Section 4.6, Section 4.7 and Section 4.8, except as expressly provided in this Agreement, or as required by Law, subject to the limitations of the Bankruptcy Code and the Bankruptcy Rules, without the consent of Purchaser, Seller will not do any of the following, it being understood that Seller has already taken steps prior to the date of this Agreement to wind down the Business:

(i) sell or transfer or create any Encumbrance upon any of the Acquired Assets (other than in the ordinary course of the Business);

(ii) fail to pay any maintenance fees by the due date therefor with respect to any of the Acquired Assets, absent Purchaser's written authorization after good faith consideration, provided that Purchaser reimburse Seller for payment of the portion of such fees attributable to the post-Closing period;

(iii) reject, cancel, terminate, amend, modify, supplement or rescind any Executory Contract or any terms of any Executory Contract without the express written approval of Purchaser, which shall not be unreasonably withheld or delayed, except for the purpose of effecting any changes in applicable Law or implementing regulatory requirements;

(iv) incur any indebtedness for borrowed money.

(v) transfer, sell, assign, abandon, permit to lapse or grant any rights or modify any existing rights to the Acquired Assets, or enter into any settlement regarding the breach or infringement, misappropriation, dilution or other violation of, or challenge the title to, any such Acquired Assets; or

(vi) institute, settle or agree to settle or modify in any manner that is adverse to the Acquired Assets, any litigation, action or other Legal Proceeding before any court or Governmental Body relating to the Acquired Assets and that is or will be an Assumed Liability (provided, however, that nothing herein shall restrict or prevent Seller from instituting, prosecuting, or settling any claims it may have against Purchaser or its Affiliates arising out of or related to this Agreement).

7.4 Access to Information.

(a) Seller agrees that, until the earlier of Closing or the termination of this Agreement in accordance with Section 4.6, Section 4.7 and Section 4.8, Purchaser shall be entitled, through its Representatives, to have such reasonable access to and make such reasonable investigation and examination of the books and records, properties, businesses, assets, accountants, auditors, counsel and operations of Seller as Purchaser's Representatives may reasonably request, provided, however, that Seller shall not be obligated to provide information that it is not permitted to provide under applicable Law. Any such investigations and examinations shall be conducted during regular business hours upon reasonable advance notice and under reasonable circumstances, including Seller's right to have its Representatives accompany Purchaser and its Representatives at the time of any on-site inspection or examination and shall be subject to restrictions under applicable Law. Pursuant to this Section 7.4, Seller shall furnish to Purchaser and its Representatives such financial, operating and property related data and other information as such Persons reasonably request. Seller shall use commercially reasonable efforts to cause its Representatives to reasonably cooperate with Purchaser and Purchaser's Representatives in connection with such investigations and examinations, and Purchaser shall, and use its commercially reasonable efforts to cause its Representatives to, reasonably cooperate with Seller and its Representatives and shall use their reasonable efforts to minimize any disruption to the Business. Purchaser and its Representatives shall be permitted to contact, or engage in discussions or otherwise communicate with Seller's landlords, clients, suppliers and other Persons with which Seller has material commercial dealings, provided, that Purchaser must obtain the prior consent of Seller, which consent shall not be unreasonably withheld or delayed, to initiate such communications and give Seller the opportunity to be present therefor.

(b) No information received pursuant to an investigation made under this Section 7.4 shall be deemed to (i) qualify, modify, amend or otherwise affect any representations, warranties, covenants or other agreements of Seller set forth in this Agreement or any certificate or other instrument delivered to Purchaser in connection with the transactions contemplated hereby, (ii) limit or restrict the remedies available to the parties under applicable Law arising out of a breach of this Agreement or otherwise available at Law or in equity, or (iii) limit or restrict the ability of either party to invoke or rely on the conditions to the obligations of the parties to consummate the transactions contemplated by this Agreement set forth in Article VIII.

7.5 Reasonable Efforts; Further Assurances of Each Party. Until the earlier of Closing or the termination of this Agreement in accordance with Section 4.6, Section 4.7 and Section 4.8, in each case, subject to the limitations of the Bankruptcy Code and Bankruptcy Rules:

(a) each party will use commercially reasonable efforts to take all actions and to do all things necessary, proper or advisable in order to consummate and make effective the transactions contemplated by this Agreement (including satisfaction, but not waiver, of the closing conditions set forth in Article VIII); and

(b) the parties will execute and deliver any documents, instruments or conveyances of any kind and take all other actions which may be reasonably necessary or advisable to carry out the intent of this Agreement and the transactions contemplated herein.

7.6 Regulatory Affairs. Until the earlier of Closing or the termination of this Agreement in accordance with Section 4.6, Section 4.7 and Section 4.8, Seller shall, to the fullest extent permitted by applicable Law, (i) promptly advise Purchaser of the receipt of any communication from the FDA, SEC or any similar state or foreign Governmental Body or other U.S. Governmental Body whether oral, written, electronic or otherwise, (ii) provide Purchaser with a reasonable opportunity to participate in the preparation of any response thereto and the preparation of any other substantive submission or communication to any such Governmental Body and to review any such response, submission or communication prior to the filing or delivery thereof, and (iii) provide Purchaser with the opportunity to participate in any meetings or substantive telephone conversations that Seller or its representatives may have from time to time with any such Governmental Body. Until the earlier of Closing or the termination of this Agreement in accordance with Section 4.6, Section 4.7 and Section 4.8, at Purchaser's request, Seller shall assist Purchaser in obtaining any meetings with, or facilitating communications between, Purchaser and the FDA, SEC or any similar state or foreign Governmental Body or other U.S. Governmental Body.

ARTICLE VIII.

CONDITIONS TO CLOSING

8.1 Conditions Precedent to the Obligations of Seller and Purchaser. The respective obligations of each party to this Agreement to consummate the transactions contemplated herein are subject to the satisfaction or written waiver, on or prior to the Closing Date, of each of the following conditions (any or all of which may be waived in writing by Seller and Purchaser in whole or in part to the extent permitted by applicable Law):

(a) there shall not be in effect any statute, rule, regulation, Law or Order enacted, issued, entered or promulgated by a Governmental Body of competent jurisdiction restraining, enjoining or otherwise prohibiting the consummation of the transactions contemplated hereby;

(b) the Court shall have entered the Bidding Procedures Order and such order shall not have been stayed, reversed, vacated, modified or amended (except as modified or amended in any immaterial respect or with the consent of Purchaser, which consent may be withheld in its sole discretion for material modifications and amendments); and

(c) the Court shall have entered the Sale Order and such order shall not have been stayed, reversed, vacated, modified or amended (except as modified or amended in any immaterial respect or with the consent of Purchaser, which consent may be withheld in its sole discretion for material modifications and amendments).

8.2 Conditions Precedent to the Obligations of Seller. The obligations of Seller to consummate the transactions contemplated by this Agreement are subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions (any or all of which may be waived in writing by Seller in whole or in part to the extent permitted by applicable Law) in addition to those set forth in Section 8.1:

(a) Covenants and Representations. Purchaser shall have performed in all material respects all agreements and covenants required hereby to be performed by Purchaser prior to or at the Closing Date, and the representations and warranties of Purchaser made in Article VI shall be correct and complete in all material respects as of the Closing Date as if made on such date.

(b) Purchase Price. On or prior to the Closing Date, Purchaser shall have satisfied the Purchase Price.

(c) Deliveries. On or prior to the Closing Date, Purchaser shall have delivered to Seller each of the items set forth in Section 4.2 of this Agreement.

8.3 Conditions Precedent to the Obligations of Purchaser. The obligations of Purchaser to consummate the transactions contemplated by this Agreement are subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions (any or all of which may be waived in writing by Purchaser in whole or in part to the extent permitted by applicable Law) in addition to those set forth in Section 8.1:

(a) Covenants and Representations. Except as would not, individually or in the aggregate, be reasonably likely to have a Material Adverse Effect, Seller shall have performed all agreements and covenants required hereby to be performed by Seller prior to or at the Closing Date, and the representations and warranties of Seller in Article V shall be correct and complete as of the Closing Date as if made on such date.

(b) Deliveries. On or prior to the Closing Date, Seller shall have delivered to Purchaser each of the items set forth in Section 4.2 of this Agreement.

(c) Regulatory Approvals. All of the Regulatory Approvals necessary for Purchaser to acquire the Acquired Assets, and assume the Assumed Liabilities, shall have been obtained, and all such Regulatory Approvals shall be in full force and effect.

ARTICLE IX.

MISCELLANEOUS

9.1 Transfer Taxes. Any sales, use, transfer, deed, fixed asset, stamp, documentary stamp or other similar type Taxes and recording charges (each, a "Transfer Tax") which may be payable by reason of the acquisition of the Acquired Assets or the assumption of the Assumed Liabilities under this Agreement or the transactions contemplated herein shall be timely paid by Purchaser. Purchaser and Seller shall cooperate to prepare and timely file any Tax Returns required to be filed in connection with Transfer Taxes described in the immediately preceding sentence.

9.2 Releases. Effective as of and conditioned upon the occurrence of Closing, Purchaser hereby releases and forever discharges Seller and Seller's directors, officers, employees, agents, representatives, successors, assigns, and holders of Claims or interests in Seller's chapter 11 bankruptcy estate, from any and all actions, suits, debts, liens, sums of money, accounts, judgments, claims and demands whatsoever, at law or in equity, either in

contract or in tort, whether known or unknown, on account of, arising out of or relating to any act or omission of any kind or character whatsoever that relates to Seller or this Agreement and the proposed transactions contemplated herein occurring at or prior to the Closing; provided that nothing in this Section 9.2 shall release or discharge any Claim of Purchaser under this Agreement. Notwithstanding any provision of the contrary herein, Purchaser agrees that, in addition to Seller, any other person or entity released and discharged under this section is a third-party beneficiary of this section and shall be entitled to rely on and enforce this section.

9.3 Survival. None of the (a) covenants or agreements to be performed by either Seller or Purchaser prior to the Closing pursuant to this Agreement and (b) representations and warranties by Seller or Purchaser contained in this Agreement shall survive Closing, and neither Seller nor Purchaser shall have liability to the other party after Closing for any breach of any such covenant, agreement, representation or warranty. Except as set forth in the immediately preceding sentence, the covenants and agreements of the parties set forth in this Agreement will survive until fully performed or until such performance is expressly waived in writing by the other party.

9.4 Injunctive Relief. Damages at Law may be an inadequate remedy for the breach by Purchaser or Seller of any of its covenants, promises and agreements contained in this Agreement and, accordingly, each of Purchaser and Seller shall be entitled to injunctive relief with respect to any such breach, including specific performance of such covenants, promises or agreements or an order enjoining a party from any threatened, or from the continuation of any actual, breach of the covenants, promises or agreements contained in this Agreement. The rights of Purchaser and Seller set forth in this Section 9.4 shall be in addition to any other rights which a party may have at Law or in equity pursuant to this Agreement.

9.5 Entire Agreement; Amendments and Waivers. This Agreement (including the Exhibits and Schedules hereto and other documents specifically referred to herein) represents the entire understanding and agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written, of the parties. Any provision of this Agreement may be amended or waived if such amendment or waiver is in writing and signed, in the case of an amendment, by Purchaser and Seller, or in the case of a waiver, by the party against whom the waiver is effective. No failure or delay by either party in exercising any right, power or privilege hereunder will operate as a waiver thereof nor will any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies provided herein will be cumulative and, except as otherwise expressly provided herein, are not exclusive of any rights or remedies provided by applicable Law.

9.6 Counterparts; Electronic Signatures. For the convenience of the parties hereto, this Agreement may be executed in any number of counterparts, each such counterpart being deemed to be an original instrument, and all such counterparts shall together constitute the same agreement. Facsimile signatures or signatures delivered by email in PDF or similar format will be deemed original signatures for purposes of this Agreement.

9.7 Governing Law. This Agreement will be governed by and construed in accordance with the Laws of the State of Delaware without regard to principles of conflicts of Law. The parties hereby submit to the exclusive jurisdiction of the United States Bankruptcy Court for the

District of Delaware and any U.S. federal appellate court therefrom (or, if the United States Bankruptcy Court for the District of Delaware declines to or may not accept authority or jurisdiction over a particular matter, the United States District Court for the District of Delaware; or if the United States District Court for the District of Delaware declines to or may not accept jurisdiction over a particular matter, any state court within Suffolk County of the Commonwealth of Massachusetts) for any actions, suits or proceedings arising out of or relating to this Agreement or the transactions contemplated herein (and each party agrees not to commence any action, suit or proceeding relating thereto except in such courts), and each party further agrees that service of any process, summons, notice or document by U.S. registered mail to its respective address set forth in Section 9.9 shall be effective service of process for any action, suit or proceeding brought against it in any such court.

9.8 Waiver of Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

9.9 Notices. Unless otherwise set forth herein, any notice, request, instruction or other document to be given hereunder by any party to the other parties shall be in writing and shall be deemed duly given (i) upon delivery, when delivered personally, (ii) one (1) day after being sent by overnight courier or when sent by facsimile transmission or email PDF format (with a confirming copy sent by overnight courier), and (iii) three (3) calendar days after being sent by registered or certified mail, postage prepaid, as follows:

If to Seller, to:

InVivo Therapeutics Corporation
1500 District Avenue
Burlington, MA 01803
Attn: Heather Hamel, Chief Legal Officer
Email: hhamel@invivotherapeutics.com

With a copy to:

Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, MA 02109
Attention: George W. Shuster, Jr.
Email: george.shuster@wilmerhale.com

If to Purchaser, to:

[Purchaser]
[ADDRESS]

[ADDRESS]
Attention: [●]
Email: [●]

With a copy to:

[Purchaser's Representative]
[ADDRESS]
[ADDRESS]
Attention: [●]
Email: [●]

or to such other Persons or addresses as may be designated in writing by the party to receive such notice.

9.10 Binding Effect; Assignment. This Agreement will be binding upon and inure to the benefit of the parties and their respective successors and permitted assigns. Except as otherwise expressly stated herein, nothing in this Agreement will create or be deemed to create any Third Party beneficiary rights in any Person or entity not a party to this Agreement. Neither party may assign or delegate its rights or obligations under this Agreement (whether by operation of Law, change of control, or otherwise), either in whole or in part, without the prior written consent of the other party, provided, however, that (a) Purchaser may assign, delegate or transfer any of its rights or obligations under this Agreement to any wholly-owned direct or indirect Subsidiary of Purchaser by sending written notice to, but without the consent of, Seller; provided, further, that such assignment, delegation or transfer shall not relieve Purchaser of any liability or obligation under this Agreement. Any attempted assignment, delegation or transfer in violation of this Section 9.10 shall be void and without effect.

9.11 Third Party Beneficiaries. Except as otherwise expressly stated herein, no Person other than the parties hereto (and any permitted assignee under Section 9.10) shall have any rights or claims under this Agreement.

9.12 Publicity. Neither Seller nor Purchaser will issue any press release or make any public statement regarding the transactions contemplated hereby, without the prior written consent of the other party.

9.13 Severability. If any provision of this Agreement is determined to be invalid or unenforceable, the validity or enforceability of the other provisions of this Agreement as a whole will not be affected; and, in such event, Seller and Purchaser shall negotiate in good faith to change and interpret such provision so as to best accomplish the objectives of such provision within the limits of applicable Law or applicable court decision.

9.14 Non-Recourse. Except as expressly contemplated by this Agreement, no past, present or future director, officer, employee, advisor, lawyer, agent, representative, incorporator, member, partner or equity holder of Seller or Purchaser shall have any liability for (i) any obligations or liabilities of Seller or Purchaser under this Agreement or the certificate of incorporation and by-laws or comparable organizational documents of Seller or Purchaser, or

(ii) any claim based on, in respect of, or by reason of, the transactions contemplated hereby and thereby.

9.15 Time of the Essence. Time is of the essence in the performance of each of the obligations of the parties and with respect to all covenants and conditions to be satisfied by the parties in this Agreement and all documents, acknowledgments and instruments delivered in connection herewith.

9.16 Miscellaneous.

(a) Certain Interpretations. Unless otherwise expressly provided, for purposes of this Agreement, the following rules of interpretation shall apply:

(i) All references in this Agreement to Articles, Sections, Schedules and Exhibits shall be deemed to refer to Articles, Sections, Schedules and Exhibits to this Agreement.

(ii) All Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein. Any capitalized terms used in any Schedule or Exhibit but not otherwise defined therein shall be defined as set forth in this Agreement.

(iii) The Article, Section and paragraph captions herein are for convenience of reference only, do not constitute part of this Agreement and shall not be deemed to limit or otherwise affect any of the provisions hereof.

(iv) The words “include,” “includes” and “including,” when used herein, shall be deemed in each case to be followed by the words “without limitation” (regardless of whether such words or similar words actually appear).

(v) When calculating the period of time before which, within which or following which any act is to be done or step taken pursuant to this Agreement, the date that is the reference date in calculating such period shall be excluded.

(vi) Any reference in this Agreement to \$ shall mean United States Dollars.

(vii) Any reference in this Agreement to gender shall include all genders, and words imparting the singular number only shall include the plural and vice versa.

(viii) The words such as “herein,” “hereinafter,” “hereof,” and “hereunder” refer to this Agreement as a whole and not merely to a subdivision in which such words appear unless the context otherwise requires.

(b) The parties hereto agree that they have been represented by legal counsel during the negotiation and execution of this Agreement and, therefore, waive the application of any Law, regulation, holding or rule of construction providing that ambiguities in

an agreement or other document shall be construed against the party drafting such agreement or document.

(c) This Agreement is the result of the joint efforts of the parties hereto, and each provision hereof has been subject to the mutual consultation, negotiation, and agreement of the parties and there is to be no construction against any party based on any presumption of that party's involvement in the drafting thereof.

(d) Purchaser acknowledges hereby that Seller may not comply with the provisions of any bulk transfer laws of any jurisdiction in connection with the transactions contemplated by this Agreement.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective duly authorized officers as of the date first above written.

SELLER:

**INVIVO THERAPEUTICS HOLDINGS
CORP.**

By: _____

Name:

Title:

-and-

INVIVO THERAPEUTICS CORPORATION

By: _____

Name:

Title:

PURCHASER:

[PURCHASER]

By: _____
Name: [●]
Title: [●]

EXHIBIT A

Acquired Assets

All of the assets relating to the Program as of the Closing Date, including the following:

1. All tangible assets, including, without limitation, (a) all fixtures, furniture, office supplies, and office equipment, (b) all computers, printers, servers, and other information technology equipment, (c) all machinery, tools and tooling, supplies, spare parts, packaging materials, and other operational and manufacturing equipment, (d) all fixtures, (e) (i) any raw materials (including work in process and inventory), finished goods and other product inventory in the possession or control of, or otherwise held by or on behalf of, or owned by Seller (for the avoidance of doubt, the Acquired Assets also include all manufactured product, packaging material, and any other similar assets relating to the Business which have already been paid for by Seller, and any assets that are under manufacture), (f) all signage, advertising materials, marketing materials, literature and manuals, (g) all Documents, and (h) all other tangible personal property, including without limitation all of the assets specifically listed on Exhibit A-[●] hereto.
2. All intangible assets, including, without limitation, (a) all Acquired Avoidance Actions, (b) all claims, prepayments, deposits (including security deposits and equipment deposits), refunds, causes of action, choses in action, rights of recovery, rights of setoff, rights of recoupment, and prepaid items relating to or arising from the Acquired Assets or the Assumed Liabilities; (c) the Acquired Claims; (d) all warranties and similar rights, (e) all certificates, licenses, permits, franchises, rights, approvals, clearances, orders, exemptions, registrations, authorizations, and similar rights issued by any governmental entity or agency, (f) all intangible books, records, files, accounts, ledgers, correspondence, and communications, (g) all rights under contracts, agreements, and instruments that are not Executory Contracts, including, without limitation, all rights under non-disclosure and confidentiality agreements that are not Executory Contracts and all rights under insurance contracts and to insurance proceeds for claims under such insurance contracts arising after the Closing Date (and to insurance proceeds relating to such claims) to the extent that the insurance proceeds are related to other Acquired Assets, (h) all good will, and (i) all other intangible personal property, including without limitation all of the assets specifically listed on Exhibit A-[●] hereto.
3. To the extent not included in the foregoing, all Seller Owned Intellectual Property, including without limitation all of the assets specifically listed on Exhibit A-[●] hereto.
4. Without limiting the generality of the foregoing, all of the assets specifically listed on Annex A-[●] hereto.

For the avoidance of doubt, notwithstanding the foregoing, (1) none of the Excluded Assets are included within the Acquired Assets, and (2) all of the Assumed Executory Contracts are Acquired Assets.

EXHIBIT B

Assumed Executory Contracts

[TBD]⁶

⁶ NTD: This list will include the Specified Licenses.
{1394.001-W0074244.}

EXHIBIT C

Assumed Liabilities

1. Obligations arising after the Closing Date under any Assumed Executory Contract (listed on Exhibit B to this Agreement).

EXHIBIT D

Excluded Assets

1. All Cash and Cash Equivalents of Seller.
2. All checking, savings, and deposit accounts of Seller, and all securities accounts of Seller.
3. All Accounts Receivable.
4. Any real estate rights, including rights under any real estate leases.
5. All royalties or milestone payment rights owed to or held by Seller relating to the patidegib program or otherwise owing to, or having been previously sold by Seller to, HealthCare Royalty Partners III, L.P.
6. All royalties or milestone payment rights owed to or held by Seller relating to the duvelisib program or otherwise owing to, or having been previously sold by Seller to, BVF Partners, L.P.
7. All claims, prepayments, deposits (including security deposits and equipment deposits), refunds, rights of recovery, rights of setoff, rights of recoupment, and prepaid items relating to or arising from the Excluded Assets or the Excluded Liabilities.
8. All benefit, retirement, pension, or similar plans relating to employees of Seller.
9. All (a) rights, claims, or causes of action that Seller may have against any Person with respect to any Excluded Asset or Excluded Liability, (b) Avoidance Actions other than the Acquired Avoidance Actions, (c) estate claims of Seller not constituting Acquired Assets.
10. Any asset of Seller, which would constitute an Acquired Asset (if owned by Seller on the Closing Date) that is conveyed or otherwise disposed of during the period from the date of this Agreement to the Closing Date to the extent such conveyance or other disposal is permitted under, and not prohibited by, Section 7.3 of this Agreement.
11. All losses, loss carry forwards and rights to receive refunds or credits with respect to any and all Taxes of Seller incurred or accrued on or before the Closing Date.
12. All corporate seals, minute books, charter documents, corporate stock record books, original tax and financial records and such other files, books and records of Seller that Seller is required by Law to retain or that exclusively relate to the Excluded Assets and

Excluded Liabilities; provided, however, that Seller shall provide Purchaser with reasonable access to and copies of any such materials.

13. All shares of capital stock or other equity interests of InVivo Therapeutics Holdings Corp. or InVivo Therapeutics Corporation or in any other entity.
14. All insurance providing coverage for or related to current and former directors and officers and the actions and omissions thereof, and all claims and proceeds thereof, and all proceeds of insurance of any type to the extent that such proceeds are the result of claims arising prior to the Closing.

EXHIBIT E

FORM OF BILL OF SALE

THIS BILL OF SALE dated as of [Closing Date], by and among [PURCHASER], a [jurisdiction of organization] [type of entity] (“Purchaser”), and **INVIVO THERAPEUTICS HOLDINGS CORP.**, a Nevada corporation (“Holdings”), and **INVIVO THERAPEUTICS CORPORATION**, a Delaware corporation (“InVivo” and, together with Holdings, “Seller”).

WHEREAS, the parties hereto have entered into an Asset Purchase Agreement dated as of [Date of APA] (the “Purchase Agreement”) providing for the acquisition by Purchaser of certain assets of Seller, and the parties now desire to carry out such transaction by Seller’s execution and delivery to Purchaser of this instrument evidencing the vesting in Purchaser of all of the assets and rights of Seller hereinafter described. Capitalized terms used but not defined herein have the meanings given them in the Purchase Agreement.

NOW, THEREFORE, in consideration of the premises and of other valuable consideration to Seller in hand paid pursuant to the Purchase Agreement, at or before the execution and delivery hereof, the receipt and sufficiency of which by Seller is hereby acknowledged, Seller hereby conveys, grants, sells, transfers, sets over, assigns, remises, releases and delivers unto Purchaser, its successors and assigns forever, effective as of 12:01 a.m. EDT on the date hereof (the “Effective Time”), all of Seller’s right, title and interest in and to the Acquired Assets, free and clear of any Encumbrances, without representation or warranty, express or implied.

PURCHASER HEREBY ACKNOWLEDGES AND AGREES THAT SELLER MAKES NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, EXPRESS OR IMPLIED, WITH RESPECT TO ANY MATTER RELATING TO THE ACQUIRED ASSETS OTHER THAN AS SET FORTH IN THE PURCHASE AGREEMENT. WITHOUT IN ANY WAY LIMITING THE FOREGOING, SELLER HEREBY DISCLAIMS ANY WARRANTY, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE AS TO ANY PORTION OF THE ACQUIRED ASSETS. PURCHASER FURTHER ACKNOWLEDGES THAT PURCHASER HAS CONDUCTED AN INDEPENDENT INSPECTION AND INVESTIGATION OF THE PHYSICAL CONDITION OF THE ACQUIRED ASSETS AND ALL SUCH OTHER MATTERS RELATING TO OR AFFECTING THE ACQUIRED ASSETS AS PURCHASER DEEMED NECESSARY OR APPROPRIATE AND THAT, IN PROCEEDING WITH ITS ACQUISITION OF THE ACQUIRED ASSETS, PURCHASER IS DOING SO BASED SOLELY UPON SUCH INDEPENDENT INSPECTIONS AND INVESTIGATIONS. ACCORDINGLY, PURCHASER WILL ACCEPT THE ACQUIRED ASSETS AT THE CLOSING “AS IS,” “WHERE IS,” AND “WITH ALL FAULTS.”

Seller hereby covenants that, from time to time after the delivery of this instrument, at Purchaser’s request and without further consideration, Seller will do, execute, acknowledge, and deliver, or will cause to be done, executed, acknowledged and delivered, all and every such further acts, deeds, conveyances, transfers, assignments, powers of attorney and assurances as reasonably may be required, and in form and substance reasonably acceptable to Seller, to effectively convey, transfer to and vest in Purchaser, and to put Purchaser in possession of, any of the Acquired Assets.

Nothing in this instrument, express or implied, is intended or shall be construed to confer upon, or give to, any person, firm or corporation other than Purchaser and its successors and assigns, any remedy or claim under or by reason of this instrument or any terms, covenants or condition hereof, and all of the terms, covenants and conditions, promises and agreements in this instrument contained shall be for the sole and exclusive benefit of Purchaser and its successors and assigns.

This instrument is executed by, and shall be binding upon, Seller and its successors and assigns for the uses and purposes above set forth and referred to, effective as of the Effective Time.

This instrument shall be governed by, interpreted under, and construed and enforceable in accordance with, the laws of the State of Delaware, without regard to its conflict of law principle provisions.

To the extent this Bill of Sale is inconsistent with any terms or conditions of the Purchase Agreement, the terms and conditions of the Purchase Agreement shall control.

This instrument may be executed in counterpart signature pages, all of which when so executed and attached hereto shall constitute one and the same original.

[Signature pages follow.]

IN WITNESS WHEREOF, the parties hereto have executed this Bill of Sale or caused this Bill of Sale to be executed on their behalf by a duly authorized officer as of the date first set forth above.

SELLER:

**INVIVO THERAPEUTICS HOLDINGS
CORP.**

By: _____

Name:

Title:

-and-

INVIVO THERAPEUTICS CORPORATION

By: _____

Name:

Title:

PURCHASER:

[PURCHASER]

By: _____

Name: [●]

Title: [●]

EXHIBIT F

FORM OF ASSIGNMENT AND ASSUMPTION AGREEMENT

This **ASSIGNMENT AND ASSUMPTION AGREEMENT** (the “Agreement”) is entered into as of [Closing Date], by and among [PURCHASER], a [jurisdiction of organization] [type of entity] (“Assignee”), and **INVIVO THERAPEUTICS HOLDINGS CORP.**, a Nevada corporation (“Holdings”), and **INVIVO THERAPEUTICS CORPORATION**, a Delaware corporation (“InVivo” and, together with Holdings, “Assignor”).

WITNESSETH:

WHEREAS, Assignor and Assignee entered into that certain Asset Purchase Agreement dated as of [Date of APA] (the “Purchase Agreement”; capitalized terms used but not otherwise defined herein have the meanings given them in the Purchase Agreement); and

WHEREAS, pursuant to the Purchase Agreement, Assignor has agreed to assign certain rights and agreements to Assignee, and Assignee has agreed to assume certain obligations of Assignor, as set forth therein and herein.

NOW, THEREFORE, in consideration of the premises, the mutual covenants set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto mutually covenant and agree as follows:

1. Effective as of 12:01 a.m. EDT on the date hereof, Assignor hereby sells, transfers and assigns (collectively the “Assignment”) to the Assignee, and Assignee hereby assumes and agrees to pay, perform and discharge, each and all of the Assumed Liabilities, as that term is defined in the Purchase Agreement.

2. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.

3. This Agreement shall be governed by, interpreted under, and construed and enforceable in accordance with, the laws of the State of Delaware, without regard to its conflict of law principle provisions and rules.

4. To the extent this Agreement is inconsistent with any terms or conditions in the Purchase Agreement, the Purchase Agreement shall control.

5. This Agreement may be executed in counterpart signature pages, all of which when so executed and attached hereto shall constitute one and the same original.

[Signature pages follow.]

IN WITNESS WHEREOF, the parties hereto have executed this Assignment and Assumption Agreement as of the date first set forth above.

ASSIGNOR:

**INVIVO THERAPEUTICS HOLDINGS
CORP.**

By: _____

Name:

Title:

-and-

INVIVO THERAPEUTICS CORPORATION

By: _____

Name:

Title:

ASSIGNEE:

[PURCHASER]

By: _____
Name: [●]
Title: [●]

EXHIBIT 2

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INVIVO THERAPEUTICS CORPORATION, *et al.*,¹

Debtors.

Chapter 11

Case No. 24-10137 (MFW)

(Jointly Administered)

**NOTICE OF BID DEADLINE, AUCTION, AND SALE HEARING IN CONNECTION
WITH THE SALE OF SUBSTANTIALLY ALL OF THE DEBTORS' ASSETS**

NOTICE IS HEREBY GIVEN, as follows:

1. On February 1, 2024, the above-captioned debtors and debtors-in-possession (the “Debtors”) filed a motion (the “Bid Procedures Motion”) with the United States Bankruptcy Court for the District of Delaware (the “Court”) seeking approval of among other things (i) bid procedures (the “Bid Procedures”) in connection with the sale (the “Sale”) of substantially all of the Debtors’ assets (the “Assets”), (ii) procedures to determine cure amounts and deadlines for objections to certain contracts and leases to be assumed and assigned by the Debtors (the “Cure Procedures”), (iii) the date, time, and place for a sale hearing (the “Sale Hearing”) and for objections to the Sale, and (iv) related relief. On February [__], 2024, the Court entered an order D.I. [●] approving the Bid Procedures Motion, the Bid Procedures and the Contract Procedures (the “Bid Procedures Order”).²

2. All interested parties are invited to submit a Qualified Bid and to make offers to purchase the Assets in accordance with the terms of the Bid Procedures and the Bid Procedures Order. Potential Bidders are encouraged to review the Bid Procedures attached to the Bid Procedures Order carefully and, for further information, are invited to contact the Debtors’ investment banker, SSG Advisors, LLC, Five Tower Bridge, Suite 420, 300 Barr Harbor Drive, West Conshohocken, Pennsylvania 19428, Attn: J. Scott Victor (e-mail: jsvictor@ssgca.com) and Teresa Kohl (tkohl@ssgca.com) (tel.: (610) 940-1094). **The Bid Deadline is March 29, 2024, at 4:00 p.m. (ET).**

3. Consistent with the Bid Procedures Order, in the event the Debtors receive one or more Qualified Bids on or before the Bid Deadline, the Debtors shall conduct the Auction for the purpose of determining the highest or otherwise best bid for the Acquired Assets. **The Auction shall be organized by the Debtors’ professionals and conducted at the offices of Landis**

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number, are: InVivo Therapeutics Corporation (6670) and InVivo Therapeutics Holdings Corp. (8166). The Debtors’ mailing address is 1500 District Avenue, Burlington, MA 01803.

² Capitalized terms not otherwise defined herein shall have the meanings given to such terms in the Bid Procedures Order.

Rath & Cobb LLP, 919 N. Market Street, Suite 1800, Wilmington, Delaware 19801, or by remote audio and/or video link, beginning at 10:00 a.m. (ET) on April 3, 2024 or such other location and time as may be announced prior to the Auction to all Qualified Bidders, the U.S. Trustee and the official committee of unsecured creditors, if any, formed in the Chapter 11 Cases (the “Committee”). The Auction will be recorded and transcribed by an authorized court reporter. The Debtors, their professionals, [the U.S. Trustee](#), the Committee, if any, Qualified Bidders and their respective members and professionals, and creditors and their respective counsel, financial advisors, and/or other authorized representatives may attend the Auction. The only persons or entities who will be permitted to bid at the Auction are the authorized representatives of each Qualified Bidder. The time and place of the Auction may change with notice. The Debtors shall file notice of any such change with the court not later 10:00 a.m. (ET) one (1) day prior to the Auction, and shall serve such notice by email or fax on all creditors who notified Debtors’ counsel of their intention to attend the Auction, in the manner and time set forth in paragraph 5 below, as well as on all bidders and Committee counsel, if any.

4. Any party-in-interest wishing to attend the Auction, whether virtually or in person, may request to attend by contacting, no later than three (3) business days prior to the start of the Auction, Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware 19801, Attn: Matthew B. McGuire, Esq. (e-mail: mcguire@Irclaw.com) and providing their e-mail address and/or fax number, so as to receive notice of any change in the date, time or location of the Auction.

5. At the Sale Hearing on April 5, 2024, at 10:00 a.m. (ET) or such other time as the Court shall determine, the Debtors intend to seek the Court approval of the sale of the Assets to the Successful Bidder at the Auction. In determining the Successful Bidder, in addition to the amount of cash or cash equivalent consideration offered, the Debtors will consider, among other factors, the assumption of liabilities contemplated by each Qualified Bid, certainty of closing, and other factors relating to the value and certainty of the bid. The Sale Hearing will be held before the Honorable Mary F. Walrath, Judge at the United States Bankruptcy Court for the District of Delaware, 824 Market Street, 5th Floor, Courtroom No. 4, Wilmington, Delaware 19801. The Sale Hearing may be adjourned from time-to-time without further notice to creditors or parties in interest other than by announcement of the adjournment in open court or on the Court’s docket.

6. In the event an Auction will occur, no later than 4:00 p.m. (ET) on April 1, 2024, the Debtors will provide e-mail or fax notice containing the identities of all Qualified Bidders (the “Qualified Bidder Notice”) to all Contract Parties who timely submitted a written request for such notice pursuant to the instructions below. The Debtors shall file notice of the ~~identity~~[identities](#) of the Successful Bidder, and the Back-Up Bidder [\(and, if the Successful Bidder or the Back-Up Bidder is a special purpose entity, the identity of the entity or entities that are the primary equity holders, or otherwise control, the special purpose entity\)](#), and the amount of the Successful Bid and Back-Up Bid with the Court ~~within one (1)~~[by the earlier of \(a\) five \(5\) business hours after the close of the Auction or \(b\) noon of the](#) day after the close of the Auction. At that same time, the Debtors shall serve notice of the foregoing information (the “Successful Bidder Notice”) by email or fax to all Contract Parties and creditors who have timely requested notice of such information. To receive a copy of the Qualified Bidder Notice and the Successful Bidder Notice, a Contract Party must submit a written request in writing to Debtors’ counsel,

Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware, Attn: Matthew B. McGuire, Esq. (e-mail: mcguire@lrclaw.com) and provide Debtors' counsel with their email addresses or fax numbers by no later than the Bid Deadline.

7. At the Sale Hearing, the Court may enter such orders as it deems appropriate under applicable law and as required by the circumstances and equities of ~~this~~these Chapter 11 Case Cases, and the Debtors, subject to the terms of the Successful Bidder's asset purchase agreement, may seek entry of an order which provides, except with respect to any Assumed Liabilities, all persons and entities, including, but not limited to, all debt security holders, equity security holders, governmental, tax and regulatory authorities, lenders, trade creditors, litigation claimants and other creditors, holding liens, claims, encumbrances or interests of any kind or nature whatsoever against or in all or any portion of the Assets (whether legal or equitable, secured or unsecured, matured or unmatured, contingent or non-contingent, liquidated or unliquidated or subordinate), arising under or out of in connection with, or in any way relating to the Debtors, the Assets, the operation of the Debtors' business prior to the Closing Date or the transfer of the Assets to the Buyer, that all such persons are forever prohibited and permanently enjoined from (i) commencing or continuing in any manner any action or other proceeding, the employment of process, or any act (whether in law or equity, in any judicial, administrative, arbitral, or other proceeding) to collect or recover any interest; (ii) enforcing, attaching, collecting, or recovering in any manner any judgment, award, decree, or order with respect to an interest, (iii) creating, perfecting, or enforcing any interest, or (iv) asserting any right of subrogation of any kind with respect to an interest, in each case as against the Successful Bidder or its designee, any of their respective affiliates or subsidiaries, or any of their respective representatives, or any of their respective property or assets, including the Assets.

8. The Debtors proposes that, to be timely and otherwise eligible for consideration by the Court, objections, if any, to the Sale of the Assets or to entry of the form of Sale Order, ("Sale Objections"), or the assumption and assignment of executory contracts and unexpired leases pursuant to the terms of the agreement reached between the Debtors and the Successful Bidder ("Contract Objections") shall be in writing, shall conform to the Federal Rules of Bankruptcy Procedure and the Local Rules of the Bankruptcy Court for the District of Delaware, shall set forth the name of the objecting party, the nature and amount of any claims or interests held or asserted against the Debtors' estates or properties, the basis for the objection and the specific grounds therefor, and shall be filed with the Court and be served upon: (i) counsel for the Debtors, Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware 19801 (Attn: Matthew B. McGuire. (e-mail: mcguire@lrclaw.com) and Joshua B. Brooks, Esq. (e-mail: brooks@lrclaw.com)); and Wilmer Cutler Pickering Hale and Dorr LLP, 7 World Trade Center, 250 Greenwich Street, New York, New York, 10007 (Attn: George Shuster, Esq. (e-mail: george.shuster@wilmerhale.com) and Benjamin Loveland, Esq. (e-mail: benjamin.loveland@wilmerhale.com)); (ii) counsel to the Committee, if any; and (iii) the Office of the United States Trustee, 844 King Street, Suite 2207, Wilmington, Delaware 19801 (Attn: Joseph Cudia, Esq. (email: Joseph.Cudia@usdoj.gov)) (collectively, the "Sale Objection Parties") **so that such Contract and Sale Objections are received by no later than 4:00 p.m. (ET) on March 29, 2024.**

9. In the event (a) an Auction is conducted, the deadline for objections related to the conduct of the Auction itself shall be at the Sale Hearing; (b) the form of Sale Order approving

such Successful Bidder's asset purchase agreement; and (c) the proposed asset purchase agreement between the Debtors and such Successful Bidder shall be at the Sale Hearing.

10. Contract Parties shall be able to assert an objection at or before the Sale Hearing to the assignment of executory contracts and unexpired leases to such Successful Bidder solely on the grounds that the proposed assignment does not comply with 11 U.S.C. § 365(b)(1)(C), with any such objection that is not resolved prior to or at the Sale Hearing to be heard at a later-scheduled hearing as the Court deems appropriate.

11. You may obtain a copy of the Motion, the Bid Procedures, the Bid Procedures Order, the form of Sale Order, and the Notice of Sale Hearing by sending a written request to the Debtor's undersigned counsel.

Dated: _____, 2024 **LANDIS RATH & COBB LLP**
Wilmington, Delaware

/s/

Matthew B. McGuire (No. 4366)
Joshua B. Brooks (No. 6765)
919 Market Street, Suite 1800
Wilmington, Delaware 19801
Telephone: (302) 467-4400
Facsimile: (302) 467-4450
Email: mcguire@lrclaw.com
brooks@lrclaw.com

*Counsel to the Debtors and
Debtors-In-Possession*

EXHIBIT 3

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INVIVO THERAPEUTICS CORPORATION, *et al.*,¹

Debtors.

Chapter 11

Case No. 24-10137 (MFW)

(Jointly Administered)

**NOTICE OF DEBTORS INTENT TO ASSUME AND ASSIGN CERTAIN UNEXPIRED
LEASES AND EXECUTORY CONTRACTS AND FIXING OF CURE AMOUNTS**

NOTICE IS HEREBY GIVEN, as follows:

1. On February [], 2024, the United States Bankruptcy Court for the District of Delaware (the “Court”) entered an order (the “Bid Procedures Order”)² approving among other things (i) bid procedures (the “Bid Procedures”) in connection with the sale of substantially all of the Debtors’ assets (the “Assets”) and (ii) procedures to determine cure amounts and deadlines for objections to certain contracts and leases to be assumed and assigned by the Debtors (the “Contract Procedures”).

2. At a hearing on April 5, 2024, at 10:00 a.m. (ET) or such other time as the Court shall determine (the “Sale Hearing”), the Debtors intend to seek approval of the sale of the Assets (the “Sale”) to such party as determined pursuant to the Bid Procedures to have submitted the highest or otherwise best bid for the Assets (the “Successful Bidder”). The Sale Hearing shall be before the Honorable Mary F. Walrath, Judge at the United States Bankruptcy Court for the District of Delaware, 824 Market Street, 5th Floor, Courtroom No. 4, Wilmington, Delaware 19801. The Sale Hearing may be adjourned, from time to time, without further notice to creditors or parties in interest other than by announcement of the adjournment in open court or on the Court’s docket.

3. The Debtors seek to have the Sale be free and clear of all liens, claims, encumbrances, defenses (including, without limitation, rights of setoff) and interests, including, without limitation, security interests of whatever kind or nature, mortgages, conditional sales or title retention agreements, pledges, deeds of trust, hypothecations, liens, encumbrances, assignments, preferences, debts, easements, charges, suits, licenses, options, rights-of-recovery, judgments, orders and decrees of any court or foreign or domestic governmental entity, taxes (including foreign, state and local taxes), licenses, covenants, restrictions, indentures, instruments, leases, options, off-sets, claims for reimbursement, contribution, indemnity or exoneration, successor, product, environmental, tax, labor, ERISA, CERCLA, alter ego and other

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number, are: InVivo Therapeutics Corporation (6670) and InVivo Therapeutics Holdings Corp. (8166). The Debtors’ mailing address is 1500 District Avenue, Burlington, MA 01803.

² Capitalized terms not otherwise defined herein shall have the meanings given to such terms in the Bid Procedures Order and/or the Bid Procedures Motion

liabilities, causes of action, contract rights and claims, to the fullest extent of the law, in each case, of any kind or nature (including, without limitation, all “claims” as defined in section 101(5) of the Bankruptcy Code), known or unknown, whether pre-petition or post-petition, secured or unsecured, choate or inchoate, filed or unfiled, scheduled or unscheduled, perfected or unperfected, liquidated or unliquidated, noticed or unnoticed, recorded or unrecorded, contingent or noncontingent, material or non-material, statutory or non-statutory, matured or unmatured, legal or equitable to the maximum extent permitted by Bankruptcy Code section 363.

4. At the Sale Hearing, the Court may enter such orders as it deems appropriate under applicable law and as required by the circumstances and equities of ~~this~~these Chapter 11 ~~Case~~Cases, and the Debtors, subject to the terms of the Successful Bidders’ asset purchase agreement, may seek entry of an order which provides, all persons and entities, including, but not limited to, all debt security holders, equity security holders, governmental, tax and regulatory authorities, lenders, trade creditors, litigation claimants and other creditors, holding liens, claims, encumbrances or interests of any kind or nature whatsoever against or in all or any portion of the Assets (whether legal or equitable, secured or unsecured, matured or unmatured, contingent or non-contingent, liquidated or unliquidated or subordinate), arising under or out of, in connection with, or in any way relating to the Debtors, the Assets, the operation of the Debtors’ business prior to the Closing Date or the transfer of the Assets to the Successful Bidder, shall be forever prohibited and permanently enjoined from (i) commencing or continuing in any manner any action or other proceeding, the employment of process, or any act (whether in law or equity, in any judicial, administrative, arbitral, or other proceeding) to collect or recover any interest; (ii) enforcing, attaching, collecting, or recovering in any manner any judgment, award, decree, or order with respect to an interest, (iii) creating, perfecting, or enforcing any interest, or (iv) asserting any right of subrogation of any kind with respect to an interest, in each case as against the Successful Bidder or its designee, any of their respective affiliates or subsidiaries, or any of their respective representatives, or any of their respective property or assets, including the Assets.

5. Pursuant to the Bid Procedures Order and the Contract Procedures approved therein, the Debtors intend to seek approval to assume and assign certain unexpired leases and executory contracts, pursuant to Bankruptcy Code section 365 (collectively, the “Contracts”) to the Successful Bidder. You have been identified as a party to a Contract (a “Contract Party”) that the Debtors *may* seek to assume and assign. The Contract with respect to which you have been identified as a non-Debtor party is set forth on **Exhibit 1** annexed hereto. The Debtors assert that no consent of any Contract Party is required for the assumption or assignment of any Contract, regardless of the applicable terms of the Contract, by operation of Bankruptcy Code section 365.

6. The Debtors believe that any and all defaults (other than the filing of ~~this~~these Chapter 11 ~~Case~~Cases), actual pecuniary losses and any amounts due under the Contract can be cured and satisfied in full by the payment of the cure amounts (the “Cure Amounts”), which are also set forth on **Exhibit 1**; provided, however, the Debtors may adjust the Cure Amount with respect to any Contract on **Exhibit 1** as necessary and in accordance with the Bid Procedures. **The inclusion of a Contract on Exhibit 1 hereto is not, and should not be deemed to be, an agreement or acknowledgement by the Debtors that such Contract is an executory contract or unexpired lease under Bankruptcy Code section 365 or that such Contract will be assumed and assigned by the Debtors; the Successful Bidder has the right up to the Closing to determine whether or not to have your Contract assigned.**

7. Any party objecting to (i) any of the Cure Amounts set forth on **Exhibit 1** hereto, and/or (ii) the proposed assumption and assignment of any Contract in connection with the Sale, including, without limitation, the Debtors' ability to assign the Contract without the Contract Party's consent, and/or (iii) the adequate assurance of future performance to be provided by the Successful Bidder, as applicable, must file with the Court and serve an objection (a "Contract Objection") in writing, setting forth with specificity any and all obligations that the objecting party asserts must be cured or satisfied in respect to the Contract, and/or any and all objections to the potential assumption and assignment of such Contract, together with all documentation supporting such cure claim or objection, upon: (i) counsel for the Debtors, Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware 19801 (Attn: Matthew B. McGuire, Esq. (e-mail: mcguire@lrclaw.com) and Joshua B. Brooks (e-mail: brooks@lrclaw.com); and Wilmer Cutler Pickering Hale and Dorr LLP, 7 World Trade Center, 250 Greenwich Street, New York, New York, 10007 (Attn: George Shuster, Esq. (e-mail: george.shuster@wilmerhale.com) and Benjamin Loveland, Esq. (e-mail: benjamin.loveland@wilmerhale.com)); (ii) counsel to the Committee, if any; and (iii) the Office of the United States Trustee, 844 King Street, Suite 2207, Wilmington, Delaware 19801 (Attn: Joseph Cudia, Esq. (email: Joseph.Cudia@usdoj.gov)) **so as to be received before 4:00 p.m. (ET) on March 29, 2024** (the "Contract Objection Deadline"); provided, however, that if the Debtors amend the Cure Notice to add a contract or lease, the Contract Party shall have until the earlier of (a) fourteen 14 days after service of the Cure Notice, and (b) the Sale Hearing to submit a Contract Objection (the "Amended Contract Objection Deadline"); provided further, that if the Debtors amend the Cure Notice to reduce the Cure Amount of a Contract, except where such reduction was upon mutual agreement of the parties, the Contract Party shall have until fourteen (14) days after service of the amended Cure Notice to object to the Cure Amount; and provided further, that Contract Parties shall be able to assert an objection at or before the Sale Hearing to the assignment of executory contracts and unexpired leases to such Successful Bidder solely on the grounds that the proposed assignment does not comply with 11 U.S.C. § 365(b)(1)(C), with any such objection that is not resolved prior to or at the Sale Hearing to be heard at a later- scheduled hearing as the Court deems appropriate.³

8. In the event an Auction will occur, no later than 4:00 p.m. (ET) on April 1, 2024, the Debtors shall provide e-mail or fax notice containing the identities of all Qualified Bidders (the "Qualified Bidder Notice") to all Contract Parties who timely submitted a written request for such notice pursuant to the instructions below. The Debtors shall file notice of the ~~identity~~identities of the Successful Bidder, ~~and the Back-up Bidder and the Back-Up Bidder (and, if the Successful Bidder or Back-Up Bidder is a special purpose entity, the identity of the entity or entities that are the primary equity holders, or otherwise control, the special purpose entity),~~ and the amount of the Successful Bid and Back-up Bid with the Court ~~no later than one (1) business~~by the earlier of (a) five (5) business hours after the close of the Auction or (b) noon on the day after the close of the Auction. At that same time, the Debtors shall serve notice of the foregoing information (the "Successful Bidder Notice") by email or fax to all Contract Parties and creditors who have timely requested notice of such information. To receive a copy of the Qualified Bidder Notice and the Successful Bidder Notice, a Contract Party must submit a written request in writing to Debtors' counsel, Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware, Attn: Matthew B. McGuire, Esq. (e-mail:

³ Bankruptcy Code section 365(b)(1)(C) provides: "If there has been a default in an executory contract or unexpired lease of the debtor, the trustee may not assume such contract or lease unless, at the time of assumption of such contract or lease, the trustee provides adequate assurance of future performance under such contract or lease."

mcguire@irelaw@irelaw.com) and provide Debtors' counsel with their email addresses or fax numbers by no later than the Bid Deadline.

9. Where a Contract Party to a Contract files an objection meeting the requirements of paragraph 6 herein, objecting to the assumption by the Debtors and assignment to the Successful Bidder of such Contract and/or asserting a cure amount higher than the proposed Cure Amount listed on this notice, the Debtors, the Contract Party and the Successful Bidder shall meet and confer in good faith to attempt to resolve any such objection without Court intervention. In the event the Contract Objection is not resolved, such Contract Objection will be heard at the Sale Hearing or thereafter. To the extent it is determined that the Cure Amount exceeds the amount set forth on **Exhibit 1** hereto, the Successful Bidder may determine not to have such Contract assumed and assigned to it.

10. If no Cure Amount is due, or no other amount is due or owing under the Contract, and the Contract Party to such agreement does not otherwise object to the Debtors' assumption, sale and assignment of such agreement, no further action needs to be taken on the part of that Contract Party.

11. Unless an objection to the assumption and assignment of a Contract is filed and served before the Objection Deadline (or the Amended Contract Objection Deadline, as applicable), all Contract Parties shall be (i) forever barred from objecting to the proposed Cure Amounts and from asserting any additional cure or other amounts (other than as may be asserted in an Additional Cure Notice), and the Debtors and the Successful Bidder shall be entitled to rely solely upon the proposed Cure Amounts set forth in the Cure Notices; (ii) deemed to have consented to the assumption and assignment of the Contracts; (iii) forever barred and estopped from asserting or claiming against the Debtors or the Successful Bidder that any additional amounts are due or other defaults exist (other than as may be asserted in an Additional Cure Notice), that conditions to assignment must be satisfied under such Contracts, including, without limitation, any consent rights, or that there is any objection or defense to the assumption and assignment of such Contracts, including without limitation adequate assurance of future performance; (iv) precluded from objecting to the Cure Amount (if any) and the assumption and assignment; and (v) barred and estopped from asserting or claiming that their Contract contains an enforceable consent right; provided, however, that a counterparty to an Assumed Executory Contract shall not be barred from seeking additional amounts on account of any defaults occurring between the service of the Cure Notice and the assumption of the Contract.

12. The Debtors' decision to assume and assign a Contract is subject to the Successful Bidder's, as applicable, designation in accordance with the Contract Procedures and the Court's approval of and consummation of the Sale. Absent consummation of the Sale, a Contract shall not be deemed assumed and assigned and shall in all respects be subject to further administration under the Bankruptcy Code. The designation of any agreement as a Contract shall not constitute or be deemed to be a determination or admission by the Debtors or the Successful Bidder that such document is, in fact, an executory contract or unexpired lease within the meaning of the Bankruptcy Code (all rights with respect thereto being expressly reserved including, for the avoidance of doubt, the Debtors' right to change the designation of any agreement as an

executory contract or unexpired lease under Bankruptcy Code section 365 at any time prior to the Closing Date).

Dated: ~~February~~ _____, 2024
Wilmington, Delaware

LANDIS RATH & COBB LLP

/s/_____

Matthew B. McGuire (No. 4366)

Joshua B. Brooks (No. 6765)

919 Market Street, Suite 1800

Wilmington, Delaware 19801

Telephone: (302) 467-4400

Facsimile: (302) 467-4450

Email: mcguire@lrclaw.com

brooks@lrclaw.com

*Counsel to the Debtors and
Debtors-In-Possession*

EXHIBIT 4

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INVIVO THERAPEUTICS CORPORATION, *et al.*,¹

Debtors.

Chapter 11

Case No. 24-10137 (MFW)

(Jointly Administered)

NOTICE OF DEBTORS INTENT TO ASSUME

**AND ASSIGN CERTAIN ADDITIONAL LEASES AND EXECUTORY
CONTRACTS AND FIXING OF ADDITIONAL CURE AMOUNTS**

NOTICE IS HEREBY GIVEN, as follows:

1. On February [], 2024, the United States Bankruptcy Court for the District of Delaware (the “Court”) entered an order (the “Bid Procedures Order”)² approving among other things (i) bid procedures (the “Bid Procedures”) in connection with the sale of substantially all of the Debtors’ assets (the “Assets”) and (ii) procedures to determine cure amounts and deadlines for objections to certain contracts and leases to be assumed and assigned by the Debtors (the “Contract Procedures”).

2. Pursuant to the Bid Procedures Order and the Contract Procedures approved therein, the non-Debtor parties to the Contracts (the “Contract Parties”) had until 4:00 p.m. (ET) on March 29, 2024, to object (a “Contract Objection”) to (i) the Cure Amounts listed by the Debtors (other than the Additional Cure Amounts (defined below)) and to propose alternative cure amounts; and/or (ii) the proposed assumption and assignment of the Contracts in connection with the Sale, including, without limitation, the Debtors’ ability to assign the Contracts without the Contract Parties⁵ consent or the adequate assurance of future performance to be provided.

3. At a hearing on April 5, 2024, at 10:00 a.m. (ET) or such other time as the Court shall determine (the “Sale Hearing”), the Debtors intend to seek approval of the sale of the Assets (the “Sale”) to such party as determined pursuant to the Bid Procedures to have submitted the highest or otherwise best bid for the Assets (the “Successful Bidder”). The Sale Hearing shall be before the Honorable Mary F. Walrath, Judge at the United States Bankruptcy Court for the District of Delaware, 824 Market Street, 5th Floor, Courtroom No. 4, Wilmington, Delaware 19801. The Sale Hearing may be adjourned, from time to time, without further notice to creditors or parties in interest other than by announcement of the adjournment in open court or on the Court’s docket.

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number, are: InVivo Therapeutics Corporation (6670) and InVivo Therapeutics Holdings Corp. (8166). The Debtors’ mailing address is 1500 District Avenue, Burlington, MA 01803.

² Capitalized terms not otherwise defined herein shall have the meanings given to such terms in the Bid Procedures Order and/or the Bid Procedures Motion.

4. The Debtors seek to have the Sale be free and clear of all liens, claims, encumbrances, defenses (including, without limitation, rights of setoff) and interests, including, without limitation, security interests of whatever kind or nature, mortgages, conditional sales or title retention agreements, pledges, deeds of trust, hypothecations, liens, encumbrances, assignments, preferences, debts, easements, charges, suits, licenses, options, rights-of-recovery, judgments, orders and decrees of any court or foreign or domestic governmental entity, taxes (including foreign, state and local taxes), licenses, covenants, restrictions, indentures, instruments, leases, options, off-sets, claims for reimbursement, contribution, indemnity or exoneration, successor, product, environmental, tax, labor, ERISA, CERCLA, alter ego and other liabilities, causes of action, contract rights and claims, to the fullest extent of the law, in each case, of any kind or nature (including, without limitation, all “claims” as defined in section 101(5) of the Bankruptcy Code), known or unknown, whether pre-petition or post-petition, secured or unsecured, choate or inchoate, filed or unfiled, scheduled or unscheduled, perfected or unperfected, liquidated or unliquidated, noticed or unnoticed, recorded or unrecorded, contingent or noncontingent, material or non-material, statutory or non-statutory, matured or unmatured, legal or equitable to the maximum extent permitted by Bankruptcy Code section 363.

5. On [], 2024, the Debtors filed the *Notice of Debtors’ Intent to Assume and Assign Certain Unexpired Leases and Executory Contracts and Fixing of Cure Amounts* (the “Initial Cure Notice”). Through this notice, the Debtors hereby supplement the Initial Cure Notice to either add Contract(s) inadvertently omitted from the Initial Cure Notice or to list the additional Cure Amounts (the “Additional Cure Amounts”) the Debtors believe are owed with respect to such Contract(s). You have been identified as a party to a Contract the Debtors *may* seek to assume and assign that is listed on the supplemental Contract list attached hereto as **Exhibit 1** (each an “Additional Assumed ~~contract~~Contract”).

6. Any objections to the Additional Cure Amounts (such objection being the only permissible grounds for objection) must be filed with the Court and served on: (i) counsel for the Debtors, Landis Rath & Cobb LLP, 919 Market Street, Suite 1800, Wilmington, Delaware 19801 (Attn: Matthew B. McGuire, Esq. (e-mail: mcguire@lrclaw.com) and Joshua B. Brooks (e-mail: brooks@lrclaw.com)); and Wilmer Cutler Pickering Hale and Dorr LLP, 7 World Trade Center, 250 Greenwich Street, New York, New York, 10007 (Attn: George Shuster, Esq. (e-mail: george.shuster@wilmerhale.com) and Benjamin Loveland, Esq. (e-mail: benjamin.loveland@wilmerhale.com)); (ii) counsel to the Committee, if any; and (iii) the Office of the United States Trustee, 844 King Street, Suite 2207, Wilmington, Delaware 19801 (Attn: Joseph Cudia, Esq. (email: Joseph.Cudia@usdoj.gov)); so as to actually be received by **4:00 p.m. (ET) on or before the earlier of (a) the date that is fourteen (14) days after service of the additional cure notice or (b) the Sale Hearing** (the “Additional Cure Deadline”), which deadline may be extended in the sole discretion of the Debtors and the Successful Bidder.

7. If no objection to the Additional Cure Amounts is filed by the Additional Cure Deadline, the Court will enter an order (an “Additional Assumption Order”) authorizing the assumption and assignment of the Additional Assumed Contract effective as of the date of this notice. In the event an objection is filed by the Additional Cure Deadline, and the parties cannot consensually agree on the Additional Cure Amounts, the Debtors will seek expedited determination of the objection by the Court on the first available hearing date.

8. If no Additional Cure Amount is due or you agree with the Additional Cure Amount set forth on **Exhibit 1**, no further action needs to be taken and the Court will enter an order authorizing the assumption by the Debtors and assignment to the Successful Bidder of the contracts listed on **Exhibit 1**.

Dated: ~~February~~ _____, 2024
Wilmington, Delaware

LANDIS RATH & COBB LLP

/s/_____

Matthew B. McGuire (No. 4366)

Joshua B. Brooks (No. 6765)

919 Market Street, Suite 1800

Wilmington, Delaware 19801

Telephone: (302) 467-4400

Facsimile: (302) 467-4450

Email: mcguire@lrclaw.com

brooks@lrclaw.com

*Counsel to the Debtors and
Debtors-In-Possession*